Photodynamic Therapy and Diagnostics
Reduced chlorin analogs address the limitations of current photosensitizers by enhancing photosensitivity and stability, enabling effective photodynamic therapy and diagnosis.
Patent Information
- Application Number
- JP2024531488
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2022-06-01
- Filing Date
- 2022-11-28
- Publication Date
- 2024-11-26
AI Technical Summary
Current photosensitizers for photodynamic therapy lack high singlet oxygen quantum yields, strong photosensitivity in organic and aqueous media, high fluorescence quantum yields, and require improved phototoxicity, lower dark toxicity, better stability, and solubility, as well as easier purification.
Development of reduced chlorin analogs and their pharmaceutically acceptable salts, specifically compounds of formula (1) or (I), which include structures such as reduced phyllochlorin free acid and esters, with various functional groups and metal complexes, to enhance photosensitivity and stability.
The reduced chlorin analogs exhibit improved photosensitivity, stability, and solubility, offering potential for better photodynamic therapy and diagnosis, particularly in treating tumors and antiviral therapy.
Smart Images

Figure 2024543926000001_ABST
Abstract
Description
[Technical Field]
[0001] The present invention relates to reduced chlorin analogs and pharmaceutically acceptable salts thereof, and compositions comprising the reduced chlorin analogs and pharmaceutically acceptable salts thereof. The reduced chlorin analogs and pharmaceutically acceptable salts thereof are suitable for use in photodynamic therapy, cytoluminescence therapy, and photodynamic diagnosis, for example, for the treatment or detection of tumors, or for antiviral therapy. The present invention also relates to the use of the reduced chlorin analogs and pharmaceutically acceptable salts thereof in the manufacture of phototherapeutic or photodiagnostic agents, and to methods of photodynamic therapy, cytoluminescence therapy, or photodynamic diagnosis, for example, for the treatment or detection of tumors, or for antiviral therapy.
[0002] The structure of "phyllochlorin" is as follows: [ka] [Background technology]
[0003] Porphyrins and their analogues are known photosensitive chemical compounds that can absorb photons and emit them at higher wavelengths. These unique properties have many applications, one of which is photodynamic therapy (PDT).
[0004] There are currently two generations of photosensitizers for PDT: the first generation contains heme porphyrins (blood derivatives), and the second generation is mostly chlorophyll analogues, the latter compounds known as chlorins and bacteriochlorins.
[0005] Chlorin e4 has been shown to exhibit good photosensitizing activity. It has also been shown to have protective effects against indomethacin-induced gastric lesions in rats and TAA- or CCl4-induced acute liver injury in mice. Therefore, it has been suggested that chlorin e4 may be a promising new drug candidate for anti-gastroenteritis and liver damage protection. International Publication No. 2009 / 040411 suggests the use of chlorin e4 zinc complexes in photodynamic therapy, and International Publication No. 2014 / 091241 suggests the use of chlorin e4 disodium in photodynamic therapy. [ka]
[0006] However, there is a continuing need for better photosensitizers. There is a need for compounds with high singlet oxygen quantum yields, and preferably compounds with strong photosensitizing properties in organic and aqueous media. There is also a need for compounds with high fluorescence quantum yields. Furthermore, there is a need for compounds and / or compositions that have higher phototoxicity, lower dark toxicity, good stability, good solubility, and / or are easily purified. Summary of the Invention
[0007] A first aspect of the present invention is a compound of formula (1) or a complex of formula (2): [ka] or a pharmaceutically acceptable salt thereof [In the formula, -R 1 is -CH2OR 2 , -CH2SR 2 , -CH2S(O)R 2 , -CH2S(O)2R 2 , -CHN(R 2 )2, -R 2 , -C(O)-OR 3 , -C(O)-SR 3 , -C(O)-N(R 3 )2, -C(S)-OR 3 , -C(S)-SR3 or -C(S)-N(R 3 )2 is selected; -R 2 are each independently H, -C(O)R 4 , -C(O)-OR 4 , -C(O)-SR 4 , -C(O)-N(R 4 )2, -C(S)-OR 4 , -C(S)-SR 4 , -C(S)-N(R 4 )2, -R α -H, -R β , -R α -R β , -R α -OH, -R α -OR β , -R α -SH, -R α -SR β , -R α -S(O)R β , -R α -S(O)2R β , -R α -NH2, -R α -NH(R β ), -R α -N(R β )2, -R α -X, -R α -[N(R 5 )3]Y, -R α -[P(R 5 )3]Y, -R α -[R 8 ]Y, -R α -[N(R 5 )2(R 5’ )], -R α -[P(R 5 )2(R 5’ )] or -R α -[R 8’ ] is selected from; -R 3 and -R 4 are independently -H and -R α -H, -R β , -R α -R β , -R α -OH, -R α-OR β , -R α -SH, -R α -SR β , -R α -NH2, -R α -NH(R β ), -R α -N(R β )2, -R α -X, -R α -[N(R 5 )3]Y, -R α -[P(R 5 )3]Y, -R α -[R 8 ]Y, -R α -[N(R 5 )2(R 5’ )], -R α -[P(R 5 )2(R 5’ )] or -R α -[R 8’ ] is selected from; -R α - are each independently C1-C 42 alkylene groups, which may be optionally substituted with one or more (e.g., 1, 2, 3, 4, or 5) C1-C4 alkyl, C1-C4 haloalkyl, or halo groups, and one or more (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10) carbon atoms in the backbone of the alkylene group may be optionally substituted with a heteroatom or group independently selected from O, S, NH, or NMe; -R β are each independently a saturated or unsaturated hydrocarbyl group which may be linear or branched or may be or contain a cyclic group which may be optionally substituted and which may optionally contain one or more (e.g., 1, 2, 3, 4 or 5) heteroatoms N, O, S, P or Se in its carbon skeleton; -R 5 are each independently C1-C4 alkyl, C1-C4 haloalkyl, -(CH2CH2O) n -H, -(CH2CH2O) nand —CH, phenyl, or C-C heteroaryl, where phenyl or C-C heteroaryl optionally comprises one or more (e.g., 1, 2, 3, 4, or 5) C-C alkyl, C-C haloalkyl, —O(C-C alkyl), —O(C-C haloalkyl), halo, —COH, —COZ, —CONH, —O—(CHCHO). n -H or -O-(CH2CH2O) n optionally substituted with -CH3 groups; -R 5’ is C1-C4 alkyl, C1-C4 haloalkyl, -(CH2CH2O) n -H, -(CH2CH2O) n -CH3, phenyl, or C5-C6 heteroaryl, each of which is -CO2 - and the phenyl or C5-C6 heteroaryl is optionally substituted with one or more (e.g., 1, 2, 3, or 4) C1-C6 alkyl, C1-C6 haloalkyl, —O(C1-C6 alkyl), —O(C1-C6 haloalkyl), halo, —CO2H, —CO2Z, —CO2NH2, —O—(CH2CHO) n -H or -O-(CH2CH2O) n may be further substituted with -CH3 groups; -R 6 is hydrogen, -C(O)-OR 3 , -C(O)-SR 3 , -C(O)-N(R 3 )2, -C(S)-OR 3 , -C(S)-SR 3 or -C(S)-N(R 3 )2 is selected; -R 7 is hydrogen, -C(O)-OR 3 , -C(O)-SR 3 , -C(O)-N(R 3 )2, -C(S)-OR 3 , -C(S)-SR 3 or -C(S)-N(R 3 )2 is selected; or -R 6 and -R 7and together form -C(O)-O-, -R 8 is one or more (e.g., 1, 2, 3, 4, or 5) C1-C6 alkyl, C1-C6 haloalkyl, -O(C1-C6 alkyl), -O(C1-C6 haloalkyl), halo, -CO2H, -CO2Z, -CO2NH2, -O-(CH2CH2O) n -H or -O-(CH2CH2O) n -[NC5H5] optionally substituted with -CH3 groups; -R 8’ is -CO2 - and optionally substituted with one or more (e.g., 1, 2, 3, or 4) C-C alkyl, C-C haloalkyl, —O(C-C alkyl), —O(C-C haloalkyl), halo, —COH, —COZ, —CONH, —O—(CHCHO) n -H or -O-(CH2CH2O) n -[NC5H5] further substituted with -CH3 groups; n is 1, 2, 3, 4, 5 or 6; X is a halo group; Y is a counteranion; Z is a countercation; M 2+ is a metal cation] to provide.
[0008] The first aspect of the present invention also relates to a compound of formula (I) or a complex of formula (II): [ka] or a pharmaceutically acceptable salt thereof [In the formula, -R 1 is -CH2OR 2 , -CH2SR 2 , -CH2S(O)R 2 , -CH2S(O)2R 2 , -CHN(R 2 )2, -R 2 , -C(O)-OR 3 , -C(O)-SR 3, -C(O)-N(R 3 )2, -C(S)-OR 3 , -C(S)-SR 3 or -C(S)-N(R 3 )2 is selected; -R 2 are each independently H, -C(O)R 4 , -C(O)-OR 4 , -C(O)-SR 4 , -C(O)-N(R 4 )2, -C(S)-OR 4 , -C(S)-SR 4 , -C(S)-N(R 4 )2, -R α -H, -R β , -R α -R β , -R α -OH, -R α -OR β , -R α -SH, -R α -SR β , -R α -S(O)R β , -R α -S(O)2R β , -R α -NH2, -R α -NH(R β ), -R α -N(R β )2, -R α -X, -R α -[N(R 5 )3]Y, -R α -[P(R 5 )3]Y, -R α -[R 8 ]Y, -R α -[N(R 5 )2(R 5’ )], -R α -[P(R 5 )2(R 5’ )] or -R α -[R 8’ ] is selected from; -R 3 and -R 4 are independently -H and -R α -H, -R β , -Rα -R β , -R α -OH, -R α -OR β , -R α -SH, -R α -SR β , -R α -NH2, -R α -NH(R β ), -R α -N(R β )2, -R α -X, -R α -[N(R 5 )3]Y, -R α -[P(R 5 )3]Y, -R α -[R 8 ]Y, -R α -[N(R 5 )2(R 5’ )], -R α -[P(R 5 )2(R 5’ )] or -R α -[R 8’ ] is selected from; -R α - are each independently C1-C 42 alkylene groups, which may be optionally substituted with one or more (e.g., 1, 2, 3, 4, or 5) C1-C4 alkyl, C1-C4 haloalkyl, or halo groups, and one or more (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10) carbon atoms in the backbone of the alkylene group may be optionally substituted with a heteroatom or group independently selected from O, S, NH, or NMe; -R β are each independently a saturated or unsaturated hydrocarbyl group which may be linear or branched or may be or contain a cyclic group which may be optionally substituted and which may optionally contain one or more (e.g., 1, 2, 3, 4 or 5) heteroatoms N, O, S, P or Se in its carbon skeleton; -R 5are each independently C1-C4 alkyl, C1-C4 haloalkyl, -(CH2CH2O) n -H, -(CH2CH2O) n and —CH, phenyl, or C-C heteroaryl, where phenyl or C-C heteroaryl optionally comprises one or more (e.g., 1, 2, 3, 4, or 5) C-C alkyl, C-C haloalkyl, —O(C-C alkyl), —O(C-C haloalkyl), halo, —COH, —COZ, —CONH, —O—(CHCHO). n -H or -O-(CH2CH2O) n optionally substituted with -CH3 groups; -R 5’ is C1-C4 alkyl, C1-C4 haloalkyl, -(CH2CH2O) n -H, -(CH2CH2O) n -CH3, phenyl, or C5-C6 heteroaryl, each of which is -CO2 - and the phenyl or C5-C6 heteroaryl is optionally substituted with one or more (e.g., 1, 2, 3, or 4) C1-C6 alkyl, C1-C6 haloalkyl, —O(C1-C6 alkyl), —O(C1-C6 haloalkyl), halo, —CO2H, —CO2Z, —CO2NH2, —O—(CH2CHO) n -H or -O-(CH2CH2O) n may be further substituted with -CH3 groups; -R 8 is one or more (e.g., 1, 2, 3, 4, or 5) C1-C6 alkyl, C1-C6 haloalkyl, -O(C1-C6 alkyl), -O(C1-C6 haloalkyl), halo, -CO2H, -CO2Z, -CO2NH2, -O-(CH2CH2O) n -H or -O-(CH2CH2O) n -[NC5H5] optionally substituted with -CH3 groups; -R 8’ is -CO2 -and optionally substituted with one or more (e.g., 1, 2, 3, or 4) C-C alkyl, C-C haloalkyl, —O(C-C alkyl), —O(C-C haloalkyl), halo, —COH, —COZ, —CONH, —O—(CHCHO) n -H or -O-(CH2CH2O) n -[NC5H5] further substituted with -CH3 groups; n is 1, 2, 3, 4, 5 or 6; X is a halo group; Y is a counteranion; Z is a countercation; M 2+ is a metal cation] to provide.
[0009] The first aspect of the present invention also relates to a compound of formula (I) or a complex of formula (II): [ka] [In the formula, -R 1 is -C(O)-OR 3 , -C(O)-SR 3 , -C(O)-N(R 3 )2, -C(S)-OR 3 , -C(S)-SR 3 or -C(S)-N(R 3 )2 is selected; -R 3 are independently -H and -R α -H, -R β , -R α -R β , -R α -OH, -R α -OR β , -R α -SH, -R α -SR β , -R α -NH2, -R α -NH(R β ), -R α -N(R β )2, -R α -X, -R α-[N(R 5 )3]Y, -R α -[P(R 5 )3]Y or -R α -[R 8 ] selected from Y; -R α - are each independently C1 to C 12 alkylene groups, wherein the alkylene groups can be optionally substituted with one or more C1-C4 alkyl, C1-C4 haloalkyl, or halo groups, and one or more carbon atoms in the backbone of the alkylene groups can be optionally substituted with one or more heteroatoms O or S; -R β are each independently a saturated or unsaturated hydrocarbyl group which may be linear or branched or which may be or include a cyclic group, which may be optionally substituted, and which may optionally include one or more heteroatoms N, O, S, P, and Se in its carbon skeleton; -R 5 are each independently C1-C4 alkyl, C1-C4 haloalkyl, halo, -(CH2CH2O) n -H, -(CH2CH2O) n -CH3, phenyl or C5-C6 heteroaryl, wherein said phenyl or C5-C6 heteroaryl optionally comprises one or more of C1-C4 alkyl, C1-C4 haloalkyl, -O(C1-C4 alkyl), -O(C1-C4 haloalkyl), halo, -O-(CH2CH2O) n -H or -O-(CH2CH2O) n may be substituted with -CH3 groups; -R 8 optionally one or more of C1-C4 alkyl, C1-C4 haloalkyl, -O(C1-C4 alkyl), -O(C1-C4 haloalkyl), halo, -O-(CH2CH2O) n -H or -O-(CH2CH2O) n -[NC5H5] substituted with -CH3 groups; n is 1, 2, 3 or 4; Y is a counterion; X is a halo group; M 2+ is a metal ion] or a pharmaceutically acceptable salt thereof.
[0010] The reduced phyllochlorin free acid has the structure: [ka] It has.
[0011] In one embodiment of the first aspect of the present invention, when the compound of formula (1) or (I) is reduced phyllochlorin free acid, reduced phyllochlorin methyl ester or a salt thereof, the reduced phyllochlorin free acid, reduced phyllochlorin methyl ester or a salt thereof is substantially enantiomerically pure.
[0012] In one embodiment of the first aspect of the invention, the compound of formula (1) or (I) is not reduced phyllochlorin free acid, reduced phyllochlorin iron salt, reduced phyllochlorin copper salt, or reduced phyllochlorin methyl ester.
[0013] In one embodiment of the first aspect of the invention, the compound of formula (1) or (I) is not reduced phyllochlorin free acid, reduced phyllochlorin methyl ester or a salt thereof.
[0014] A second aspect of the present invention relates to a compound of formula (1) or a complex of formula (2): [ka] or a pharmaceutically acceptable salt thereof [In the formula, -R 1 is -CH2OR 2 , -CH2SR 2 , -CH2S(O)R 2 , -CH2S(O)2R 2 , -CHN(R 2 )2, -R 2 , -C(O)-OR3 , -C(O)-SR 3 , -C(O)-N(R 3 )2, -C(S)-OR 3 , -C(S)-SR 3 or -C(S)-N(R 3 )2 is selected; -R 2 are each independently H, -C(O)R 4 , -C(O)-OR 4 , -C(O)-SR 4 , -C(O)-N(R 4 )2, -C(S)-OR 4 , -C(S)-SR 4 , -C(S)-N(R 4 )2, -R α -H, -R β , -R α -R β , -R α -OH, -R α -OR β , -R α -SH, -R α -SR β , -R α -S(O)R β , -R α -S(O)2R β , -R α -NH2, -R α -NH(R β ), -R α -N(R β )2, -R α -X, -R α -[N(R 5 )3]Y, -R α -[P(R 5 )3]Y, -R α -[R 8 ]Y, -R α -[N(R 5 )2(R 5’ )], -R α -[P(R 5 )2(R 5’ )] or -R α -[R 8’ ] is selected from; -R 3 and -R 4 are independently -H and -Rα -H, -R β , -R α -R β , -R α -OH, -R α -OR β , -R α -SH, -R α -SR β , -R α -NH2, -R α -NH(R β ), -R α -N(R β )2, -R α -X, -R α -[N(R 5 )3]Y, -R α -[P(R 5 )3]Y, -R α -[R 8 ]Y, -R α -[N(R 5 )2(R 5’ )], -R α -[P(R 5 )2(R 5’ )] or -R α -[R 8’ ] is selected from; -R α - are each independently C1-C 42 alkylene groups, which may be optionally substituted with one or more (e.g., 1, 2, 3, 4, or 5) C1-C4 alkyl, C1-C4 haloalkyl, or halo groups, and one or more (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10) carbon atoms in the backbone of the alkylene group may be optionally substituted with a heteroatom or group independently selected from O, S, NH, or NMe; -R β are each independently a saturated or unsaturated hydrocarbyl group which may be linear or branched or may be or contain a cyclic group which may be optionally substituted and which may optionally contain one or more (e.g., 1, 2, 3, 4 or 5) heteroatoms N, O, S, P or Se in its carbon skeleton; -R 5are each independently C1-C4 alkyl, C1-C4 haloalkyl, -(CH2CH2O) n -H, -(CH2CH2O) n and —CH, phenyl, or C-C heteroaryl, where phenyl or C-C heteroaryl optionally comprises one or more (e.g., 1, 2, 3, 4, or 5) C-C alkyl, C-C haloalkyl, —O(C-C alkyl), —O(C-C haloalkyl), halo, —COH, —COZ, —CONH, —O—(CHCHO). n -H or -O-(CH2CH2O) n optionally substituted with -CH3 groups; -R 5’ is C1-C4 alkyl, C1-C4 haloalkyl, -(CH2CH2O) n -H, -(CH2CH2O) n -CH3, phenyl, or C5-C6 heteroaryl, each of which is -CO2 - and the phenyl or C5-C6 heteroaryl is optionally substituted with one or more (e.g., 1, 2, 3, or 4) C1-C6 alkyl, C1-C6 haloalkyl, —O(C1-C6 alkyl), —O(C1-C6 haloalkyl), halo, —CO2H, —CO2Z, —CO2NH2, —O—(CH2CHO) n -H or -O-(CH2CH2O) n may be further substituted with -CH3 groups; -R 6 is hydrogen, -C(O)-OR 3 , -C(O)-SR 3 , -C(O)-N(R 3 )2, -C(S)-OR 3 , -C(S)-SR 3 or -C(S)-N(R 3 )2 is selected; -R 7 is hydrogen, -C(O)-OR 3 , -C(O)-SR 3 , -C(O)-N(R 3 )2, -C(S)-OR 3 , -C(S)-SR 3 or -C(S)-N(R3 )2 is selected; or -R 6 and -R 7 and together form -C(O)-O-, -R 8 is one or more (e.g., 1, 2, 3, 4, or 5) C1-C6 alkyl, C1-C6 haloalkyl, -O(C1-C6 alkyl), -O(C1-C6 haloalkyl), halo, -CO2H, -CO2Z, -CO2NH2, -O-(CH2CH2O) n -H or -O-(CH2CH2O) n -[NC5H5] optionally substituted with -CH3 groups; -R 8’ is -CO2 - and optionally substituted with one or more (e.g., 1, 2, 3, or 4) C-C alkyl, C-C haloalkyl, —O(C-C alkyl), —O(C-C haloalkyl), halo, —COH, —COZ, —CONH, —O—(CHCHO) n -H or -O-(CH2CH2O) n -[NC5H5] further substituted with -CH3 groups; n is 1, 2, 3, 4, 5 or 6; X is a halo group; Y is a counteranion; Z is a countercation; M 2+ is a metal cation] to provide.
[0015] A second aspect of the present invention also relates to a compound of formula (I) or a complex of formula (II) for use in medicine: [ka] or a pharmaceutically acceptable salt thereof [In the formula, -R 1 is -CH2OR 2 , -CH2SR 2 , -CH2S(O)R 2 , -CH2S(O)2R 2 , -CHN(R2 )2, -R 2 , -C(O)-OR 3 , -C(O)-SR 3 , -C(O)-N(R 3 )2, -C(S)-OR 3 , -C(S)-SR 3 or -C(S)-N(R 3 )2 is selected; -R 2 are each independently H, -C(O)R 4 , -C(O)-OR 4 , -C(O)-SR 4 , -C(O)-N(R 4 )2, -C(S)-OR 4 , -C(S)-SR 4 , -C(S)-N(R 4 )2, -R α -H, -R β , -R α -R β , -R α -OH, -R α -OR β , -R α -SH, -R α -SR β , -R α -S(O)R β , -R α -S(O)2R β , -R α -NH2, -R α -NH(R β ), -R α -N(R β )2, -R α -X, -R α -[N(R 5 )3]Y, -R α -[P(R 5 )3]Y, -R α -[R 8 ]Y, -R α -[N(R 5 )2(R 5’ )], -R α -[P(R 5 )2(R 5’ )] or -R α -[R 8’ ] is selected from; -R3 and -R 4 are independently -H and -R α -H, -R β , -R α -R β , -R α -OH, -R α -OR β , -R α -SH, -R α -SR β , -R α -NH2, -R α -NH(R β ), -R α -N(R β )2, -R α -X, -R α -[N(R 5 )3]Y, -R α -[P(R 5 )3]Y, -R α -[R 8 ]Y, -R α -[N(R 5 )2(R 5’ )], -R α -[P(R 5 )2(R 5’ )] or -R α -[R 8’ ] is selected from; -R α - are each independently C1-C 42 alkylene groups, which may be optionally substituted with one or more (e.g., 1, 2, 3, 4, or 5) C1-C4 alkyl, C1-C4 haloalkyl, or halo groups, and one or more (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10) carbon atoms in the backbone of the alkylene group may be optionally substituted with a heteroatom or group independently selected from O, S, NH, or NMe; -R βare each independently a saturated or unsaturated hydrocarbyl group which may be linear or branched or may be or contain a cyclic group which may be optionally substituted and which may optionally contain one or more (e.g., 1, 2, 3, 4 or 5) heteroatoms N, O, S, P or Se in its carbon skeleton; -R 5 are each independently C1-C4 alkyl, C1-C4 haloalkyl, -(CH2CH2O) n -H, -(CH2CH2O) n and —CH, phenyl, or C-C heteroaryl, where phenyl or C-C heteroaryl optionally comprises one or more (e.g., 1, 2, 3, 4, or 5) C-C alkyl, C-C haloalkyl, —O(C-C alkyl), —O(C-C haloalkyl), halo, —COH, —COZ, —CONH, —O—(CHCHO). n -H or -O-(CH2CH2O) n optionally substituted with -CH3 groups; -R 5’ is C1-C4 alkyl, C1-C4 haloalkyl, -(CH2CH2O) n -H, -(CH2CH2O) n -CH3, phenyl, or C5-C6 heteroaryl, each of which is -CO2 - and the phenyl or C5-C6 heteroaryl is optionally substituted with one or more (e.g., 1, 2, 3, or 4) C1-C6 alkyl, C1-C6 haloalkyl, —O(C1-C6 alkyl), —O(C1-C6 haloalkyl), halo, —CO2H, —CO2Z, —CO2NH2, —O—(CH2CHO) n -H or -O-(CH2CH2O) n may be further substituted with -CH3 groups; -R 8is one or more (e.g., 1, 2, 3, 4, or 5) C1-C6 alkyl, C1-C6 haloalkyl, -O(C1-C6 alkyl), -O(C1-C6 haloalkyl), halo, -CO2H, -CO2Z, -CO2NH2, -O-(CH2CH2O) n -H or -O-(CH2CH2O) n -[NC5H5] optionally substituted with -CH3 groups; -R 8’ is -CO2 - and optionally substituted with one or more (e.g., 1, 2, 3, or 4) C-C alkyl, C-C haloalkyl, —O(C-C alkyl), —O(C-C haloalkyl), halo, —COH, —COZ, —CONH, —O—(CHCHO) n -H or -O-(CH2CH2O) n -[NC5H5] further substituted with -CH3 groups; n is 1, 2, 3, 4, 5 or 6; X is a halo group; Y is a counteranion; Z is a countercation; M 2+ is a metal cation] Provides for the use of
[0016] A second aspect of the present invention also relates to a compound of formula (I) or a complex of formula (II) for use in medicine: [ka] [In the formula, -R 1 is -C(O)-OR 3 , -C(O)-SR 3 , -C(O)-N(R 3 )2, -C(S)-OR 3 , -C(S)-SR 3 or -C(S)-N(R 3 )2 is selected; -R 3 are independently -H and -R α -H, -R β , -R α-R β , -R α -OH, -R α -OR β , -R α -SH, -R α -SR β , -R α -NH2, -R α -NH(R β ), -R α -N(R β )2, -R α -X, -R α -[N(R 5 )3]Y, -R α -[P(R 5 )3]Y or -R α -[R 8 ] selected from Y; -R α - are each independently C1 to C 12 alkylene groups, wherein the alkylene groups can be optionally substituted with one or more C1-C4 alkyl, C1-C4 haloalkyl, or halo groups, and one or more carbon atoms in the backbone of the alkylene groups can be optionally substituted with one or more heteroatoms O or S; -R β are each independently a saturated or unsaturated hydrocarbyl group which may be linear or branched or which may be or include a cyclic group, which may be optionally substituted, and which may optionally include one or more heteroatoms N, O, S, P, and Se in its carbon skeleton; -R 5 are each independently C1-C4 alkyl, C1-C4 haloalkyl, halo, -(CH2CH2O) n -H, -(CH2CH2O) n -CH3, phenyl or C5-C6 heteroaryl, wherein said phenyl or C5-C6 heteroaryl optionally comprises one or more of C1-C4 alkyl, C1-C4 haloalkyl, -O(C1-C4 alkyl), -O(C1-C4 haloalkyl), halo, -O-(CH2CH2O) n -H or -O-(CH2CH2O)n may be substituted with -CH3 groups; -R 8 optionally one or more of C1-C4 alkyl, C1-C4 haloalkyl, -O(C1-C4 alkyl), -O(C1-C4 haloalkyl), halo, -O-(CH2CH2O) n -H or -O-(CH2CH2O) n -[NC5H5] substituted with -CH3 groups; n is 1, 2, 3 or 4; Y is a counterion; X is a halo group; M 2+ is a metal ion] or a pharmaceutically acceptable salt thereof provide.
[0017] In some embodiments of the second aspect of the invention, the compound is (1) reduced phyllochlorin free acid; or (2) Reduced phyllochlorin methyl ester.
[0018] In one embodiment of the first or second aspect of the invention, the compound of formula (1), (2), (I), (II), (III), (IV), (V), (VI), (VII) or (VIII) is: (i) reduced phyllochlorin free acid; (ii) reduced phyllochlorin iron salt; (iii) reduced phyllochlorin copper salt; (iv) reduced phyllochlorin methyl ester; (v) 3-(13,18-diethyl-2,5,8,12,17pentamethyl-7H,8H-porphyrin-7-yl)propanoate zinc complex; (vi) 3-(13,18-diethyl-2,5,8,12,17pentamethyl-7H,8H-porphyrin-7-yl)propanoic acid zinc complex; (vii) (7-(3-((carboxymethyl)amino)-3-oxopropyl)-13,18-diethyl-2,5,8,12,17pentamethyl-7H,8H-porphyrin-3-carbonyl)glycine; (viii) 3-(7-(3-((carboxymethyl)amino)-3-oxopropyl)-13,18-diethyl-2,5,8,12,17pentamethyl-7H,8H-porphyrin-3-carboxamido)propanoic acid; (ix) (7-(3-((1-carboxyethyl)amino)-3-oxopropyl)-13,18-diethyl-2,5,8,12,17pentamethyl-7H,8H-porphyrin-3-carbonyl)alanine; or any of its enantiomers; or a racemic mixture of either; Or any of its salts.
[0019] In one embodiment of the first or second aspect of the invention, -R 1 , -R 6 and -R 7 is -CO2H, -CO2Me or -CONHR 3 are not selected at the same time.
[0020] In one embodiment of the first or second aspect of the invention, -R 1 and -R 7 If both are -CO2Me, then -R 6 is not -CO-NMe2.
[0021] In one embodiment of the first or second aspect of the present invention, in the compound of formula (1) or (2), -R 6 is hydrogen, and -R 7 is hydrogen.
[0022] In one embodiment of the first or second aspect of the present invention, in the compound of formula (1) or (2), -R 6 is -CO2H and -R 7 is hydrogen.
[0023] In one embodiment of the first or second aspect of the present invention, in the compound of formula (1) or (2), -R 6 is -CO2H and -R 7 is -CO2H.
[0024] In one embodiment of the first or second aspect of the present invention, in the compound of formula (1) or (2), -R 6 and -R 7 together to form -C(O)-O-.
[0025] In the context of this specification, a "hydrocarbyl" substituent or hydrocarbyl moiety in a substituent contains only carbon and hydrogen atoms, but does not include any heteroatoms such as N, O, S, P, or Se in its carbon skeleton, unless otherwise specified. Hydrocarbyl groups / moieties can be saturated or unsaturated (including aromatic), straight or branched chain, or can be or include cyclic groups, and unless otherwise specified, cyclic groups do not include heteroatoms such as N, O, S, P, or Se in its carbon skeleton. Examples of hydrocarbyl groups include alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, and aryl groups / moieties, and all combinations of these groups / moieties. Typically, hydrocarbyl groups are C1-C 60 Hydrocarbyl groups, more typically C1-C 40 Hydrocarbyl groups, more typically C1-C 20 More typically, the hydrocarbyl group is a C1-C 12 More typically, the hydrocarbyl group is a C1-C 10 A "hydrocarbylene" group is defined as a divalent hydrocarbyl group.
[0026] An "alkyl" substituent or alkyl moiety in a substituent can be linear (i.e., straight-chain) or branched. Examples of alkyl groups / moieties include methyl, ethyl, n-propyl, i-propyl, n-butyl, i-butyl, t-butyl, and n-pentyl groups / moieties. Unless otherwise specified, the term "alkyl" does not include "cycloalkyl." Typically, alkyl groups are C1-C6 12 It is an alkyl group. More typically, the alkyl group is a C1-C6 alkyl group. An "alkylene" group is defined similarly as a divalent alkyl group.
[0027] An "alkenyl" substituent or alkenyl moiety in a substituent refers to an unsaturated alkyl group or moiety having one or more carbon-carbon double bonds. Examples of alkenyl groups / moieties include ethenyl, propenyl, 1-butenyl, 2-butenyl, 1-pentenyl, 1-hexenyl, 1,3-butadienyl, 1,3-pentadienyl, 1,4-pentadienyl, and 1,4-hexadienyl groups / moieties. Unless otherwise specified, the term "alkenyl" does not include "cycloalkenyl." Typically, alkenyl groups are C2-C6 12 It is an alkenyl group. More typically, the alkenyl group is a C2-C6 alkenyl group. An "alkenylene" group is defined similarly as a divalent alkenyl group.
[0028] An "alkynyl" substituent or alkynyl moiety in a substituent refers to an unsaturated alkyl group or moiety having one or more carbon-carbon triple bonds. Examples of alkynyl groups / moieties include ethynyl, propargyl, but-1-ynyl, and but-2-ynyl. Typically, alkynyl groups are C2-C 12 It is an alkynyl group. More typically, the alkynyl group is a C2-C6 alkynyl group. An "alkynylene" group is defined similarly as a divalent alkynyl group.
[0029] A "cyclic" substituent or cyclic moiety in a substituent refers to any hydrocarbyl ring, which may be saturated or unsaturated (including aromatic) and may contain one or more heteroatoms, such as N, O, S, P, or Se, in its carbon skeleton. Examples of cyclic groups include cycloalkyl, cycloalkenyl, heterocyclic, aryl, and heteroaryl groups, discussed below. Cyclic groups may be monocyclic, bicyclic (e.g., bridged, fused, or spiro), or polycyclic. Typically, cyclic groups are 3- to 12-membered cyclic groups, meaning they contain 3 to 12 ring atoms. More typically, cyclic groups are 3- to 7-membered monocyclic groups, meaning they contain 3 to 7 ring atoms.
[0030] A "heterocyclic" substituent or heterocyclic moiety in a substituent refers to a cyclic group or moiety that includes one or more carbon atoms and one or more (e.g., 1, 2, 3, or 4) heteroatoms, such as N, O, S, P, or Se, in the ring structure. Examples of heterocyclic groups include the heteroaryl groups discussed below, as well as non-aromatic heterocyclic groups such as azetidinyl, azetinyl, tetrahydrofuranyl, pyrrolidinyl, tetrahydrothiophenyl, tetrahydropyranyl, piperidinyl, piperazinyl, morpholinyl, thiomorpholinyl, oxetanyl, thietanyl, pyrazolidinyl, imidazolidinyl, dioxolanyl, oxathiolanyl, thianyl, and dioxanyl groups.
[0031] A "cycloalkyl" substituent or cycloalkyl moiety in a substituent refers to a saturated hydrocarbyl ring containing, for example, 3 to 7 carbon atoms, examples of which include cyclopropyl, cyclobutyl, cyclopentyl, and cyclohexyl. Unless otherwise specified, a cycloalkyl substituent or moiety can include monocyclic, bicyclic, or polycyclic hydrocarbyl rings.
[0032] A "cycloalkenyl" substituent or cycloalkenyl moiety in a substituent refers to a non-aromatic unsaturated hydrocarbyl ring having one or more carbon-carbon double bonds and containing, for example, 3 to 7 carbon atoms, examples of which include cyclopent-1-en-1-yl, cyclohex-1-en-1-yl, and cyclohexa-1,3-dien-1-yl. Unless otherwise specified, a cycloalkenyl substituent or moiety can include monocyclic, bicyclic, or polycyclic hydrocarbyl rings.
[0033] An "aryl" substituent or aryl moiety in a substituent refers to an aromatic hydrocarbyl ring. The term "aryl" includes monocyclic aromatic hydrocarbons and polycyclic fused-ring aromatic hydrocarbons, in which all of the fused ring systems (excluding ring systems that are part of or formed by any substituent) are aromatic. Examples of aryl groups / moieties include phenyl, naphthyl, anthracenyl, and phenanthrenyl. Unless otherwise specified, the term "aryl" does not include "heteroaryl."
[0034] A "heteroaryl" substituent or heteroaryl moiety in a substituent refers to an aromatic heterocyclic group or moiety. The term "heteroaryl" includes monocyclic aromatic heterocycles and polycyclic fused-ring aromatic heterocycles, in which all of the fused ring systems (excluding ring systems that are part of or formed by any substituent) are aromatic. Examples of heteroaryl groups / moieties include: [ka] where G=O, S or NH.
[0035] For purposes of this specification, when a combination of moieties is referred to as a group, e.g., arylalkyl, arylalkenyl, arylalkynyl, alkylaryl, alkenylaryl, or alkynylaryl, the last-mentioned moiety includes the atom by which the group is attached to the remainder of the molecule. An example of an arylalkyl group is benzyl.
[0036] For purposes of this specification, an optionally substituted group or moiety (—R β etc.): (i) each hydrogen atom is optionally replaced by halo; -CN; -NO; -N; -R x ;-OH;-OR x ;-R y -Haro;-R y -CN;-R y -NO2;-R y -N3;-R y -R x ;-R y -OH;-R y -OR x ;-SH;-SR x ;-SOR x ;-SO2H;-SO2R x ;-SO2NH2;-SO2NHR x ;-SO2N(R x )2;-R y -SH;-R y -SR x ;-R y-SOR x ;-R y -SO2H;-R y -SO2R x ;-R y -SO2NH2;-R y -SO2NHR x ;-R y -SO2N(R x )2;-NH2;-NHR x ;-N(R x )2;-N + (R x )3;-R y -NH2;-R y -NHR x ;-R y -N(R x )2;-R y -N + (R x )3;-CHO;-COR x ;-COOH;-COOR x ;-OCOR x ;-R y -CHO;-R y -COR x ;-R y -COOH;-R y -COOR x Or -R y -OCOR x and / or (ii) Any two hydrogen atoms attached to the same carbon atom are oxo (=O), =S, =NH, or =NR x and / or (iii) Any two hydrogen atoms bonded to the same or different atoms within the same optionally substituted group or moiety may be replaced by —O—, —S—, —NH—, —N(R x )-, -N + (R x )2- or -R y -, and optionally substituted with a bridging substituent independently selected from where each -R y- is independently selected from an alkylene, alkenylene, or alkynylene group which contains 1 to 6 atoms in its backbone; one or more carbon atoms in the backbone of an alkylene, alkenylene, or alkynylene group can optionally be replaced with one or more heteroatoms N, O, or S; and the alkylene, alkenylene, or alkynylene group can optionally contain one or more halo and / or -R x may be substituted with a group; and Each-R x are independently selected from C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, or C2-C6 cyclic groups, or any two or three -R attached to the same nitrogen atom x may form a C2-C7 cyclic group together with the nitrogen atom to which they are attached, and any -R x can be optionally substituted with one or more C1-C4 alkyl, C1-C4 haloalkyl, —O(C1-C4 alkyl), —O(C1-C4 haloalkyl), halo, —OH, —NH2, —CN, or oxo (═O) groups.
[0037] Typically, the substituents include 1, 2, 3 or 4 substituents, more typically 1, 2 or 3 substituents, more typically 1 or 2 substituents, more typically 1 substituent.
[0038] Unless otherwise specified, any divalent bridging substituent (e.g., —O—, —S—, —NH—, —N(R x )-, -N + (R x )2- or -R y -) or moiety must be attached only to the specified group or moiety and cannot be attached to a second group or moiety, even if the second group or moiety itself may be optionally substituted.
[0039] The term "halo" includes fluoro, chloro, bromo and iodo.
[0040] Unless otherwise specified, when a group is prefixed with the term "halo," such as a haloalkyl or halomethyl group, it is understood that the group in question is substituted with one or more halo groups independently selected from fluoro, chloro, bromo, and iodo. Typically, the maximum number of halo substituents is limited only by the number of hydrogen atoms available for substitution in the corresponding group without the halo prefix. For example, a halomethyl group may contain one, two, or three halo substituents. A haloethyl or halophenyl group may contain one, two, three, four, or five halo substituents. Similarly, unless otherwise specified, when a group begins with a particular halo group, it is understood that the group in question is substituted with one or more of the specified halo groups. For example, the term "fluoromethyl" refers to a methyl group substituted with one, two, or three fluoro groups.
[0041] Unless otherwise specified, when a group is referred to as "halo-substituted," it is understood that the group in question is substituted with one or more halo groups independently selected from fluoro, chloro, bromo, and iodo. Typically, the maximum number of halo substituents is limited only by the number of hydrogen atoms available for substitution in the group referred to as halo-substituted. For example, a halo-substituted methyl group may contain one, two, or three halo substituents. A halo-substituted ethyl or halo-substituted phenyl group may contain one, two, three, four, or five halo substituents.
[0042] Unless otherwise specified, a reference to an element is considered to be a reference to all isotopes of that element, so for example, unless otherwise specified, a reference to hydrogen is considered to encompass all isotopes of hydrogen, including deuterium and tritium.
[0043] Unless otherwise stated, a reference to a compound or group should be understood to refer to all tautomeric forms of that compound or group.
[0044] When referring to a hydrocarbyl or other group that contains one or more heteroatoms N, O, S, P or Se in its carbon skeleton, or to a carbon atom of a hydrocarbyl or other group that is substituted by an N, O, S, P or Se atom, what is intended is: [ka] is replaced by; -CH2- is replaced by -NH-, -PH-, -O-, -S- or -Se-; -CH3 is replaced by -NH2, -PH2, -OH, -SH, or -SeH; -CH= is replaced by -N= or -P=; -CH2- is replaced by -NH-, -PH-, -O-, -S- or -Se-; or CH≡ is replaced by N≡ or P≡; provided that the resulting group contains at least one carbon atom. For example, methoxy, dimethylamino, and aminoethyl groups are considered to be hydrocarbyl groups containing one or more heteroatoms N, O, S, P, or Se in their carbon skeleton.
[0045] In the context of this specification, unless otherwise stated, C x ~C y A group is defined as a group containing x to y carbon atoms. For example, a C1-C4 alkyl group is defined as an alkyl group containing 1 to 4 carbon atoms. When calculating the total number of carbon atoms in a parent group, including any substituted and / or moieties, optional substituents and moieties are not taken into account. For the avoidance of doubt, substituted heteroatoms, e.g., N, O, S, P, or Se, are not included in the C x ~C y When calculating the number of carbon atoms in a group, they should be counted as carbon atoms. For example, a morpholinyl group should be considered a C6 heterocyclic group, not a C4 heterocyclic group.
[0046] Because the pi electrons of the chlorin ring are delocalized, the chlorin ring can be represented by multiple resonance structures. Resonance structures are different ways of depicting the same compound. Two of the resonance structures of the chlorin ring are shown directly below: [ka]
[0047] Typically, a complex contains a central metal atom or ion, known as a coordination center, and a binding molecule or ion, known as a ligand. Typically, a complex contains a central metal atom or ion, known as a coordination center, and a binding molecule or ion, known as a ligand. Herein, the bond between the coordination center and the ligand is represented as shown in the complex below on the left (the attraction between the anionic ligand and the central metal cation is represented by four dashed lines), but equivalently, it can be represented as shown in the complex below on the right (the attraction between the ligand molecule and the central metal atom is represented by two covalent bonds and two dashed lines): [ka]
[0048] As used herein, -[NC5H5]Y refers to: [ka]
[0049] In one embodiment of the first or second aspect of the invention, X is a halo group selected from fluoro, chloro, bromo, or iodo. In one embodiment, X is chloro or bromo.
[0050] In one embodiment of the first or second aspect of the present invention, there is provided a compound of formula (I):
[0051] In one embodiment of the first or second aspect of the invention, Y is a halide (e.g., fluoride, chloride, bromide, or iodide) or other inorganic anion (e.g., bisulfate, hexafluorophosphate (PF6), nitrate, perchlorate, phosphate, or sulfate) or an organic anion (e.g., acetate, ascorbate, aspartate, benzoate, besylate (benzenesulfonate), bicarbonate, bis(trifluoromethanesulfonyl)imide (TFSI), tartrate, butyrate, camsylate (camphorsulfonate), carbonate, citrate, decanoate, edetate, esylate (ethanesulfonate), fumarate, galactarate, gluceptate, gluconate, glutamate, glycolate, hexanoate, β-hydroxybutyrate, 2-hydroxyethanesulfonate, hydroxypropyl methyl acrylate ... and the counter anion is selected from the group consisting of roximaleate, hydroxynaphthoate, isethionate, lactate, lactobionate, malate, maleate, mandelate, mesylate (methanesulfonate), methylsulfate, mucate, napsylate (naphthalene-2-sulfonate), octanoate, oleate, ornithine, pamoate, pantothenate, polygalacturonate, propanoate, propionate, salicylate, stearate, succinate, tartrate, teoclate, tetrakis[3,5-bis(trifluoromethyl)phenyl]borate (BARF), tetrakis(pentafluorophenyl)borate (F5-TPB), tetraphenylborate (TPB), tosylate (toluene-p-sulfonate), or triflate (trifluoromethanesulfonate).
[0052] In another embodiment of the first or second aspect of the invention, Y is a halide (e.g., fluoride, chloride, bromide, or iodide) or other inorganic anion (e.g., bisulfate, nitrate, perchlorate, phosphate, or sulfate) or an organic anion (e.g., acetate, aspartate, benzoate, besylate (benzenesulfonate), butyrate, camsylate (camphorsulfonate), citrate, esylate (ethanesulfonate), fumarate, galactarate, gluconate, or the like). , glutamate, glycolate, 2-hydroxyethanesulfonate, hydroxymaleate, lactate, malate, maleate, mandelate, mesylate (methanesulfonate), napsylate (naphthalene-2-sulfonate), ornithine, pamoate, pantothenate, propanoate, salicylate, succinate, tartrate, tosylate (toluene-p-sulfonate), or triflate (trifluoromethanesulfonate). In one embodiment, Y is fluoride, chloride, bromide, or iodide. In one embodiment, Y is chloride or bromide.
[0053] In one embodiment of the first or second aspect of the invention, Z is a counter cation selected from an inorganic cation (e.g., lithium, sodium, potassium, magnesium, calcium, or ammonium cation) or an organic cation (e.g., an amine cation (e.g., choline or meglumine cation) or an amino acid cation (e.g., arginine cation).
[0054] In one embodiment of the first or second aspect of the invention, M 2+ Zn 2+ , Cu 2+ , Fe 2+ , Pd 2+ or Pt 2+ In one embodiment, M 2+ is Zn 2+ is.
[0055] In one embodiment of the first or second aspect of the invention, -R 1is -C(O)-OR 3 , -C(O)-SR 3 , -C(O)-N(R 3 )2, -C(S)-OR 3 , -C(S)-SR 3 or -C(S)-N(R 3 )2. In one embodiment, -R 1 is -C(O)-OR 3 , -C(O)-SR 3 , -C(O)-N(R 3 )2 or -C(S)-N(R 3 )2. In one embodiment, -R 1 is -C(O)-OR 3 , -C(O)-SR 3 or -C(O)-N(R 3 )2 is selected.
[0056] In one embodiment of the first or second aspect of the invention, -R 1 is -C(O)-OR 3 , -C(O)-SR 3 , -C(O)-N(R 3 )2, -C(S)-OR 3 , -C(S)-SR 3 or -C(S)-N(R 3 )2, each of which is selected from -R 3 is C1-C4 alkyl (preferably methyl). In one embodiment, -R 1 is -C(O)-OR 3 , -C(O)-SR 3 , -C(O)-N(R 3 )2 or -C(S)-N(R 3 )2, each of which is selected from -R 3 is C1-C4 alkyl (preferably methyl). In one embodiment, -R 1 is -C(O)-OR 3 , -C(O)-SR 3 or -C(O)-N(R 3 )2, each of which is selected from -R 3 is C1-C4 alkyl (preferably methyl). In one embodiment, -R 1 -C(O)-OR 3and -R 3 is C1-C4 alkyl (preferably methyl).
[0057] In one embodiment of the first or second aspect of the invention, -R 1 is -C(O)-OR 3 , -C(O)-SR 3 , -C(O)-N(R 3 )2, -C(S)-OR 3 , -C(S)-SR 3 or -C(S)-N(R 3 )2, each of which is selected from -R 3 -R α -OR β or -R α -SR β -R β is a saccharidyl group. In one embodiment, -R 1 is -C(O)-OR 3 , -C(O)-SR 3 or -C(O)-N(R 3 )2, each of which is selected from -R 3 -R α -OR β or -R α -SR β -R β is a saccharidyl group. In one embodiment, -R 1 is -C(O)-OR 3 or -C(O)-SR 3 -R 3 -R α -OR β or -R α -SR β -R β is a saccharidyl group. Typically, in these embodiments, -R α - is C1-C 12 an alkylene group (preferably a C1-C8 alkylene group or a C1-C6 alkylene group), —(CH2CH2O) m -CH2CH2- group or -(CH2CH2S) m a —CH 2 CH 2 — group, all optionally substituted, and m is 1, 2, 3, or 4.
[0058] In one embodiment of the first or second aspect of the invention, -R 1 -R 2 , -C(O)-OR 3 , -C(O)-SR 3 , -C(O)-N(R 3 )2, -C(O)-N(R 3 )(R 3’ ), -C(S)-OR 3 , -C(S)-SR 3 , -C(S)-N(R 3 )2 or -C(S)-N(R 3 )(R 3’ ), where -R 2 or -R 3 -R α -OR β , -R α -SR β , -R α -S(O)R β or -R α -S(O)2R β -R β is a saccharidyl group, and -R 3’ is H or C1-C4 alkyl (preferably methyl). In one embodiment, -R 1 is -C(O)-OR 3 , -C(O)-SR 3 , -C(O)-N(R 3 )(R 3’ ) or -C(S)-N(R 3 )(R 3’ ), where -R 3 -R α -OR β or -R α -SR β -R β is a saccharidyl group, and -R 3’ is H or C1-C4 alkyl (preferably methyl). In one embodiment, -R 1 is -C(O)-N(R 3 )(R 3’ ) where -R 3 -R α -ORβ or -R α -SR β -R β is a saccharidyl group, and -R 3’ is H or C1-C4 alkyl (preferably methyl). Typically, in these embodiments, -R α - is C1-C 12 alkylene groups, wherein 1, 2, 3, or 4 carbon atoms in the backbone of the alkylene group are optionally replaced with heteroatoms or groups independently selected from O, S, NH, or NMe. Alternatively, in these embodiments, -R α - is C1-C 12 an alkylene group (preferably a C1-C8 alkylene group or a C1-C6 alkylene group), —(CH2CH2O) m -CH2CH2- group or -(CH2CH2S) m a —CH 2 CH 2 — group, all of which are optionally substituted, where m is 1, 2, 3, or 4.
[0059] In one embodiment of the first or second aspect of the invention, -R 1 -R 2 , -C(O)-OR 3 , -C(O)-SR 3 , -C(O)-N(R 3 )(R 3’ ) or -C(S)-N(R 3 )(R 3’ ), where -R 2 or -R 3 -R α -OR β , -R α -SR β , -R α -S(O)R β or -R α -S(O)2R β -R β is a saccharidyl group, and -R 3’ is H or C1-C4 alkyl (preferably methyl). In one embodiment, -R 1 is -C(O)-OR 3, -C(O)-SR 3 , -C(O)-N(R 3 )(R 3’ ) or -C(S)-N(R 3 )(R 3’ ), where -R 3 -R α -OR β , -R α -SR β , -R α -S(O)R β or -R α -S(O)2R β -R β is a saccharidyl group, and -R 3’ is H or C1-C4 alkyl (preferably methyl). In one embodiment, -R 1 is -C(O)-N(R 3 )(R 3’ ) where -R 3 Ha-R α -OR β , -R α -SR β , -R α -S(O)R β or -R α -S(O)2R β -R β is a saccharidyl group, and -R 3’ is H or C1-C4 alkyl (preferably methyl). In one embodiment, -R 1 is -C(O)-N(R 3 )(R 3’ ) where -R 3 -R α -OR β or -R α -SR β -R β is a saccharidyl group, and -R 3’ is H or C1-C4 alkyl (preferably methyl). In one embodiment, -R 1 is -C(O)-N(R 3 )(R 3’ ) and -R 3 -R α -OR β , -Rα -SR β , -R α -S(O)R β or -R α -S(O)2R β -R β is a saccharidyl group, and -R 3’ is C1-C4 alkyl (preferably methyl). In one embodiment, -R 1 is -C(O)-N(R 3 )(R 3’ ) where -R 3 Ha-R α -OR β or -R α -SR β -R β is a saccharidyl group, and -R 3’ is C1-C4 alkyl (preferably methyl). Typically, in these embodiments, -R α - is C1-C 12 alkylene groups, wherein 1, 2, 3, or 4 carbon atoms in the backbone of the alkylene group are optionally replaced with heteroatoms or groups independently selected from O, S, NH, or NMe. Alternatively, in these embodiments, -R α - is C1-C 12 an alkylene group (preferably a C1-C8 alkylene group or a C1-C6 alkylene group), —(CH2CH2O) m -CH2CH2- group or -(CH2CH2S) m a —CH 2 CH 2 — group, all of which are optionally substituted, where m is 1, 2, 3, or 4.
[0060] -R 3’ The group is another -R 3 -R bonded to the same atom as the group 3 -R refers to the group 3 and -R 3’ may be the same or different. Preferably, -R 3 and -R 3’ is different.
[0061] In one embodiment of the first or second aspect of the invention, -R 1 -R 2 , -C(O)-OR 3 , -C(O)-SR 3 , -C(O)-N(R 3 )2, -C(O)-N(R 3 )(R 3’ ), -C(S)-OR 3 , -C(S)-SR 3 , -C(S)-N(R 3 )2 or C(S)-N(R 3 )(R 3’ ) wherein -R 2 or -R 3 -R α -R β or -R β -R β is a saccharidyl group, and -R 3’ is H or C1-C4 alkyl (preferably methyl). In one embodiment, -R 1 -C(O)-OR 3 , -C(O)-SR 3 , -C(O)-N(R 3 )(R 3’ ) or -C(S)-N(R 3 )(R 3’ ) wherein -R 3 Ha-R α -R β or -R β -R β is a saccharidyl group, and -R 3’ is H or C1-C4 alkyl (preferably methyl). In one embodiment, -R 1 is -C(O)-N(R 3 )(R 3’ ) where -R 3 -R α -R β or -R β -R β is a saccharidyl group, and -R 3’ is H or C1-C4 alkyl (preferably methyl). Typically, in these embodiments, -R α - is C1~C12 an alkylene group (preferably a C1-C8 alkylene group or a C1-C6 alkylene group), —(CH2CH2O) m - group or -(CH2CH2S) m - groups, all optionally substituted, where m is 1, 2, 3, or 4.
[0062] In any of the embodiments of the previous four paragraphs, the saccharidyl group may optionally be substituted, for example, with a protecting group such as acetyl or a natural amino acid such as valine. The amino acid may be attached to the saccharidyl group, for example, by forming an ester between the carboxylic acid group of the amino acid and the hydroxyl group of the saccharidyl group.
[0063] In one embodiment of the first or second aspect of the invention, -R 1 -R 2 , -C(O)-OR 3 , -C(O)-SR 3 , -C(O)-N(R 3 )2, -C(O)-N(R 3 )(R 3’ ), -C(S)-OR 3 , -C(S)-SR 3 , -C(S)-N(R 3 )2 or -C(S)-N(R 3 )(R 3’ ) and -R 2 or -R 3 -R α -R β or -R β -R β is a C1-C8 alkyl group optionally substituted with one or more (e.g., 1, 2, 3, 4, 5, 6, 7, or 8) —OH or —OAc groups; —R 3’ is H or C1-C4 alkyl (preferably methyl). In one embodiment, -R 1 is -C(O)-OR 3 , -C(O)-SR 3 , -C(O)-N(R 3 )(R 3’ ) or -C(S)-N(R 3 )(R3’ ) wherein -R 3 -R α -R β or -R β -R β is a C1-C8 alkyl group optionally substituted with one or more (e.g., 1, 2, 3, 4, 5, 6, 7, or 8) hydroxyl groups, and -R 3’ is H or C1-C4 alkyl (preferably methyl). In one embodiment, -R 1 is -C(O)-N(R 3 )(R 3’ ) where -R 3 Ha-R α -R β or -R β -R β is a C1-C8 alkyl group optionally substituted with one or more (e.g., 1, 2, 3, 4, 5, 6, 7, or 8) hydroxyl groups, and -R 3’ is H or C1-C4 alkyl (preferably methyl). Typically, in these embodiments, -R α - is an unsubstituted C1 to C6 alkylene group, or an unsubstituted C1 to C4 alkylene group, or an unsubstituted C1 to C2 alkylene group.
[0064] In one embodiment of the first or second aspect of the invention, -R 1 -R 2 , -C(O)-OR 3 , -C(O)-SR 3 , -C(O)-N(R 3 )2, -C(O)-N(R 3 )(R 3’ ), -C(S)-OR 3 , -C(S)-SR 3 , -C(S)-N(R 3 )2 or C(S)-N(R 3 )(R 3’ ), where -R 2 or -R 3 -R α -H or -R α -OH; -R α - is C1-C 12alkylene groups, which may be optionally substituted with one or more C1-C4 alkyl, C1-C4 haloalkyl, or halo groups, and one or more carbon atoms in the backbone of the alkylene group may be optionally substituted with one or more heteroatoms O or S; -R 3’ is H or C1-C4 alkyl (preferably methyl). In one embodiment, -R 1 is -C(O)-OR 3 , -C(O)-SR 3 , -C(O)-N(R 3 )(R 3’ ) or -C(S)-N(R 3 )(R 3’ ) where -R 3 -R α -H or -R α -OH; -R α - is C1-C 12 alkylene groups, which may be optionally substituted with one or more C1-C4 alkyl, C1-C4 haloalkyl, or halo groups, and one or more carbon atoms in the backbone of the alkylene group may be optionally substituted with one or more heteroatoms O or S; -R 3’ is H or C1-C4 alkyl (preferably methyl). In one embodiment, -R 1 is -C(O)-N(R 3 )(R 3’ ) where -R 3 -R α -H or -R α -OH, -R α - is C1-C 12 alkylene groups, wherein one or more carbon atoms in the backbone of the alkylene group can be optionally replaced by one or more heteroatoms O or S; 3’ is H or C1-C4 alkyl (preferably methyl).
[0065] In one embodiment of the first or second aspect of the invention, -R 1 -R 2 , -C(O)-OR 3 , -C(O)-SR 3 , -C(O)-N(R3 )2, -C(O)-N(R 3 )(R 3’ ), -C(S)-OR 3 , -C(S)-SR 3 , -C(S)-N(R 3 )2 or -C(S)-N(R 3 )(R 3’ ) where -R 2 or -R 3 Ha-R β and;-R β Halo, -CN, -NO2, -N3, -OH, -OR x , -SH, -SR x , -SOR x , -SO2H, -SO2R x , -SO2NH2, -SO2NHR x , -SO2N(R x )2, -NH2, -NHR x , -N(R x )2, -N + (R x )3, -CHO, -COR x , -COOH, -COOR x , -OCOR x or -NH-CO-CR z C1-C optionally substituted with one or more (e.g., 1, 2, 3, 4, or 5) substituents independently selected from —NH2 12 Alkyl or C2-C 12 alkenyl group; each -R x is independently selected from C1-C4 alkyl; -R z is the side chain of a natural amino acid; -R 3’ is H or C1-C4 alkyl (preferably methyl). In one embodiment, -R 1 is -C(O)-OR 3 , -C(O)-SR 3 , -C(O)-N(R 3 )(R 3’ ) or -C(S)-N(R 3 )(R 3’ ), where -R 3 Ha-R β and;-R βHalo, -CN, -NO2, -N3, -OH, -OR x , -SH, -SR x , -SOR x , -SO2H, -SO2R x , -SO2NH2, -SO2NHR x , -SO2N(R x )2, -NH2, -NHR x , -N(R x )2, -N + (R x )3, -CHO, -COR x , -COOH, -COOR x , -OCOR x or -NH-CO-CR z C1-C optionally substituted with one or more (e.g., 1, 2, 3, 4, or 5) substituents independently selected from —NH2 12 is an alkyl group; each -R x is independently selected from C1-C4 alkyl; -R z is the side chain of a natural amino acid; -R 3’ is H or C1-C4 alkyl (preferably methyl). In one embodiment, -R 1 is -C(O)-N(R 3 )(R 3’ ) where -R 3 Ha-R β and -R β are independently halo, -CN, -NO2, -N3, -OH, -OR x , -SH, -SR x , -SOR x , -SO2H, -SO2R x , -SO2NH2, -SO2NHR x , -SO2N(R x )2, -NH2, -NHR x , -N(R x )2, -N + (R x )3, -CHO, -COR x , -COOH, -COOR x , -OCOR x or -NH-CO-CR z-NH2, wherein each -R x are independently selected from C1-C4 alkyl, -R z is the side chain of a natural amino acid, and -R 3’ is H or C1-C4 alkyl (preferably methyl).
[0066] In one embodiment of the first or second aspect of the invention, -R 1 is -CO-(NR zz -CHR z -CO) v -N(R zz )2 and -CO-(NR zz -CHR z -CO) v -OR zz where each -R z are independently selected from the side chains of natural amino acids; each -R zz is independently selected from hydrogen and C1-C4 alkyl (preferably methyl); and v is 1, 2, 3, 4, 5, 6, 7 or 8.
[0067] In one embodiment of the first or second aspect of the invention, -R 1 is R 2 , -C(O)-OR 3 , -C(O)-SR 3 , -C(O)-N(R 3 )2, -C(O)-N(R 3 )(R 3’ ), -C(S)-OR 3 , -C(S)-SR 3 , -C(S)-N(R 3 )2 or C(S)-N(R 3 )(R 3’ where -R 2 or -R 3 Ha-R β and;-R β is C1-C 20alkyl groups, wherein the alkyl group is optionally substituted with 1, 2, 3, or 4 halo groups, and wherein 1, 2, 3, 4, 5, or 6 carbon atoms in the backbone of the alkyl group are optionally replaced with heteroatoms or groups independently selected from O, S, NH, or NMe; -R 3’ is H or C1-C4 alkyl (preferably methyl).
[0068] In one embodiment of the first or second aspect of the invention, -R 1 -R 2 , -C(O)-OR 3 , -C(O)-SR 3 , -C(O)-N(R 3 )2, -C(O)-N(R 3 )(R 3’ ), -C(S)-OR 3 , -C(S)-SR 3 , -C(S)-N(R 3 )2 or C(S)-N(R 3 )(R 3’ ) are selected from;-R 3’ is H or C1-C4 alkyl (preferably methyl); -R 2 or -R 3 -R α -[N(R 5 )3]Y, -R α -[P(R 5 )3]Y or -R α -[R 8 ]Y. In one embodiment, -R 1 -R 2 , -C(O)-OR 3 , -C(O)-SR 3 , -C(O)-N(R 3 )(R 3’ ) or -C(S)-N(R 3 )(R 3’ ) are selected from;-R 3’ is H or C1-C4 alkyl (preferably methyl); -R 2 or -R 3 -R α -[N(R 5 )3]Y, -R α -[P(R5 )3]Y, or -R α -[R 8 ]Y; each -R 5 is independently selected from C1-C4 alkyl or phenyl, wherein phenyl is optionally substituted with 1, 2, or 3 C1-C4 alkyl or C1-C4 alkoxy groups; -R 8 is —[NC5H5] optionally substituted with 1, 2, or 3 C1-C4 alkyl or C1-C4 alkoxy groups; —R α - is C1-C 12 alkylene groups, wherein 1, 2, 3, or 4 carbon atoms in the backbone of the alkylene group may optionally be replaced by a heteroatom or group independently selected from O, S, NH, or NMe; and Y is a counterion (preferably a halide).
[0069] In one embodiment of the first or second aspect of the invention, -R 1 -R 2 , -C(O)-OR 3 , -C(O)-SR 3 , -C(O)-N(R 3 )2, -C(O)-N(R 3 )(R 3’ ), -C(S)-OR 3 , -C(S)-SR 3 , -C(S)-N(R 3 )2 or C(S)-N(R 3 )(R 3’ ) where -R 2 or -R 3 Ha-R α -[P(R 5 ) 3] Y; each -R 5 is independently selected from phenyl or C5-C6 heteroaryl, wherein phenyl or C5-C6 heteroaryl is optionally selected from one or more of C1-C4 alkyl, C1-C4 haloalkyl, —O(C1-C4 alkyl), —O(C1-C4 haloalkyl), halo, —O—(CH2CHO) n -H or -O-(CH2CH2O) nn is 1, 2, 3, or 4; Y is fluoride, chloride, bromide, or iodide; -R 3’ is H or C1-C4 alkyl (preferably methyl). In one embodiment, -R 1 is -C(O)-OR 3 , -C(O)-SR 3 , -C(O)-N(R 3 )(R 3’ ) or -C(S)-N(R 3 )(R 3’ ) where -R 3 Ha-R α -[P(R 5 ) 3] Y; each -R 5 is independently selected from phenyl or C5-C6 heteroaryl, wherein phenyl or C5-C6 heteroaryl is optionally selected from one or more of C1-C4 alkyl, C1-C4 haloalkyl, —O(C1-C4 alkyl), —O(C1-C4 haloalkyl), halo, —O—(CH2CHO) n -H or -O-(CH2CH2O) n n is 1, 2, 3, or 4; Y is fluoride, chloride, bromide, or iodide; -R 3’ is H or C1-C4 alkyl (preferably methyl). In one embodiment, -R 1 is -C(O)-N(R 3 )(R 3’ ) where -R 3 Ha-R α -[P(R 5 )3]Y, and each -R 5 is independently selected from phenyl or C5-C6 heteroaryl, and the phenyl or C5-C6 heteroaryl optionally comprises one or more of C1-C4 alkyl, C1-C4 haloalkyl, -O(C1-C4 alkyl), -O(C1-C4 haloalkyl), halo, -O-(CH2CHO) n -H or -O-(CH2CH2O) n -CH3 groups, n is 1, 2, 3 or 4, Y is fluoride, chloride, bromide or iodide, -R 3’is H or C1-C4 alkyl (preferably methyl). Typically, in these embodiments, -R α - is C1-C 12 an alkylene group (preferably a C1-C8 alkylene group or a C1-C6 alkylene group), —(CH2CH2O) m -CH2CH2- group or -(CH2CH2S) m a —CH 2 CH 2 — group, all optionally substituted, and m is 1, 2, 3, or 4.
[0070] In one embodiment of the first or second aspect of the invention, -R 1 -C(O)-OR 3 where -R 3 is selected from C1-C4 alkyl (preferably methyl), or cations (such as lithium, sodium, potassium, magnesium, calcium, ammonium, amine (such as choline or meglumine) or amino acid (such as arginine) cations).
[0071] In one embodiment of the first or second aspect of the invention, -R 1 is -C(O)-N(R 3 )2. In one embodiment, -R 1 is -C(O)-N(C1-C4 alkyl)(R 3 ) or -C(O)-NHR 3 In one embodiment, -R 1 is -C(O)-N(CH3)(R 3 ) or -C(O)-NHR 3 In one embodiment, -R 1 is -C(O)-N(C1-C4 alkyl)(R 3 In one embodiment, -R 1 is -C(O)-N(CH3)(R 3 )
[0072] In one embodiment of the first or second aspect of the invention, -R 1 is -CH2OR 2 , -CH2SR 2 , -CH2S(O)R 2, -CH2S(O)2R 2 , -CHN(R 2 )2 or -R 2 In one embodiment, -R 1 is -CH2OR 2 , -CH2SR 2 , -CHN(R 2 )2 or -R 2 In one embodiment, -R 1 is -CH2OR 2 , -CH2SR 2 or -CHN(R 2 )2. In one embodiment, -R 1 is -CH2OR 2 or -CH2SR 2 In one embodiment, -R 1 Ha-CH2OR 2 In one embodiment, -R 1 Ha-R 2 and -R 2 Ha-R α -X.
[0073] In one embodiment of the first or second aspect of the invention, -R 2 Ha-R α -H, -R β , -R α -R β , -R α -OH, -R α -OR β , -R α -SH, -R α -SR β , -R α -S(O)R β , -R α -S(O)2R β , -R α -NH2, -R α -NH(R β ), -R α -N(R β )2, -R α -X, -R α -[N(R 5 )3]Y, -R α -[P(R 5 )3]Y or -Rα In one embodiment, -R 2 -R α -OR β , -R α -SR β , -R α -S(O)R β or -R α -S(O)2R β In one embodiment, -R 2 -R α -OR β , -R α -SR β , -R α -S(O)R β or -R α -S(O)2R β -R β is a saccharidyl group. In one embodiment, -R 2 -R α -OR β or -R α -SR β In one embodiment, -R 2 -R α -OR β or -R α -SR β -R β is a saccharidyl group.
[0074] In one embodiment of the first or second aspect of the invention, -R 2 is -C(O)R 4 , -C(O)-OR 4 , -C(O)-SR 4 , -C(O)-N(R 4 )2, -C(S)-OR 4 , -C(S)-SR 4 or -C(S)-N(R 4 )2. In one embodiment, -R 2 is -C(O)R 4 , -C(O)-OR 4 , -C(O)-SR 4 , -C(O)-N(R 4 )2 or -C(S)-N(R 4)2. In one embodiment, -R 2 is -C(O)R 4 , -C(O)-OR 4 , -C(O)-SR 4 or -C(O)-N(R 4 )2 is selected.
[0075] In one embodiment of the first or second aspect of the invention, -R 2 is -C(O)-N(R 4 )(R 4’ ) and -R 4 Ha-R α -OR β , -R α -SR β , -R α -S(O)R β or -R α -S(O)2R β -R β is a saccharidyl group, and -R 4’ is H or C1-C4 alkyl (preferably methyl). In one embodiment, -R 2 is -C(O)-N(R 4 )(R 4’ ) and -R 4 Ha-R α -OR β or -R α -SR β -R β is a saccharidyl group, and -R 4’ is H or C1-C4 alkyl (preferably methyl). In one embodiment, -R 2 is -C(O)-N(R 4 )(R 4’ ) where -R 4 Ha-R α -OR β , -R α -SR β , -R α -S(O)R β or -R α -S(O)2R β -R β is a saccharidyl group, and -R 4’is C1-C4 alkyl (preferably methyl). In one embodiment, -R 2 is -C(O)-N(R 4 )(R 4’ ) where -R 4 Ha-R α -OR β or -R α -SR β -R β is a saccharidyl group, and -R 4’ is C1-C4 alkyl (preferably methyl).
[0076] -R 4’ The group is another -R 4 -R bonded to the same atom as the group 4 -R refers to the group 4 and -R 4’ may be the same or different. Preferably, -R 4 and -R 4’ is different.
[0077] In one embodiment of the first or second aspect of the invention, -R 2 is -C(O)-N(R 4 )2. In one embodiment, -R 2 is -C(O)-N(C1-C4 alkyl)(R 4 In one embodiment, -R 2 is -C(O)-N(CH3)(R 4 )
[0078] In one embodiment of the first or second aspect of the invention, -R 6 is hydrogen.
[0079] In one embodiment of the first or second aspect of the invention, -R 6 is -C(O)-OR 3 , -C(O)-SR 3 , -C(O)-N(R 3 )2, -C(S)-OR 3 , -C(S)-SR 3 or -C(S)-N(R 3 )2, each of which is selected from -R3 is C1-C4 alkyl, and preferably each -R 3 is methyl. In one embodiment, -R 6 is -C(O)-OR 3 , -C(O)-SR 3 or -C(O)-N(R 3 )2, each of which is selected from -R 3 is C1-C4 alkyl, and preferably each -R 3 is methyl. In one embodiment, -R 6 -C(O)-OR 3 and -R 3 is C1-C4 alkyl, preferably -R 3 is methyl.
[0080] In one embodiment of the first or second aspect of the invention, -R 6 -C(O)-OR 3 where -R 3 is selected from hydrogen, C1-C4 alkyl (preferably methyl), or a cation (e.g., lithium, sodium, potassium, magnesium, calcium, ammonium, an amine (e.g., choline or meglumine), or an amino acid (e.g., arginine) cation).
[0081] In one embodiment of the first or second aspect of the invention, -R 6 is C(O)-OR 3 , -C(O)-SR 3 , -C(O)-N(R 3 )2, -C(O)-N(R 3 )(R 3’ ), -C(S)-OR 3 , -C(S)-SR 3 , -C(S)-N(R 3 )2 or -C(S)-N(R 3 )(R 3’ ) where -R 3 Ha-R β and;-R β is C1-C 20alkyl groups, wherein the alkyl group is optionally substituted with 1, 2, 3, or 4 halo groups, and wherein 1, 2, 3, 4, 5, or 6 carbon atoms in the backbone of the alkyl group are optionally replaced with heteroatoms or groups independently selected from O, S, NH, or NMe; -R 3’ is H or C1-C4 alkyl (preferably methyl).
[0082] In one embodiment of the first or second aspect of the invention, -R 6 is C(O)-OR 3 , -C(O)-SR 3 , -C(O)-N(R 3 )2, -C(S)-OR 3 , -C(S)-SR 3 or -C(S)-N(R 3 )2, each of which is selected from -R 3 -R α -OR β , -R α -SR β , -R α -S(O)R β or -R α -S(O)2R β -R β is a saccharidyl group. In one embodiment, -R 6 is -C(O)-OR 3 , -C(O)-SR 3 or -C(O)-N(R 3 )2, each of which is selected from -R 3 -R α -OR β , -R α -SR β , -R α -S(O)R β or -R α -S(O)2R β -R β is a saccharidyl group. In one embodiment, -R 6 -C(O)-OR 3 or -C(O)-SR 3 -R 3 Ha-R α -OR βor -R α -SR β -R β is a saccharidyl group. Typically, in these embodiments, -R α - is C1-C 12 alkylene groups, wherein 1, 2, 3, or 4 carbon atoms in the backbone of the alkylene group are optionally replaced with heteroatoms or groups independently selected from O, S, NH, or NMe. Alternatively, in these embodiments, -R α - is C1-C 12 an alkylene group (preferably a C1-C8 alkylene group or a C1-C6 alkylene group), —(CH2CH2O) m -CH2CH2- group or -(CH2CH2S) m a —CH 2 CH 2 — group, all of which are optionally substituted, where m is 1, 2, 3, or 4.
[0083] In one embodiment of the first or second aspect of the invention, -R 6 is -C(O)-OR 3 , -C(O)-SR 3 , -C(O)-N(R 3 )(R 3’ ) or -C(S)-N(R 3 )(R 3’ ), where -R 3 -R α -OR β , -R α -SR β , -R α -S(O)R β or -R α -S(O)2R β -R β is a saccharidyl group, and -R 3’ is H or C1-C4 alkyl (preferably methyl). In one embodiment, -R 6 is -C(O)-OR 3 , -C(O)-SR 3 or -C(O)-N(R 3 )(R 3’ ), where -R 3 -Rα -OR β , -R α -SR β , -R α -S(O)R β or -R α -S(O)2R β -R β is a saccharidyl group, and -R 3’ is H or C1-C4 alkyl (preferably methyl). In one embodiment, -R 6 -C(O)-OR 3 , -C(O)-SR 3 or -C(O)-N(R 3 )(R 3’ ), where -R 3 Ha-R α -OR β or -R α -SR β -R β is a saccharidyl group, and -R 3’ is H or C1-C4 alkyl (preferably methyl). Typically, in these embodiments, -R α - is C1-C 12 alkylene groups, wherein 1, 2, 3, or 4 carbon atoms in the backbone of the alkylene group are optionally replaced with heteroatoms or groups independently selected from O, S, NH, or NMe. Alternatively, in these embodiments, -R α - is C1-C 12 an alkylene group (preferably a C1-C8 alkylene group or a C1-C6 alkylene group), —(CH2CH2O) m -CH2CH2- group or -(CH2CH2S) m a —CH 2 CH 2 — group, all of which are optionally substituted, where m is 1, 2, 3, or 4.
[0084] -R 3’ The group is another -R 3 -R bonded to the same atom as the group 3 -R refers to the group 3 and -R 3’ may be the same or different. Preferably, -R3 and -R 3’ is different.
[0085] In one embodiment of the first or second aspect of the invention, -R 6 is -C(O)-N(R 3 )2. In one embodiment, -R 6 is -C(O)-N(C1-C4 alkyl)(R 3 ) or -C(O)-NHR 3 In one embodiment, -R 6 is -C(O)-N(CH3)(R 3 ) or -C(O)-NHR 3 is.
[0086] In one embodiment of the first or second aspect of the invention, -R 7 is hydrogen.
[0087] In one embodiment of the first or second aspect of the invention, -R 7 is -C(O)-OR 3 , -C(O)-SR 3 , -C(O)-N(R 3 )2, -C(S)-OR 3 , -C(S)-SR 3 or -C(S)-N(R 3 )2, each of which is selected from -R 3 is C1-C4 alkyl, and preferably each -R 3 is methyl. In one embodiment, -R 7 is -C(O)-OR 3 , -C(O)-SR 3 or -C(O)-N(R 3 )2, each of which is selected from -R 3 is C1-C4 alkyl, and preferably each -R 3 is methyl. In one embodiment, -R 7 -C(O)-OR 3 and -R 3 is C1-C4 alkyl, preferably -R 3 is methyl.
[0088] In one embodiment of the first or second aspect of the invention, -R 7 -C(O)-OR 3 where -R 3 is selected from hydrogen, C1-C4 alkyl (preferably methyl), or a cation (e.g., lithium, sodium, potassium, magnesium, calcium, ammonium, an amine (e.g., choline or meglumine), or an amino acid (e.g., arginine) cation).
[0089] In one embodiment of the first or second aspect of the invention, -R 7 is -C(O)-OR 3 , -C(O)-SR 3 , -C(O)-N(R 3 )2, -C(O)-N(R 3 )(R 3’ ), -C(S)-OR 3 , -C(S)-SR 3 , -C(S)-N(R 3 )2 or -C(S)-N(R 3 )(R 3’ ) where -R 3 Ha-R β and;-R β is C1-C 20 alkyl groups, wherein the alkyl group is optionally substituted with 1, 2, 3, or 4 halo groups, and wherein 1, 2, 3, 4, 5, or 6 carbon atoms in the backbone of the alkyl group are optionally replaced with heteroatoms or groups independently selected from O, S, NH, or NMe; -R 3’ is H or C1-C4 alkyl (preferably methyl).
[0090] In one embodiment of the first or second aspect of the invention, -R 7 is -C(O)-OR 3 , -C(O)-SR 3 , -C(O)-N(R 3 )2, -C(S)-OR 3 , -C(S)-SR 3 or -C(S)-N(R 3 )2, each of which is selected from -R 3 -Rα -OR β , -R α -SR β , -R α -S(O)R β or -R α -S(O)2R β -R β is a saccharidyl group. In one embodiment, -R 7 is -C(O)-OR 3 , -C(O)-SR 3 or -C(O)-N(R 3 )2, each of which is selected from -R 3 -R α -OR β , -R α -SR β , -R α -S(O)R β or -R α -S(O)2R β -R β is a saccharidyl group. In one embodiment, -R 7 -C(O)-OR 3 or -C(O)-SR 3 -R 3 Ha-R α -OR β or -R α -SR β -R β is a saccharidyl group. Typically, in these embodiments, -R α - is C1-C 12 alkylene groups, wherein 1, 2, 3, or 4 carbon atoms in the backbone of the alkylene group are optionally replaced with heteroatoms or groups independently selected from O, S, NH, or NMe. Alternatively, in these embodiments, -R α - is C1-C 12 an alkylene group (preferably a C1-C8 alkylene group or a C1-C6 alkylene group), —(CH2CH2O) m -CH2CH2- group or -(CH2CH2S) m a —CH 2 CH 2 — group, all of which are optionally substituted, where m is 1, 2, 3, or 4.
[0091] In one embodiment of the first or second aspect of the invention, -R 7 is -C(O)-OR 3 , -C(O)-SR 3 , -C(O)-N(R 3 )(R 3’ ) or -C(S)-N(R 3 )(R 3’ ), where -R 3 -R α -OR β , -R α -SR β , -R α -S(O)R β or -R α -S(O)2R β -R β is a saccharidyl group, and -R 3’ is H or C1-C4 alkyl (preferably methyl). In one embodiment, -R 7 is -C(O)-OR 3 , -C(O)-SR 3 or -C(O)-N(R 3 )(R 3’ ), where -R 3 -R α -OR β , -R α -SR β , -R α -S(O)R β or -R α -S(O)2R β -R β is a saccharidyl group, and -R 3’ is H or C1-C4 alkyl (preferably methyl). In one embodiment, -R 7 is -C(O)-OR 3 , -C(O)-SR 3 or -C(O)-N(R 3 )(R 3’ ), where -R 3 -R α -OR β or -R α -SR β-R β is a saccharidyl group, and -R 3’ is H or C1-C4 alkyl (preferably methyl). Typically, in these embodiments, -R α - is C1-C 12 alkylene groups, wherein 1, 2, 3, or 4 carbon atoms in the backbone of the alkylene group are optionally replaced with heteroatoms or groups independently selected from O, S, NH, or NMe. Alternatively, in these embodiments, -R α - is C1-C 12 an alkylene group (preferably a C1-C8 alkylene group or a C1-C6 alkylene group), —(CH2CH2O) m -CH2CH2- group or -(CH2CH2S) m a —CH 2 CH 2 — group, all of which are optionally substituted, where m is 1, 2, 3, or 4.
[0092] -R 3’ The group is another -R 3 -R bonded to the same atom as the group 3 -R refers to the group 3 and -R 3’ may be the same or different. Preferably, -R 3 and -R 3’ is different.
[0093] In one embodiment of the first or second aspect of the invention, -R 7 is -C(O)-N(R 3 )2. In one embodiment, -R 7 is -C(O)-N(C1-C4 alkyl)(R 3 ) or -C(O)-NHR 3 In one embodiment, -R 7 is -C(O)-N(CH3)(R 3 ) or -C(O)-NHR 3 is.
[0094] In one embodiment of the first or second aspect of the invention, -R 6 and -R 7together form -C(O)-O-.
[0095] In one embodiment of the first or second aspect of the invention, each -R α -Independently, C1-C 12 Alkylene group, -(CH2CH2O) m - group, -(CH2CH2S) m - group, -(CH2CH2O) m -CH2CH2- group or -(CH2CH2S) m -CHCH- groups, all optionally substituted, and m is 1, 2, 3, or 4. In one embodiment, each -R α -Independently, C1-C 12 Alkylene group, -(CH2CH2O) m - group or -(CH2CH2S) m - groups, all optionally substituted, and m is 1, 2, 3, or 4. In one embodiment, each -R α -Independently, C1-C 12 Alkylene group or -(CH2CH2O) m - groups, both of which are optionally substituted, where m is 1, 2, 3, or 4. In one embodiment, each -R α - is independently an optionally substituted -(CH2CH2O) m - group, where m is 1, 2, 3 or 4.
[0096] In one embodiment of the first or second aspect of the invention, each -R α - is independently a C1-C8 alkylene group, or a C1-C6 alkylene group, or a C2-C4 alkylene group, all optionally substituted.
[0097] In one embodiment of the first or second aspect of the invention, each -R α - is independently unsubstituted or substituted with one or more substituents independently selected from halo, C1-C4 alkyl, or C1-C4 haloalkyl. In one embodiment, each -R α- is independently unsubstituted or substituted with one or two substituents independently selected from halo, C1-C4 alkyl, or C1-C4 haloalkyl. In one embodiment, each -R α - is unsubstituted.
[0098] In one embodiment of the first or second aspect of the invention, each -R β are independently saturated or unsaturated hydrocarbyl groups which may be linear or branched or which may be or include cyclic groups, which may be optionally substituted, and which may optionally include one or more heteroatoms N, O and S in its carbon skeleton.
[0099] In one embodiment of the first or second aspect of the invention, at least one -R β is independently a C1-C6 alkyl group, or a C1-C4 alkyl group, or a methyl group, all of which are optionally substituted. In one embodiment, each -R β is independently a C1-C6 alkyl group, or a C1-C4 alkyl group, or a methyl group, all of which are optionally substituted. β are independently a C1-C6 alkyl group, or a C1-C4 alkyl group, or a methyl group.
[0100] In one embodiment of the first or second aspect of the invention, at least one -R β is independently a saccharidyl group. In one embodiment, each -R β are independently saccharidyl groups.
[0101] In one embodiment of the first or second aspect of the invention, each -R β is independently unsubstituted or substituted with one or more substituents independently selected from halo, C1-C4 alkyl, or C1-C4 haloalkyl. βis independently unsubstituted or substituted with one or two substituents independently selected from halo, C1-C4 alkyl, or C1-C4 haloalkyl. In one embodiment, each -R β is non-substituted.
[0102] In one embodiment of the first or second aspect of the invention, each -R 3 -R α -H, -R β , -R α -R β , -R α -OH, -R α -OR β , -R α -SH, -R α -SR β , -R α -NH2, -R α -NH(R β ), -R α -N(R β )2, -R α -X, -R α -[N(R 5 )3]Y, -R α -[P(R 5 )3]Y or -R α In one embodiment, each -R 3 -R α -OR β or -R α -SR β In one embodiment, each -R 3 -R α -OR β or -R α -SR β are independently selected from -R β is a saccharidyl group.
[0103] In one embodiment of the first or second aspect of the invention, each -R 3 independently, -R α -H, -R β , -R α -R β , -R α -OH, -R α -ORβ , -R α -SH, -R α -SR β , -R α -S(O)R β , -R α -S(O)2R β , -R α -NH2, -R α -NH(R β ), -R α -N(R β )2, -R α -X, -R α -[N(R 5 )3]Y, -R α -[P(R 5 )3]Y or -R α -[NC5H5]Y. In one embodiment, each -R 3 independently, -R α -OR β , -R α -SR β , -R α -S(O)R β or -R α -S(O)2R β In one embodiment, each -R 3 independently, -R α -OR β , -R α -SR β , -R α -S(O)R β or -R α -S(O)2R β -R β is a saccharidyl group. In one embodiment, each -R 3 independently, -R α -OR β or -R α -SR β In one embodiment, each -R 3 independently, -R α -OR β or -R α -SR β -R β is a saccharidyl group.
[0104] In one embodiment of the first or second aspect of the invention, each -R 4 -R α -H, -R β , -R α -R β , -R α -OH, -R α -OR β , -R α -SH, -R α -SR β , -R α -NH2, -R α -NH(R β ), -R α -N(R β )2, -R α -X, -R α -[N(R 5 )3]Y, -R α -[P(R 5 )3]Y or -R α In one embodiment, each -R 4 -R α -OR β or -R α -SR β In one embodiment, each -R 4 -R α -OR β or -R α -SR β are independently selected from -R β is a saccharidyl group.
[0105] In one embodiment of the first or second aspect of the invention, each -R 4 independently, -R α -H, -R β , -R α -R β , -R α -OH, -R α -OR β , -R α -SH, -R α -SR β , -R α -S(O)R β , -R α -S(O)2R β , -R α-NH2, -R α -NH(R β ), -R α -N(R β )2, -R α -X, -R α -[N(R 5 )3]Y, -R α -[P(R 5 )3]Y or -R α -[NC5H5]Y. In one embodiment, each -R 4 independently, -R α -OR β , -R α -SR β , -R α -S(O)R β or -R α -S(O)2R β In one embodiment, each -R 4 -R α -OR β , -R α -SR β , -R α -S(O)R β or -R α -S(O)2R β are independently selected from -R β is a saccharidyl group. In one embodiment, each -R 4 -R α -OR β or -R α -SR β In one embodiment, each -R 4 -R α -OR β or -R α -SR β are independently selected from -R β is a saccharidyl group.
[0106] In one embodiment of the first or second aspect of the invention, -R 2 , -R 3 or -R 4 At least one of the following must be -R α -OR β , -R α -SR β , -Rα -S(O)R β or -R α -S(O)2R β are independently selected from -R β is a saccharidyl group. In one embodiment, -R 2 , -R 3 or -R 4 At least one of the following must be -R α -OR β or -R α -SR β are independently selected from -R β is a saccharidyl group.
[0107] For purposes of the present invention, a "saccharidyl group" is any group comprising at least one monosaccharide subunit, each of which may be optionally substituted and / or modified. Typically, a saccharidyl group is composed of one or more monosaccharide subunits, each of which may be optionally substituted and / or modified.
[0108] Usually, the carbon atom of a single monosaccharide subunit of each saccharidyl group is directly attached to the remainder of the compound, most typically via a single bond.
[0109] For purposes of this specification, when a first atom or group is said to be "directly bonded" to a second atom or group, it is to be understood that the first atom or group is covalently bonded to the second atom or group and that there are no intervening atom(s) or group(s). For example, in the group -(C=O)N(CH), the carbon atom of each methyl group is directly bonded to the nitrogen atom and the carbon atom of the carbonyl group is directly bonded to the nitrogen atom, but the carbon atom of the carbonyl group is not directly bonded to the carbon atoms of either methyl group.
[0110] Typically, each saccharidyl group is derived from the corresponding saccharide by replacing a hydroxyl group of the saccharide with a group defined by the remainder of the compound.
[0111] The single bond between the anomeric carbon of a monosaccharide subunit and a substituent is called a glycosidic bond. A glycosidic group is attached to the anomeric carbon of a monosaccharide subunit by a glycosidic bond. The bond between the saccharidyl group and the rest of the compound can be a glycosidic or non-glycosidic bond. Typically, the bond between the saccharidyl group and the rest of the compound is a glycosidic bond, and the saccharidyl group is a glycosyl group. When the bond between the saccharidyl group and the rest of the compound is a glycosidic bond, the glycosidic bond can be in the α or β configuration. Typically, such glycosidic bond is in the β configuration.
[0112] For purposes of the present invention, when a saccharidyl group "contains x monosaccharide subunits," this means that the saccharidyl group has x monosaccharide subunits and no more. In contrast, when a saccharidyl group "comprises x monosaccharide subunits," this means that the saccharidyl group has x or more monosaccharide subunits.
[0113] Each saccharidyl group can be independently selected from a monosaccharide, disaccharide, oligosaccharide, or polysaccharide group. As will be understood, a monosaccharide group contains a single monosaccharide subunit. Similarly, a disaccharide group contains two monosaccharide subunits. As used herein, an "oligosaccharide group" contains two to nine monosaccharide subunits. Examples of oligosaccharide groups include trisaccharide, tetrasaccharide, pentasaccharide, hexasaccharide, heptasaccharide, octasaccharide, and nonasaccharide groups. As used herein, a "polysaccharide group" contains 10 or more monosaccharide subunits (such as 10 to 50, or 10 to 30, or 10 to 20, or 10 to 15 monosaccharide subunits).
[0114] Each monosaccharide subunit within a disaccharide, oligosaccharide, or polysaccharide group can be the same or different. Each monosaccharide subunit within a disaccharide, oligosaccharide, or polysaccharide group can be linked to another monosaccharide subunit within the group via a glycosidic or non-glycosidic bond. Typically, each monosaccharide subunit within a disaccharide, oligosaccharide, or polysaccharide group is linked to another monosaccharide subunit within the group via a glycosidic bond, which can be in the α or β configuration.
[0115] Each oligosaccharidyl or polysaccharidyl group may be a linear, branched or macrocyclic oligosaccharidyl or polysaccharidyl group. Typically, each oligosaccharidyl or polysaccharidyl group is a linear or branched oligosaccharidyl or polysaccharidyl group.
[0116] In one embodiment, at least one -R β is a monosaccharide or disaccharide group.
[0117] In a further embodiment, at least one -R β is a monosaccharidyl group. For example, at least one -R β can be a glycosyl group containing a single monosaccharide subunit, where the monosaccharide subunit can be optionally substituted and / or modified. Typically, at least one -R β is a glycosyl group containing a single monosaccharide subunit, where the monosaccharide subunit can be optionally substituted. More typically, at least one -R β is a glycosyl group containing a single monosaccharide subunit, where the monosaccharide subunit is unsubstituted.
[0118] In one embodiment, at least one -R β is an aldosyl group, where the aldosyl group can be optionally substituted and / or modified. For example, at least one -R βmay be selected from a glycerosyl, aldotetrosyl (such as erythrosyl or threosyl), aldopentosyl (such as ribosyl, arabinosyl, xylosyl or lyxosyl) or aldohexosyl (such as allosyl, altrosyl, glucosyl, mannosyl, gulosyl, idosyl, galactosyl or talosyl) group, any of which may be optionally substituted and / or modified.
[0119] In another embodiment, at least one -R β is a ketosyl group, where the ketosyl group can be optionally substituted and / or modified. For example, at least one -R β may be selected from an erythrulosyl, ketopentosyl (such as ribulosyl or xylulosyl) or ketohexosyl (such as psicosyl, fructosyl, sorbosyl or tagatosyl) group, any of which may be optionally substituted and / or modified.
[0120] Each monosaccharide subunit can exist in a closed (cyclic) or open (acyclic) form. Typically, at least one -R β Each monosaccharide subunit in β can be a glycosyl group containing a single closed-ring monosaccharide subunit, where the monosaccharide subunit can be optionally substituted and / or modified. Typically, in such a scenario, at least one -R β is a pyranosyl or furanosyl group, such as an aldopyranosyl, aldofuranosyl, ketopyranosyl, or ketofuranosyl group, any of which may be optionally substituted and / or modified. More typically, at least one -R β is a pyranosyl group, such as an aldopyranosyl or ketopyranosyl group, either of which can be optionally substituted and / or modified.
[0121] In one embodiment, at least one -R βis selected from a ribopyranosyl, arabinopyranosyl, xylopyranosyl, lyxopyranosyl, allopyranosyl, altropyranosyl, glucopyranosyl, mannopyranosyl, gulopyranosyl, idopyranosyl, galactopyranosyl or talopyranosyl group, any of which may be optionally substituted and / or modified.
[0122] In a further embodiment, at least one -R β is a glucosyl group, such as a glucopyranosyl group, where the glucosyl or glucopyranosyl group may be optionally substituted and / or modified. Typically, at least one -R β is a glucosyl group, where the glucosyl group can be optionally substituted. More typically, at least one -R β is an unsubstituted glucosyl group.
[0123] Each monosaccharide subunit can be in the D-configuration or the L-configuration. Typically, each monosaccharide subunit is present in the configuration most commonly found in nature.
[0124] In one embodiment, at least one -R β is a D-glucosyl group, such as a D-glucopyranosyl group, where the D-glucosyl or D-glucopyranosyl group may be optionally substituted and / or modified. Typically, at least one -R β is a D-glucosyl group, where the D-glucosyl group can be optionally substituted. More typically, at least one -R β is an unsubstituted D-glucosyl group.
[0125] For purposes of the present invention, in the substituted monosaccharide group or monosaccharide subunit: (a) One or more hydroxyl groups of a monosaccharide group or monosaccharide subunit may each independently be -H, -F, -Cl, -Br, -I, -CF3, -CCl3, -CBr3, -CI3, -SH, -NH2, -N3, -NH=NH2, -CN, -NO2, -COOH, -R b , -OR b、-S-R b 、-R a -O-R b 、-R a -S-R b 、-SO-R b 、-SO2-R b 、-SO2-OR b 、-O-SO-R b 、-O-SO2-R b 、-O-SO2-OR b 、-NR b -SO-R b 、-NR b -SO2-R b 、-NR b -SO2-OR b 、-R a -SO-R b 、-R a -SO2-R b 、-R a -SO2-OR b 、-SO-N(R b )2、-SO2-N(R b )2、-O-SO-N(R b )2、-O-SO2-N(R b )2、-NR b -SO-N(R b )2、-NR b -SO2-N(R b )2、-R a -SO-N(R b )2、-R a -SO2-N(R b )2、-N(R b )2、-N(R b )3 + 、-R a -N(R b )2、-R a -N(R b )3 + 、-P(R b )2、-PO(R b )2、-OP(R b )2、-OPO(R b )2、-R a -P(R b )2、-R a -PO(R b )2、-OSi(R b )3、-Ra -Si(R b )3, -CO-R b , -CO-OR b , -CO-N(R b )2, -O-CO-R b , -O-CO-OR b , -O-CO-N(R b )2, -NR b -CO-R b , -NR b -CO-OR b , -NR b -CO-N(R b )2, -R a -CO-R b , -R a -CO-OR b , or -R a -CO-N(R b )2; and / or (b) one, two, or three hydrogen atoms directly attached to a carbon atom of a monosaccharide group or monosaccharide subunit are each independently -F, -Cl, -Br, -I, -CF3, -CCl3, -CBr3, -CI3, -OH, -SH, -NH2, -N3, -NH=NH2, -CN, -NO2, -COOH, -R b , -OR b , -SR b , -R a -OR b , -R a -SR b , -SO-R b , -SO2-R b , -SO2-OR b , -O-SO-R b , -O-SO2-R b , -O-SO2-OR b , -NR b -SO-R b , -NR b -SO2-R b , -NR b -SO2-OR b , -R a -SO-R b , -R a -SO2-R b , -R a -SO2-ORb , -SO-N(R b )2, -SO2-N(R b )2, -O-SO-N(R b )2, -O-SO2-N(R b )2, -NR b -SO-N(R b )2, -NR b -SO2-N(R b )2, -R a -SO-N(R b )2, -R a -SO2-N(R b )2, -N(R b )2, -N(R b )3 + , -R a -N(R b )2, -R a -N(R b )3 + , -P(R b )2, -PO(R b )2, -OP(R b )2, -OPO(R b )2, -R a -P(R b )2, -R a -PO(R b )2, -OSi(R b )3, -R a -Si(R b )3, -CO-R b , -CO-OR b , -CO-N(R b )2, -O-CO-R b , -O-CO-OR b , -O-CO-N(R b )2, -NR b -CO-R b , -NR b -CO-OR b , -NR b -CO-N(R b )2, -R a -CO-R b , -R a -CO-OR b , or -R a -CO-N(R b )2; and / or (c) one or more hydroxyl groups of a monosaccharide group or monosaccharide subunit, together with the hydrogen bonded to the same carbon atom as the hydroxyl group, are each independently represented by ═O, ═S, or ═NR b , or =N(R b )2 + and / or (d) Any two hydroxyl groups of a monosaccharide group or monosaccharide subunit together form -OR c -, -SR c -, -SO-R c -, -SO2-R c -, or -NR b -R c - is replaced by; where: Each-R a - is independently a substituted or unsubstituted alkylene, alkenylene, or alkynylene group which optionally contains one or more heteroatoms each independently selected from O, N, and S in its carbon skeleton and which preferably contains 1 to 10 carbon atoms; Each-R b - is independently hydrogen or a substituted or unsubstituted straight-chain, branched, or cyclic alkyl, alkenyl, alkynyl, aryl, arylalkyl, arylalkenyl, arylalkynyl, alkylaryl, alkenylaryl, or alkynylaryl group optionally containing in its carbon skeleton one or more heteroatoms each independently selected from O, N, and S and preferably containing 1 to 15 carbon atoms; Each-R c - is independently a chemical bond or a substituted or unsubstituted alkylene, alkenylene, or alkynylene group optionally containing one or more heteroatoms each independently selected from O, N, and S in its carbon skeleton and preferably containing 1 to 10 carbon atoms; However, the monosaccharide group or monosaccharide subunit has at least one, preferably at least two or at least three, -OH, -OR b , -O-SO-R b , -O-SO2-R b , -O-SO2-ORb , -O-SO-N(R b )2, -O-SO2-N(R b )2, -OP(R b )2, -OPO(R b )2, -OSi(R b )3, -O-CO-R b , -O-CO-OR b , -O-CO-N(R b )2, or -OR c - is subject to inclusion.
[0126] Typically, in substituted monosaccharide groups or monosaccharide subunits, (a) one or more hydroxyl groups of a monosaccharide group or monosaccharide subunit are each independently -H, -F, -CF, -SH, -NH, -N, -CN, -NO, -COOH, -R b , -OR b , -SR b , -N(R b )2, -OPO(R b )2, -OSi(R b )3, -O-CO-R b , -O-CO-OR b , -O-CO-N(R b )2, -NR b -CO-R b , -NR b -CO-OR b , or -NR b -CO-N(R b )2; and / or (b) one or two of the hydrogen atoms directly attached to a carbon atom of a monosaccharide group or a monosaccharide subunit are each independently -F, -CF3, -OH, -SH, -NH2, -N3, -CN, -NO2, -COOH, -R b , -OR b , -SR b , -N(R b )2, -OPO(R b )2, -OSi(R b )3, -O-CO-R b , -O-CO-OR b , -O-CO-N(Rb )2, -NR b -CO-R b , -NR b -CO-OR b , or -NR b -CO-N(R b )2; and / or (c) one hydroxyl group of the monosaccharide group or monosaccharide subunit is replaced with =0, together with the hydrogen bonded to the same carbon atom as the hydroxyl group; and / or (d) Any two hydroxyl groups of a monosaccharide group or monosaccharide subunit together form -OR c -, -NR b -R c - is replaced by; where: Each-R b - is independently hydrogen or a substituted or unsubstituted straight-chain, branched, or cyclic alkyl, alkenyl, alkynyl, aryl, arylalkyl, arylalkenyl, arylalkynyl, alkylaryl, alkenylaryl, or alkynylaryl group containing 1 to 8 carbon atoms and optionally containing in its carbon skeleton one, two, or three heteroatoms each independently selected from O and N; Each-R c - is independently a substituted or unsubstituted alkylene, alkenylene, or alkynylene group optionally containing in its carbon skeleton one, two, or three heteroatoms each independently selected from O and N, and containing from 1 to 8 carbon atoms; However, the monosaccharide group or monosaccharide subunit has at least two, preferably at least three, -OH, -OR b , -OPO(R b )2, -OSi(R b )3, -O-CO-R b , -O-CO-OR b , -O-CO-N(R b )2, or -OR c - is subject to inclusion.
[0127] In one embodiment, -Rβ is a saccharidyl group, and one or more hydroxyl groups of the saccharidyl group are each independently -O-CO-R b Each -R b is independently C1-C4 alkyl, preferably methyl. In one embodiment, -R β is a saccharidyl group, and all hydroxyl groups of the saccharidyl group are each independently -O-CO-R b Each -R b are independently C1-C4 alkyl, preferably methyl.
[0128] In the modified monosaccharide group or monosaccharide subunit, (a) the ring of the modified monosaccharide group or monosaccharide subunit, or the ring that forms the closed form of the modified monosaccharide group or monosaccharide subunit, is partially unsaturated; and / or (b) The ring oxygen of the modified monosaccharide group or monosaccharide subunit, or what would become the ring oxygen of the closed ring form of the modified monosaccharide group or monosaccharide subunit, is -S- or -NR d -, where each -R d - is independently hydrogen or a substituted or unsubstituted straight-chain, branched, or cyclic alkyl, alkenyl, alkynyl, aryl, arylalkyl, arylalkenyl, arylalkynyl, alkylaryl, alkenylaryl, or alkynylaryl group optionally containing one or more heteroatoms each independently selected from O, N, and S in its carbon skeleton and preferably containing 1 to 15 carbon atoms.
[0129] Alternatively, if the modified monosaccharide subunit forms part of a disaccharide, oligosaccharide, or polysaccharide group, -R d may be a further monosaccharide subunit or a subunit forming part of a disaccharide, oligosaccharide or polysaccharide group, and such further monosaccharide subunit or subunits may optionally be substituted and / or modified.
[0130] Typically, in modified monosaccharide groups or monosaccharide subunits, (a) the ring of the modified monosaccharide group or monosaccharide subunit, or what would become the ring in the closed form of the modified monosaccharide group or monosaccharide subunit, contains a single C=C; and / or (b) The ring oxygen of a modified monosaccharide group or monosaccharide subunit, or the ring oxygen of the closed ring form of a modified monosaccharide group or monosaccharide subunit, is -NR d -, where each -R d are independently hydrogen or a substituted or unsubstituted straight-chain, branched, or cyclic alkyl, alkenyl, alkynyl, aryl, arylalkyl, arylalkenyl, arylalkynyl, alkylaryl, alkenylaryl, or alkynylaryl group containing from 1 to 8 carbon atoms and optionally containing in its carbon skeleton one, two, or three heteroatoms each independently selected from O and N.
[0131] Typical examples of substituted and / or modified monosaccharide subunits include those corresponding to the following: (i) deoxysugars, such as deoxyribose, fucose, fuculose, and rhamnose, in which the monosaccharidyl group or the hydroxyl group of the monosaccharide subunit is replaced by -H; (ii) amino sugars, such as glucosamine and galactosamine, in which the monosaccharide group or the hydroxyl group of the monosaccharide subunit is substituted with -NH, most typically at the 2-position; and (iii) Sugar acids containing a -COOH group, such as aldonic acids (e.g., gluconic acid), urosonic acid, uronic acids (e.g., glucuronic acid), and aldaric acids (e.g., gulanic or galactaric acid).
[0132] In one embodiment of the first or second aspect of the invention, at least one -R β is the following: [ka] is a monosaccharidyl group selected from:
[0133] Preferably, in the compound or complex according to the first or second aspect of the invention, at least one -R β teeth, [ka] is.
[0134] In one embodiment of the first or second aspect of the invention, -R 2 , -R 3 or -R 4 At least one of the following must be -R α -OR β , -R α -SR β , -R α -S(O)R β or -R α -S(O)2R β (preferably -R α -OR β or -R α -SR β ) are independently selected from -R β is the following: [ka] Selected from TIFF2024543926000019.tif116159.
[0135] In one embodiment of the first or second aspect of the invention, -R 2 , -R 3 or -R 4 At least one of the following must be -R α -[N(R 5 )3]Y, -R α -[P(R 5 )3]Y, -R α -[R 8 ]Y, -R α -[N(R 5 )2(R 5’ )], -R α -[P(R5 )2(R 5’ )], or -R α -[R 8’ In one embodiment, -R 2 , -R 3 or -R 4 At least one of the following must be -R α -[N(R 5 )3]Y, -R α -[P(R 5 )3]Y, or -R α -[R 8 ]Y. In one embodiment, -R 2 , -R 3 or -R 4 At least one of the following: [ka] are independently selected from
[0136] In the first or second aspect of the present invention, each -R 5 may be the same or different. In a preferred embodiment, each -R 5 is the same.
[0137] In one embodiment of the first or second aspect of the invention, each -R 5 is independently unsubstituted or substituted with one or two substituents. In one embodiment, each -R 5 is non-substituted.
[0138] In one embodiment of the first or second aspect of the invention, -R 8 is unsubstituted or substituted with one or two substituents. In one embodiment, -R 8 is non-substituted.
[0139] In one embodiment, -R 8 is not substituted with a halo group at the 4-position of the pyridine ring. 8 is unsubstituted at the 4-position of the pyridine ring. 8is non-substituted.
[0140] In one embodiment of the first or second aspect of the invention, -R 1 contains 1 to 100 atoms other than hydrogen, preferably 1 to 80 atoms other than hydrogen, preferably 1 to 60 atoms other than hydrogen, preferably 1 to 50 atoms other than hydrogen, preferably 1 to 45 atoms other than hydrogen.
[0141] In a particularly preferred embodiment, the first or second aspect of the present invention relates to a compound of formula (I) or a complex of formula (II): [ka] or a pharmaceutically acceptable salt thereof [In the formula, -R 1 is -CH2OR 2 , -CH2SR 2 , -CH2S(O)R 2 , -CH2S(O)2R 2 , -CHN(R 2 )(R 2’ ), -R 2 , -C(O)-OR 3 , -C(O)-SR 3 , -C(O)-N(R 3 )(R 3’ ), -C(S)-OR 3 , -C(S)-SR 3 or -C(S)-N(R 3 )(R 3’ ) [preferably, -R 1 is -C(O)-OR 3 , -C(O)-SR 3 , -C(O)-N(R 3 )(R 3’ ), -C(S)-OR 3 , -C(S)-SR 3 or -C(S)-N(R 3 )(R 3’ ) is selected from; more preferably, -R 1 is -C(O)-N(R 3 )(R 3’ ) is]; -R2 and -R 3 is -[(CH2) p Q] r -(CH2) s -[N(R 5 )3]Y, -[(CH2) p Q] r -(CH2) s -[P(R 5 )3]Y, -[(CH2) p Q] r -(CH2) s -[R 8 ]Y, -[(CH2) p Q] r -(CH2) s -[N(R 5 )2(R 5’ )], -[(CH2) p Q] r -(CH2) s -[P(R 5 )2(R 5’ )] or -[(CH2) p Q] r -(CH2) s -[R 8’ ] is selected from; -R 2’ and -R 3’ is selected from hydrogen or C1-C6 alkyl [preferably, -R 2’ and -R 3’ is selected from hydrogen or C1-C3 alkyl; more preferably, -R 2’ and -R 3’ is selected from hydrogen or methyl; -R 5 are each independently C1-C4 alkyl, C1-C4 haloalkyl, -(CH2CH2O) n -H, -(CH2CH2O) n and —CH, phenyl, or C-C heteroaryl, where phenyl or C-C heteroaryl optionally comprises one or more (e.g., 1, 2, 3, 4, or 5) C-C alkyl, C-C haloalkyl, —O(C-C alkyl), —O(C-C haloalkyl), halo, —COH, —COZ, —CONH, —O—(CHCHO). n-H or -O-(CH2CH2O) n optionally substituted with -CH3 groups; -R 5’ is C1-C4 alkyl, C1-C4 haloalkyl, -(CH2CH2O) n -H, -(CH2CH2O) n -CH3, phenyl, or C5-C6 heteroaryl, each of which is -CO2 - and the phenyl or C5-C6 heteroaryl is optionally substituted with one or more (e.g., 1, 2, 3, or 4) C1-C6 alkyl, C1-C6 haloalkyl, —O(C1-C6 alkyl), —O(C1-C6 haloalkyl), halo, —CO2H, —CO2Z, —CO2NH2, —O—(CH2CHO) n -H or -O-(CH2CH2O) n may be further substituted with -CH3 groups; -R 8 is one or more (e.g., 1, 2, 3, 4, or 5) C1-C6 alkyl, C1-C6 haloalkyl, -O(C1-C6 alkyl), -O(C1-C6 haloalkyl), halo, -CO2H, -CO2Z, -CO2NH2, -O-(CH2CH2O) n -H or -O-(CH2CH2O) n -[NC5H5] optionally substituted with -CH3 groups; -R 8’ is -CO2 - and optionally substituted with one or more (e.g., 1, 2, 3, or 4) C-C alkyl, C-C haloalkyl, —O(C-C alkyl), —O(C-C haloalkyl), halo, —COH, —COZ, —CONH, —O—(CHCHO) n -H or -O-(CH2CH2O) n -[NC5H5] further substituted with -CH3 groups; Q is O, S, NH, or NMe [preferably Q is O]; Y is a counteranion; Z is a countercation; M 2+ is a metal cation; n is 1, 2, 3, 4, 5 or 6; p is 0, 1, 2, 3 or 4; r is 0, 1, 2, 3, 4, 5, or 6; s is 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 or 12].
[0142] In a particularly preferred embodiment, the first or second aspect of the present invention relates to a compound of formula (I) or a complex of formula (II): [ka] or a pharmaceutically acceptable salt thereof [In the formula, -R 1 is -C(O)-N(R 3 )(R 3’ ) and -R 3 -[(CH2) p Q] r -(CH2) s -[N(R 5 )3]Y, -[(CH2) p Q] r -(CH2) s -[P(R 5 )3]Y, -[(CH2) p Q] r -(CH2) s -[R 8 ]Y, -[(CH2) p Q] r -(CH2) s -[N(R 5 )2(R 5’ )], -[(CH2) p Q] r -(CH2) s -[P(R 5 )2(R 5’ )] or -[(CH2) p Q] r -(CH2) s -[R 8’ ] is selected from; -R 3’ is selected from hydrogen or C1-C3 alkyl (preferably hydrogen or methyl); -R 5 are each independently selected from C1-C3 alkyl or phenyl, and phenyl is optionally selected from C1-C6 alkyl, —O(C1-C6 alkyl), —CO2H, —CO2Z, —CO2NH2, —O—(CH2CH2O) n -H or -O-(CH2CH2O) n optionally substituted with 1, 2, 3, 4, or 5 substituents independently selected from -CH3; -R 5’ is -CO2 - C1-C3 alkyl substituted with -CO2 - phenyl optionally substituted with C1-C6 alkyl, —O(C1-C6 alkyl), —CO2H, —CO2Z, —CO2NH2, —O—(CH2CH2O) n -H or -O-(CH2CH2O) n may be further substituted with 1, 2, 3, or 4 substituents independently selected from -CH3; -R 8 is C1-C6 alkyl, -O(C1-C6 alkyl), -CO2H, -CO2Z, -CO2NH2, -O-(CH2CH2O) n -H or -O-(CH2CH2O) n -[NC5H5] optionally substituted with 1, 2, 3, 4, or 5 substituents independently selected from -CH3; -R 8’ is -CO2 - Substituted with C1-C6 alkyl, -O(C1-C6 alkyl), -CO2H, -CO2Z, -CO2NH2, -O-(CH2CH2O) n -H or -O-(CH2CH2O) n -[NC5H5] optionally further substituted with 1, 2, 3, or 4 substituents independently selected from -CH3; Q is O, S, NH or NMe (preferably O); Y is a counteranion; Z is a countercation; M 2+ is a metal cation; n is 1, 2, 3, 4, 5 or 6; p is 0, 1, 2, 3 or 4; r is 0, 1, 2, 3, 4, 5, or 6; s is 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 or 12].
[0143] In these two preferred embodiments of the previous paragraph, each -R 5 may be the same or different. Preferably, each -R 5 is the same.
[0144] In another preferred embodiment of the first or second aspect of the invention, the compound is a compound of formula (IA), (IB), (IC), (ID), (IE), (IF) or (IG): [ka] TIFF2024543926000024.tif149159 or a metal cation complex thereof, or a pharmaceutically acceptable salt thereof, wherein: -R 3’ is selected from hydrogen or C1-C3 alkyl (preferably hydrogen or methyl); -R δ is selected from C1-C3 alkyl; -R ε is C1-C6 alkyl, -O(C1-C6 alkyl), -CO2H, -CO2Z, -CO2NH2, -O-(CH2CH2O) n -H or -O-(CH2CH2O) n - selected from CH3; Y is a counteranion; Z is a countercation; n is 1, 2, 3 or 4; p is 0, 1, 2, 3 or 4; r is 0, 1, 2, 3, 4, 5, or 6; s is 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, or 12; t is 0, 1, 2, 3, 4, or 5; and u is 0, 1, 2, 3 and 4.
[0145] The compounds of formula (IA), (IB), (IC), (ID), (IE), (IF), (IG) and their complexes and salts according to the first and second aspects of the present invention comprise a moiety -[(CH) p O] r -(CH2) s -including, where: p is 0, 1, 2, 3 or 4; r is 0, 1, 2, 3, 4, 5, or 6; s is 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, or 12.
[0146] In one embodiment, p is 2, 3, or 4; r is 1; and s is 2, 3, or 4. In a preferred embodiment, p is 3; r is 1; s is 3; -[(CH) p O] r -(CH2) s - is intended to be -(CH2)3-O-(CH2)3-.
[0147] In another embodiment, p is 2 or 3; r is 2 or 3; and s is 2 or 3. In a preferred embodiment, p is 2; r is 2; and s is 2; -[(CH) p O] r -(CH2) s - is intended to be -(CH2CH2O)2-(CH2)2-.
[0148] In yet another embodiment, r is 0; s is 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, or 12; -[(CH) p O] r -(CH2) s - is -(CH2) 1-12 -It is designed to be.
[0149] Preferably, in the compound or complex according to the first or second aspect of the present invention, the compound or complex is [ka] wherein Y is a counter anion and q is 0, 1, 2, 3, or 4 (preferably, q is 1). or a metal cation complex thereof, or a pharmaceutically acceptable salt thereof.
[0150] In a particularly preferred embodiment, the first or second aspect of the present invention relates to a compound of formula (III) or a complex of formula (IV): [ka] or a pharmaceutically acceptable salt thereof [In the formula, -R 1 is -C(O)-OR 3 , -C(O)-SR 3 or -C(O)-N(R 3 )(R 3’ ) and -R 3 is R α -OR β or -R α -SR β -R β is a saccharidyl group, and -R 3’ is H or C1-C4 alkyl; -R 6 is as follows: (a)-C(O)-OR 3 , -C(O)-SR 3 or -C(O)-N(R 3 )2, and -R 3 are each independently C1-C4 alkyl, preferably -R 6 -C(O)-OR 3 and -R 3 is C1-C4 alkyl; or (b)-C(O)-OR 3 , -C(O)-SR 3 or -C(O)-N(R 3 )(R 3’ ) wherein -R 3 -R α -ORβ or -R α -SR β -R β is a saccharidyl group, and -R 3’ is H or C1-C4 alkyl; -R α - is C1-C 12 alkylene groups, which may be substituted with one or more C1-C4 alkyl, C1-C4 haloalkyl or halo groups, and one or more carbon atoms in the backbone of the alkylene group may be substituted with one or more heteroatoms O or S; M 2+ is a metal cation] to provide.
[0151] In a particularly preferred embodiment, the first or second aspect of the present invention relates to a compound of formula (III) or a complex of formula (IV): [ka] or a pharmaceutically acceptable salt thereof [In the formula, -R 1 is as follows: (a)-C(O)-OR 3 , -C(O)-SR 3 or -C(O)-N(R 3 )2, and -R 3 are each independently -R β and -R β is a C1-C4 alkyl group, more preferably -R 1 is -C(O)-OR 3 and -R 3 -R β and -R β is a C1-C4 alkyl group; or (b)-C(O)-OR 3 , -C(O)-SR 3 or -C(O)-N(R 3 )(R 3’ ) and -R 3 Ha-R α -OR βor -R α -SR β -R β is a saccharidyl group, and -R 3’ is H or C1-C4 alkyl; -R 6 is -C(O)-OR 3 , -C(O)-SR 3 or -C(O)-N(R 3 )(R 3’ ) and -R 3 is R α -OR β or -R α -SR β -R β is a saccharidyl group, and -R 3’ is H or C1-C4 alkyl; -R α - is C1-C 12 alkylene groups, which may be substituted with one or more C1-C4 alkyl, C1-C4 haloalkyl or halo groups, and one or more carbon atoms in the backbone of the alkylene group may be substituted with one or more heteroatoms O or S; M 2+ is a metal cation] to provide.
[0152] In a particularly preferred embodiment, the first or second aspect of the present invention relates to a compound of formula (III) or a complex of formula (IV): [ka] or a pharmaceutically acceptable salt thereof [In the formula, -R 1 is -C(O)-OR 3 , -C(O)-SR 3 or -C(O)-N(R 3 )(R 3’ ) and -R 3 is R α -OR β or -R α -SR β -Rβ is a saccharidyl group, and -R 3’ is H or C1-C4 alkyl; -R 6 is -C(O)-OR 3 , -C(O)-SR 3 or -C(O)-N(R 3 )(R 3’ ) wherein -R 3 -R α -OR β or -R α -SR β -R β is a saccharidyl group, and -R 3’ is H or C1-C4 alkyl; -R α - is C1-C 12 alkylene groups, which may be substituted with one or more C1-C4 alkyl, C1-C4 haloalkyl or halo groups, and one or more carbon atoms in the backbone of the alkylene group may be substituted with one or more heteroatoms O or S; M 2+ is a metal cation] to provide.
[0153] In a particularly preferred embodiment, the first or second aspect of the present invention relates to a compound of formula (III) or a complex of formula (IV): [ka] or a pharmaceutically acceptable salt thereof [In the formula, -R 1 is -CH2OR 2 , -CH2SR 2 , -CH2S(O)R 2 , -CH2S(O)2R 2 , -CHN(R 2 )(R 2’ ), -R 2 , -C(O)-OR 3 , -C(O)-SR 3 , -C(O)-N(R 3 )(R 3’), -C(S)-OR 3 , -C(S)-SR 3 or -C(S)-N(R 3 )(R 3’ ) [preferably, -R 1 is -C(O)-OR 3 , -C(O)-SR 3 , -C(O)-N(R 3 )(R 3’ ), -C(S)-OR 3 , -C(S)-SR 3 or -C(S)-N(R 3 )(R 3’ ) is selected from; more preferably, -R 1 is -C(O)-N(R 3 )(R 3’ ) is]; -R 2 -H, -C(O)R 4 , -C(O)-OR 4 , -C(O)-SR 4 , -C(O)-N(R 4 )(R 4’ ), -C(S)-OR 4 , -C(S)-SR 4 , -C(S)-N(R 4 )(R 4’ ), -R α -H, -R β , -R α -R β , -R α -OH, -R α -OR β , -R α -SH, -R α -SR β , -R α -S(O)R β , -R α -S(O)2R β , -R α -NH2, -R α -NH(R β ), -R α -N(R β )2, -R α -X, -[(CH2) p Q] r -(CH2) s -[N(R 5)3]Y, -[(CH2) p Q] r -(CH2) s -[P(R 5 )3]Y, -[(CH2) p Q] r -(CH2) s -[R 8 ]Y, -[(CH2) p Q] r -(CH2) s -[N(R 5 )2(R 5’ )], -[(CH2) p Q] r -(CH2) s -[P(R 5 )2(R 5’ )] or -[(CH2) p Q] r -(CH2) s -[R 8’ ] is selected from; -R 3 and -R 4 are each independently -H, -R α -H, -R β , -R α -R β , -R α -OH, -R α -OR β , R α -SH, -R α -SR β , -R α -S(O)R β , -R α -S(O)2R β , -R α -NH2, -R α -NH(R β ), -R α -N(R β )2, -R α -X, -[(CH2) p Q] r -(CH2) s -[N(R 5 )3]Y, -[(CH2) p Q] r -(CH2) s -[P(R 5 )3]Y, -[(CH2) p Q]r -(CH2) s -[R 8 ]Y, -[(CH)2] p Q] r -(CH2) s -[N(R 5 )2(R 5’ )], -[(CH2) p Q] r -(CH2) s -[P(R 5 )2(R 5’ )] or -[(CH2) p Q] r -(CH2) s -[R 8’ ] is selected from -R 2 , -R 3 , and -R 4 At least one of the -[(CH2) p Q] r -(CH2) s -[N(R 5 )3]Y, -[(CH2) p Q] r -(CH2) s -[P(R 5 )3]Y, -[(CH2) p Q] r -(CH2) s -[R 8 ]Y, -[(CH2) p Q] r -(CH2) s -[N(R 5 )2(R 5’ )], -[(CH2) p Q] r -(CH2) s -[P(R 5 )2(R 5’ )] or -[(CH2) p Q] r -(CH2) s -[R 8’ ] is selected from; -R 2’ , -R 3’ , and -R 4’ are each independently selected from hydrogen or C1-C6 alkyl, preferably -R 2’ , -R3’ , and -R 4’ are each independently selected from hydrogen or C1-C3 alkyl; more preferably, -R 2’ , -R 3’ , and -R 4’ are each independently selected from hydrogen or methyl; -R α - are each independently C1-C 42 alkylene groups, which may be optionally substituted with one or more (e.g., 1, 2, 3, 4, or 5) C1-C4 alkyl, C1-C4 haloalkyl, or halo groups, and one or more (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10) carbon atoms in the backbone of the alkylene group may be optionally substituted with a heteroatom or group independently selected from O, S, NH, or NMe; -R β are each independently a saturated or unsaturated hydrocarbyl group which may be linear or branched or may be or contain a cyclic group which may be optionally substituted and which may optionally contain one or more (e.g., 1, 2, 3, 4 or 5) heteroatoms N, O, S, P or Se in its carbon skeleton; -R 5 are each independently C1-C4 alkyl, C1-C4 haloalkyl, -(CH2CH2O) n -H, -(CH2CH2O) n and —CH, phenyl, or C-C heteroaryl, where phenyl or C-C heteroaryl optionally comprises one or more (e.g., 1, 2, 3, 4, or 5) C-C alkyl, C-C haloalkyl, —O(C-C alkyl), —O(C-C haloalkyl), halo, —COH, —COZ, —CONH, —O—(CHCHO). n -H or -O-(CH2CH2O) n optionally substituted with -CH3 groups; -R 5’ is C1-C4 alkyl, C1-C4 haloalkyl, -(CH2CH2O) n-H, -(CH2CH2O) n -CH3, phenyl, or C5-C6 heteroaryl, each of which is -CO2 - and the phenyl or C5-C6 heteroaryl is optionally substituted with one or more (e.g., 1, 2, 3, or 4) C1-C6 alkyl, C1-C6 haloalkyl, —O(C1-C6 alkyl), —O(C1-C6 haloalkyl), halo, —CO2H, —CO2Z, —CO2NH2, —O—(CH2CHO) n -H or -O-(CH2CH2O) n may be further substituted with -CH3 groups; -R 6 is -C(O)-OR 3 , -C(O)-SR 3 , -C(O)-N(R 3 )(R 3’ ), -C(S)-OR 3 , -C(S)-SR 3 or -C(S)-N(R 3 )(R 3’ ) [preferably -R 6 is -C(O)-N(R 3 )(R 3’ ) is]; -R 8 is one or more (e.g., 1, 2, 3, 4, or 5) C1-C6 alkyl, C1-C6 haloalkyl, -O(C1-C6 alkyl), -O(C1-C6 haloalkyl), halo, -CO2H, -CO2Z, -CO2NH2, -O-(CH2CH2O) n -H or -O-(CH2CH2O) n -[NC5H5] optionally substituted with -CH3 groups; -R 8’ is -CO2 - and optionally substituted with one or more (e.g., 1, 2, 3, or 4) C-C alkyl, C-C haloalkyl, —O(C-C alkyl), —O(C-C haloalkyl), halo, —COH, —COZ, —CONH, —O—(CHCHO) n -H or -O-(CH2CH2O) n -[NC5H5] further substituted with -CH3 groups; Q is O, S, NH, or NMe [preferably Q is O]; X is a halo group; Y is a counteranion; Z is a countercation; M 2+ is a metal cation; n is 1, 2, 3, 4, 5 or 6; p is 0, 1, 2, 3 or 4; r is 0, 1, 2, 3, 4, 5, or 6; s is 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 or 12].
[0154] In a particularly preferred embodiment, the first or second aspect of the present invention relates to a compound of formula (III) or a complex of formula (IV): [ka] or a pharmaceutically acceptable salt thereof [In the formula, -R 1 is -C(O)-OR 3 , -C(O)-SR 3 , -C(O)-N(R 3 )(R 3’ ), -C(S)-OR 3 , -C(S)-SR 3 or -C(S)-N(R 3 )(R 3’ ) [preferably -R 1 is -C(O)-N(R 3 )(R 3’ ) is]; -R 3 are each independently -H, -R α -H, -R β , -R α -R β , -R α -OH, -R α -OR β , -R α -SH, -R α -SR β , -R α -S(O)Rβ , -R α -S(O)2R β , -R α -NH2, -R α -NH(R β ), -R α -N(R β )2, -R α -X, -[(CH2) p Q] r -(CH2) s -[N(R 5 )3]Y, -[(CH2) p Q] r -(CH2) s -[P(R 5 )3]Y, -[(CH2) p Q] r -(CH2) s -[R 8 ]Y, -[(CH2) p Q] r -(CH2) s -[N(R 5 )2(R 5’ )], -[(CH2) p Q] r -(CH2) s -[P(R 5 )2(R 5’ )] or -[(CH2) p Q] r -(CH2) s -[R 8’ ]; where at least one -R 3 is -[(CH2) p Q] r -(CH2) s -[N(R 5 )3]Y, -[(CH2) p Q] r -(CH2) s -[P(R 5 )3]Y, -[(CH2) p Q] r -(CH2) s -[R 8 ]Y, -[(CH2) p Q] r -(CH2) s -[N(R 5 )2(R 5’)], -[(CH2) p Q] r -(CH2) s -[P(R 5 )2(R 5’ )] or -[(CH2) p Q] r -(CH2) s -[R 8’ ] is selected from -R 3’ is selected from hydrogen or C1-C3 alkyl, preferably -R 3’ is hydrogen or methyl]; -R α - are each independently C1-C 42 alkylene groups, which may be optionally substituted with one or more (e.g., 1, 2, 3, 4, or 5) C1-C4 alkyl, C1-C4 haloalkyl, or halo groups, and one or more (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10) carbon atoms in the backbone of the alkylene group may be optionally substituted with a heteroatom or group independently selected from O, S, NH, or NMe; -R β are each independently a saturated or unsaturated hydrocarbyl group which may be linear or branched or may be or contain a cyclic group which may be optionally substituted and which may optionally contain one or more (e.g., 1, 2, 3, 4 or 5) heteroatoms N, O, S, P or Se in its carbon skeleton; -R 5 are each independently selected from C1-C3 alkyl or phenyl, and phenyl is optionally selected from C1-C6 alkyl, —O(C1-C6 alkyl), —CO2H, —CO2Z, —CO2NH2, —O—(CH2CH2O) n -H or -O-(CH2CH2O) n optionally substituted with 1, 2, 3, 4, or 5 substituents independently selected from -CH3; -R 5’ is -CO2 - C1-C3 alkyl substituted with -CO2 -phenyl optionally substituted with C1-C6 alkyl, —O(C1-C6 alkyl), —CO2H, —CO2Z, —CO2NH2, —O—(CH2CH2O) n -H or -O-(CH2CH2O) n may be further substituted with 1, 2, 3, or 4 substituents independently selected from -CH3; -R 6 is -C(O)-OR 3 , -C(O)-SR 3 , -C(O)-N(R 3 )(R 3’ ), -C(S)-OR 3 , -C(S)-SR 3 or -C(S)-N(R 3 )(R 3’ ) [preferably -R 6 is -C(O)-N(R 3 )(R 3’ ) is]; -R 8 is C1-C6 alkyl, -O(C1-C6 alkyl), -CO2H, -CO2Z, -CO2NH2, -O-(CH2CH2O) n -H or -O-(CH2CH2O) n -[NC5H5] optionally substituted with 1, 2, 3, 4, or 5 substituents independently selected from -CH3; -R 8’ is -CO2 - Substituted with C1-C6 alkyl, -O(C1-C6 alkyl), -CO2H, -CO2Z, -CO2NH2, -O-(CH2CH2O) n -H or -O-(CH2CH2O) n -[NC5H5] optionally further substituted with 1, 2, 3, or 4 substituents independently selected from -CH3; Q is O, S, NH, or NMe [preferably Q is O]; X is a halo group; Y is a counteranion; Z is a countercation; M 2+ is a metal cation; n is 1, 2, 3, 4, 5 or 6; p is 0, 1, 2, 3 or 4; r is 0, 1, 2, 3, 4, 5, or 6; s is 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 or 12].
[0155] In these two preferred embodiments of the previous paragraph, each -R 5 may be the same or different. Preferably, each -R 5 is the same.
[0156] In another preferred embodiment of the first or second aspect of the invention, the compound is a compound of formula (IIIA), (IIIB), (IIIC), (IIID), (IIIE), (IIIF), (IIIG), (IIIH), (IIIJ), (IIIK), (IIIL), (IIIM), (IIIN) or (IIIO): [ka] TIFF2024543926000032.tif239159TIFF2024543926000033.tif133159 or a metal cation complex thereof, or a pharmaceutically acceptable salt thereof, wherein: -R 1 is -C(O)-OR 3 , -C(O)-SR 3 , -C(O)-N(R 3 )(R 3’ ), -C(S)-OR 3 , -C(S)-SR 3 or -C(S)-N(R 3 )(R 3’ ) are selected from; -R 3 -H, -R α -H, -R β , -R α -R β , -R α -OH, -R α -OR β , -R α -SH, -R α-SR β , -R α -S(O)R β , -R α -S(O)2R β , -R α -NH2, -R α -NH(R β ), -R α -N(R β )2, or -R α -X is selected from; -R 3’ is selected from hydrogen or C1-C3 alkyl (preferably hydrogen or methyl); -R 6 is -C(O)-OR 3 , -C(O)-SR 3 , -C(O)-N(R 3 )(R 3’ ), -C(S)-OR 3 , -C(S)-SR 3 or -C(S)-N(R 3 )(R 3’ ) are selected from; -R α - are each independently C1-C 12 alkylene groups, which may be optionally substituted with one or more (e.g., 1, 2, 3, 4, or 5) C1-C4 alkyl, C1-C4 haloalkyl, or halo groups, and one or more (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10) carbon atoms in the backbone of the alkylene group may be optionally substituted with a heteroatom or group independently selected from O, S, NH, or NMe; -R β are each independently a saturated or unsaturated hydrocarbyl group which may be linear or branched or may be or contain a cyclic group which may be optionally substituted and which may optionally contain one or more (e.g., 1, 2, 3, 4 or 5) heteroatoms N, O, S, P or Se in its carbon skeleton; -R δ is selected from C1-C3 alkyl; -R εis C1-C6 alkyl, -O(C1-C6 alkyl), -CO2H, -CO2Z, -CO2NH2, -O-(CH2CH2O) n -H or -O-(CH2CH2O) n - selected from CH3; X is a halo group; Y is a counteranion; Z is a countercation; n is 1, 2, 3 or 4; p is 0, 1, 2, 3 or 4; r is 0, 1, 2, 3, 4, 5, or 6; s is 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, or 12; t is 0, 1, 2, 3, 4, or 5; and u is 0, 1, 2, 3 and 4.
[0157] The compounds of formula (IIIA), (IIIB), (IIIC), (IIID), (IIIE), (IIIF), (IIIG), (IIIH), (IIIJ), (IIIK), (IIIL), (IIIM), (IIIN), (IIIO) and complexes and salts thereof according to the first and second aspects of the present invention comprise a moiety -[(CH2) p O] r -(CH2) s -, wherein p is 0, 1, 2, 3 or 4; r is 0, 1, 2, 3, 4, 5, or 6; s is 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 or 12].
[0158] In one embodiment, p is 2, 3, or 4; r is 1; and s is 2, 3, or 4. In a preferred embodiment, p is 3; r is 1; s is 3; -[(CH) p O] r -(CH2) s - is intended to be -(CH2)3-O-(CH2)3-.
[0159] In another embodiment, p is 2 or 3; r is 2 or 3; and s is 2 or 3. In a preferred embodiment, p is 2; r is 2; and s is 2; -[(CH) p O] r -(CH2) s - is intended to be -(CH2CH2O)2-(CH2)2-.
[0160] In yet another embodiment, r is 0; s is 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, or 12; -[(CH) p O] r -(CH2) s - is -(CH2) 1-12 -It is designed to be.
[0161] Preferably, in the compound or complex according to the first or second aspect of the present invention, the compound or complex is [ka] wherein Y is a counter anion and q is 0, 1, 2, 3, or 4 (preferably, q is 1). or a metal cation complex thereof, or a pharmaceutically acceptable salt thereof.
[0162] In a particularly preferred embodiment, the first or second aspect of the present invention provides a compound of formula (V) or a complex of formula (VI): [ka] or a pharmaceutically acceptable salt thereof [In the formula, -R 1 is -C(O)-OR 3 , -C(O)-SR 3 or -C(O)-N(R 3 )(R 3’ ) and -R 3 is R α -OR β or -R α -SR β -Rβ is a saccharidyl group, and -R 3’ is H or C1-C4 alkyl; -R 6 is as follows: (a)-C(O)-OR 3 , -C(O)-SR 3 or -C(O)-N(R 3 )2, and -R 3 are each independently C1-C4 alkyl, preferably -R 6 -C(O)-OR 3 and -R 3 is C1-C4 alkyl; or (b)-C(O)-OR 3 , -C(O)-SR 3 or -C(O)-N(R 3 )(R 3’ ) wherein -R 3 -R α -OR β or -R α -SR β -R β is a saccharidyl group, and -R 3’ is H or C1-C4 alkyl; -R 7 is as follows: (a)-C(O)-OR 3 , -C(O)-SR 3 or -C(O)-N(R 3 )2, and -R 3 are each independently C1-C4 alkyl, preferably -R 7 -C(O)-OR 3 and -R 3 is C1-C4 alkyl; or (b)-C(O)-OR 3 , -C(O)-SR 3 or -C(O)-N(R 3 )(R 3’ ) wherein -R 3 -R α -OR β or -R α -SR β-R β is a saccharidyl group, and -R 3’ is H or C1-C4 alkyl; -R α - is C1-C 12 alkylene groups, which may be substituted with one or more C1-C4 alkyl, C1-C4 haloalkyl or halo groups, and one or more carbon atoms in the backbone of the alkylene group may be substituted with one or more heteroatoms O or S; M 2+ is a metal cation] to provide.
[0163] In a particularly preferred embodiment, the first or second aspect of the present invention provides a compound of formula (V) or a complex of formula (VI): [ka] or a pharmaceutically acceptable salt thereof [In the formula, -R 1 is as follows: (a)-C(O)-OR 3 , -C(O)-SR 3 or -C(O)-N(R 3 )2, and -R 3 are each independently -R β and -R β is a C1-C4 alkyl group, more preferably -R 1 is -C(O)-OR 3 and -R 3 -R β and -R β is a C1-C4 alkyl group; or (b)-C(O)-OR 3 , -C(O)-SR 3 or -C(O)-N(R 3 )(R 3’ ) and -R 3 Ha-R α -OR β or -R α -SR β -Rβ is a saccharidyl group, and -R 3’ is H or C1-C4 alkyl; -R 6 is -C(O)-OR 3 , -C(O)-SR 3 or -C(O)-N(R 3 )(R 3’ ) and -R 3 is R α -OR β or -R α -SR β -R β is a saccharidyl group, and -R 3’ is H or C1-C4 alkyl; -R 7 is as follows: (a)-C(O)-OR 3 , -C(O)-SR 3 or -C(O)-N(R 3 )2, and -R 3 are each independently C1-C4 alkyl, preferably -R 7 -C(O)-OR 3 and -R 3 is C1-C4 alkyl; or (b)-C(O)-OR 3 , -C(O)-SR 3 or -C(O)-N(R 3 )(R 3’ ) wherein -R 3 -R α -OR β or -R α -SR β -R β is a saccharidyl group, and -R 3’ is H or C1-C4 alkyl; -R α - is C1-C 12 alkylene groups, which may be substituted with one or more C1-C4 alkyl, C1-C4 haloalkyl or halo groups, and one or more carbon atoms in the backbone of the alkylene group may be substituted with one or more heteroatoms O or S; M 2+ is a metal cation] to provide.
[0164] In a particularly preferred embodiment, the first or second aspect of the present invention provides a compound of formula (V) or a complex of formula (VI): [ka] or a pharmaceutically acceptable salt thereof [In the formula, -R 1 is as follows: (a)-C(O)-OR 3 , -C(O)-SR 3 or -C(O)-N(R 3 )2, and -R 3 are each independently -R β and -R β is a C1-C4 alkyl group, more preferably -R 1 is -C(O)-OR 3 and -R 3 -R β and -R β is a C1-C4 alkyl group; or (b)-C(O)-OR 3 , -C(O)-SR 3 or -C(O)-N(R 3 )(R 3’ ) and -R 3 Ha-R α -OR β or -R α -SR β -R β is a saccharidyl group, and -R 3’ is H or C1-C4 alkyl; -R 6 is as follows: (a)-C(O)-OR 3 , -C(O)-SR 3 or -C(O)-N(R 3 )2, and -R 3 are each independently C1-C4 alkyl, preferably -R6 -C(O)-OR 3 and -R 3 is C1-C4 alkyl; or (b)-C(O)-OR 3 , -C(O)-SR 3 or -C(O)-N(R 3 )(R 3’ ) wherein -R 3 -R α -OR β or -R α -SR β -R β is a saccharidyl group, and -R 3’ is H or C1-C4 alkyl; -R 7 is -C(O)-OR 3 , -C(O)-SR 3 or -C(O)-N(R 3 )(R 3’ ) and -R 3 is R α -OR β or -R α -SR β -R β is a saccharidyl group, and -R 3’ is H or C1-C4 alkyl; -R α - is C1-C 12 alkylene groups, which may be substituted with one or more C1-C4 alkyl, C1-C4 haloalkyl or halo groups, and one or more carbon atoms in the backbone of the alkylene group may be substituted with one or more heteroatoms O or S; M 2+ is a metal cation] to provide.
[0165] In a particularly preferred embodiment, the first or second aspect of the present invention provides a compound of formula (V) or a complex of formula (VI): [ka] or a pharmaceutically acceptable salt thereof [In the formula, -R 1 is -CH2OR 2 , -CH2SR 2 , -CH2S(O)R 2 , -CH2S(O)2R 2 , -CHN(R 2 )(R 2’ ), -R 2 , -C(O)-OR 3 , -C(O)-SR 3 , -C(O)-N(R 3 )(R 3’ ), -C(S)-OR 3 , -C(S)-SR 3 or -C(S)-N(R 3 )(R 3’ ) [preferably, -R 1 is -C(O)-OR 3 , -C(O)-SR 3 , -C(O)-N(R 3 )(R 3’ ), -C(S)-OR 3 , -C(S)-SR 3 or -C(S)-N(R 3 )(R 3’ ) is selected from; more preferably, -R 1 is -C(O)-N(R 3 )(R 3’ ) is]; -R 2 -H, -C(O)R 4 , -C(O)-OR 4 , -C(O)-SR 4 , -C(O)-N(R 4 )(R 4’ ), -C(S)-OR 4 , -C(S)-SR 4 , -C(S)-N(R 4 )(R 4’ ), -R α -H, -R β , -R α -R β , -R α -OH, -R α -OR β , -R α -SH, -R α-SR β , -R α -S(O)R β , -R α -S(O)2R β , -R α -NH2, -R α -NH(R β ), -R α -N(R β )2, -R α -X, -[(CH2) p Q] r -(CH2) s -[N(R 5 )3]Y, -[(CH2) p Q] r -(CH2) s -[P(R 5 )3]Y, -[(CH2) p Q] r -(CH2) s -[R 8 ]Y, -[(CH2) p Q] r -(CH2) s -[N(R 5 )2(R 5’ )], -[(CH2) p Q] r -(CH2) s -[P(R 5 )2(R 5’ )] or -[(CH2) p Q] r -(CH2) s -[R 8’ ] is selected from; -R 3 and -R 4 are each independently -H, -R α -H, -R β , -R α -R β , -R α -OH, -R α -OR β , R α -SH, -R α -SR β , -R α -S(O)R β , -R α -S(O)2R β , -R α-NH2, -R α -NH(R β ), -R α -N(R β )2, -R α -X, -[(CH2) p Q] r -(CH2) s -[N(R 5 )3]Y, -[(CH2) p Q] r -(CH2)- s -[P(R 5 )3]Y, -[(CH2) p Q] r -(CH2) s -[R 8 ]Y, -[(CH2) p Q] r -(CH2) s -[N(R 5 )2(R 5’ )], -[(CH2) p Q] r -(CH2) s -[P(R 5 )2(R 5’ )] or -[(CH2) p Q] r -(CH2) s -[R 8’ ] is selected from -R 2 , -R 3 , and -R 4 At least one of the -[(CH2) p Q] r -(CH2) s -[N(R 5 )3]Y, -[(CH2) p Q] r -(CH2) s -[P(R 5 )3]Y, -[(CH2) p Q] r -(CH2) s -[R 8 ]Y, -[(CH2) p Q] r -(CH2) s -[N(R 5 )2(R 5’ )], -[(CH2) p Q]r -(CH2) s -[P(R 5 )2(R 5’ )] or -[(CH2) p Q] r -(CH2) s -[R 8’ ] is selected from; -R 2’ , -R 3’ , and -R 4’ are each independently selected from hydrogen or C1-C6 alkyl, preferably -R 2’ , -R 3’ , and -R 4’ are each independently selected from hydrogen or C1-C3 alkyl; more preferably, -R 2’ , -R 3’ , and -R 4’ are each independently selected from hydrogen or methyl; -R α - are each independently C1-C 42 alkylene groups, which may be optionally substituted with one or more (e.g., 1, 2, 3, 4, or 5) C1-C4 alkyl, C1-C4 haloalkyl, or halo groups, and one or more (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10) carbon atoms in the backbone of the alkylene group may be optionally substituted with a heteroatom or group independently selected from O, S, NH, or NMe; -R β are each independently a saturated or unsaturated hydrocarbyl group which may be linear or branched or may be or contain a cyclic group which may be optionally substituted and which may optionally contain one or more (e.g., 1, 2, 3, 4 or 5) heteroatoms N, O, S, P or Se in its carbon skeleton; -R 5 are each independently C1-C4 alkyl, C1-C4 haloalkyl, -(CH2CH2O) n -H, -(CH2CH2O) nand —CH, phenyl, or C-C heteroaryl, where phenyl or C-C heteroaryl optionally comprises one or more (e.g., 1, 2, 3, 4, or 5) C-C alkyl, C-C haloalkyl, —O(C-C alkyl), —O(C-C haloalkyl), halo, —COH, —COZ, —CONH, —O—(CHCHO). n -H or -O-(CH2CH2O) n optionally substituted with -CH3 groups; -R 5’ is C1-C4 alkyl, C1-C4 haloalkyl, -(CH2CH2O) n -H, -(CH2CH2O) n -CH3, phenyl, or C5-C6 heteroaryl, each of which is -CO2 - and the phenyl or C5-C6 heteroaryl is optionally substituted with one or more (e.g., 1, 2, 3, or 4) C1-C6 alkyl, C1-C6 haloalkyl, —O(C1-C6 alkyl), —O(C1-C6 haloalkyl), halo, —CO2H, —CO2Z, —CO2NH2, —O—(CH2CHO) n -H or -O-(CH2CH2O) n may be further substituted with -CH3 groups; -R 6 is -C(O)-OR 3 , -C(O)-SR 3 , -C(O)-N(R 3 )(R 3’ ), -C(S)-OR 3 , -C(S)-SR 3 or -C(S)-N(R 3 )(R 3’ ) [preferably -R 6 is -C(O)-N(R 3 )(R 3’ ) is]; -R 7 is -C(O)-OR 3 , -C(O)-SR 3 , -C(O)-N(R 3 )(R 3’ ), -C(S)-OR 3 , -C(S)-SR3 or -C(S)-N(R 3 )(R 3’ ) [preferably -R 7 is -C(O)-N(R 3 )(R 3’ ) is]; -R 8 is one or more (e.g., 1, 2, 3, 4, or 5) C1-C6 alkyl, C1-C6 haloalkyl, -O(C1-C6 alkyl), -O(C1-C6 haloalkyl), halo, -CO2H, -CO2Z, -CO2NH2, -O-(CH2CH2O) n -H or -O-(CH2CH2O) n -[NC5H5] optionally substituted with -CH3 groups; -R 8’ is -CO2 - and optionally substituted with one or more (e.g., 1, 2, 3, or 4) C-C alkyl, C-C haloalkyl, —O(C-C alkyl), —O(C-C haloalkyl), halo, —COH, —COZ, —CONH, —O—(CHCHO) n -H or -O-(CH2CH2O) n -[NC5H5] further substituted with -CH3 groups; Q is O, S, NH, or NMe [preferably Q is O]; X is a halo group; Y is a counteranion; Z is a countercation; M 2+ is a metal cation; n is 1, 2, 3, 4, 5 or 6; p is 0, 1, 2, 3 or 4; r is 0, 1, 2, 3, 4, 5, or 6; s is 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 or 12].
[0166] In a particularly preferred embodiment, the first or second aspect of the present invention provides a compound of formula (V) or a complex of formula (VI): [ka] or a pharmaceutically acceptable salt thereof [In the formula, -R 1 is -C(O)-OR 3 , -C(O)-SR 3 , -C(O)-N(R 3 )(R 3’ ), -C(S)-OR 3 , -C(S)-SR 3 or -C(S)-N(R 3 )(R 3’ ) [preferably -R 1 is -C(O)-N(R 3 )(R 3’ ) is]; -R 3 are each independently -H, -R α -H, -R β , -R α -R β , -R α -OH, -R α -OR β , -R α -SH, -R α -SR β , -R α -S(O)R β , -R α -S(O)2R β , -R α -NH2, -R α -NH(R β ), -R α -N(R β )2, -R α -X, -[(CH2) p Q] r -(CH2) s -[N(R 5 )3]Y, -[(CH2) p Q] r -(CH2) s -[P(R 5 )3]Y, -[(CH2) p Q] r -(CH2) s -[R 8 ]Y, -[(CH2) p Q] r -(CH2)s -[N(R 5 )2(R 5’ )], -[(CH2) p Q] r -(CH2) s -[P(R 5 )2(R 5’ )] or -[(CH2) p Q] r -(CH2) s -[R 8’ ]; where at least one -R 3 is -[(CH2) p Q] r -(CH2) s -[N(R 5 )3]Y, -[(CH2) p Q] r -(CH2) s -[P(R 5 )3]Y, -[(CH2) p Q] r -(CH2) s -[R 8 ]Y, -[(CH2) p Q] r -(CH2) s -[N(R 5 )2(R 5’ )], -[(CH2) p Q] r -(CH2) s -[P(R 5 )2(R 5’ )] or -[(CH2) p Q] r -(CH2) s -[R 8’ ] is selected from -R 3’ is selected from hydrogen or C1-C3 alkyl, preferably -R 3’ is hydrogen or methyl]; -R α - are each independently C1-C 42alkylene groups, which may be optionally substituted with one or more (e.g., 1, 2, 3, 4, or 5) C1-C4 alkyl, C1-C4 haloalkyl, or halo groups, and one or more (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10) carbon atoms in the backbone of the alkylene group may be optionally substituted with a heteroatom or group independently selected from O, S, NH, or NMe; -R β are each independently a saturated or unsaturated hydrocarbyl group which may be linear or branched or may be or contain a cyclic group which may be optionally substituted and which may optionally contain one or more (e.g., 1, 2, 3, 4 or 5) heteroatoms N, O, S, P or Se in its carbon skeleton; -R 5 are each independently selected from C1-C3 alkyl or phenyl, and phenyl is optionally selected from C1-C6 alkyl, —O(C1-C6 alkyl), —CO2H, —CO2Z, —CO2NH2, —O—(CH2CH2O) n -H or -O-(CH2CH2O) n optionally substituted with 1, 2, 3, 4, or 5 substituents independently selected from -CH3; -R 5’ is -CO2 - C1-C3 alkyl substituted with -CO2 - phenyl optionally substituted with C1-C6 alkyl, —O(C1-C6 alkyl), —CO2H, —CO2Z, —CO2NH2, —O—(CH2CH2O) n -H or -O-(CH2CH2O) n may be further substituted with 1, 2, 3, or 4 substituents independently selected from -CH3; -R 6 is -C(O)-OR 3 , -C(O)-SR 3 , -C(O)-N(R 3 )(R 3’ ), -C(S)-OR 3 , -C(S)-SR3 or -C(S)-N(R 3 )(R 3’ ) [preferably -R 6 is -C(O)-N(R 3 )(R 3’ ) is]; -R 7 is -C(O)-OR 3 , -C(O)-SR 3 , -C(O)-N(R 3 )(R 3’ ), -C(S)-OR 3 , -C(S)-SR 3 or -C(S)-N(R 3 )(R 3’ ) [preferably -R 7 is -C(O)-N(R 3 )(R 3’ ) is]; -R 8 is C1-C6 alkyl, -O(C1-C6 alkyl), -CO2H, -CO2Z, -CO2NH2, -O-(CH2CH2O) n -H or -O-(CH2CH2O) n -[NC5H5] optionally substituted with 1, 2, 3, 4, or 5 substituents independently selected from -CH3; -R 8’ is -CO2 - Substituted with C1-C6 alkyl, -O(C1-C6 alkyl), -CO2H, -CO2Z, -CO2NH2, -O-(CH2CH2O) n -H or -O-(CH2CH2O) n -[NC5H5] optionally further substituted with 1, 2, 3, or 4 substituents independently selected from -CH3; Q is O, S, NH, or NMe [preferably Q is O]; X is a halo group; Y is a counteranion; Z is a countercation; M 2+ is a metal cation; n is 1, 2, 3, 4, 5 or 6; p is 0, 1, 2, 3 or 4; r is 0, 1, 2, 3, 4, 5, or 6; s is 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 or 12].
[0167] In these two preferred embodiments of the previous paragraph, each -R 5 may be the same or different. Preferably, each -R 5 is the same.
[0168] In another preferred embodiment of the first or second aspect of the invention, the compound is a compound of formula (VA), (VB), (VC), (VD), (VE), (VF), (VG), (VH), (VJ), (VK), (VL), (VM), (VN), (VO), (VP), (VQ), (VR), (VS), (VT), (VU) or (VV): [ka] TIFF2024543926000041.tif233159TIFF2024543926000042.tif201159TIFF2024543926000043.tif229159TIFF2024543926000044.tif131159 or a metal cation complex thereof, or a pharmaceutically acceptable salt thereof, wherein -R 1 is -C(O)-OR 3 , -C(O)-SR 3 , -C(O)-N(R 3 )(R 3’ ), -C(S)-OR 3 , -C(S)-SR 3 or -C(S)-N(R 3 )(R 3’ ) are selected from; -R 3 are independently -H, -R α -H, -R β , -R α -R β , -R α -OH, -R α -ORβ , -R α -SH, -R α -SR β , -R α -S(O)R β , -R α -S(O)2R β , -R α -NH2, -R α -NH(R β ), -R α -N(R β )2, or-R α -X is selected from; -R 3’ is selected from hydrogen or C1-C3 alkyl (preferably hydrogen or methyl); -R 6 is -C(O)-OR 3 , -C(O)-SR 3 , -C(O)-N(R 3 )(R 3’ ), -C(S)-OR 3 , -C(S)-SR 3 or -C(S)-N(R 3 )(R 3’ ) are selected from; -R 7 is -C(O)-OR 3 , -C(O)-SR 3 , -C(O)-N(R 3 )(R 3’ ), -C(S)-OR 3 , -C(S)-SR 3 or -C(S)-N(R 3 )(R 3’ ) are selected from; -R α - are each independently C1-C 12 alkylene groups, which may be optionally substituted with one or more (e.g., 1, 2, 3, 4, or 5) C1-C4 alkyl, C1-C4 haloalkyl, or halo groups, and one or more (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10) carbon atoms in the backbone of the alkylene group may be optionally substituted with a heteroatom or group independently selected from O, S, NH, or NMe; -R βare each independently a saturated or unsaturated hydrocarbyl group which may be linear or branched or may be or contain a cyclic group which may be optionally substituted and which may optionally contain one or more (e.g., 1, 2, 3, 4 or 5) heteroatoms N, O, S, P or Se in its carbon skeleton; -R δ is selected from C1-C3 alkyl; -R ε is C1-C6 alkyl, -O(C1-C6 alkyl), -CO2H, -CO2Z, -CO2NH2, -O-(CH2CH2O) n -H or -O-(CH2CH2O) n - selected from CH3; X is a halo group; Y is a counteranion; Z is a countercation; n is 1, 2, 3 or 4; p is 0, 1, 2, 3 or 4; r is 0, 1, 2, 3, 4, 5, or 6; s is 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, or 12; t is 0, 1, 2, 3, 4, or 5; and u is 0, 1, 2, 3 and 4.
[0169] The compounds of formula (VA), (VB), (VC), (VD), (VE), (VF), (VG), (VH), (VJ), (VK), (VL), (VM), (VN), (VO), (VP), (VQ), (VR), (VS), (VT), (VU), (VV) and complexes and salts thereof according to the first and second aspects of the present invention comprise a moiety -[(CH2) p O] r -(CH2) s -, wherein p is 0, 1, 2, 3 or 4; r is 0, 1, 2, 3, 4, 5, or 6; s is 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 or 12].
[0170] In one embodiment, p is 2, 3, or 4; r is 1; and s is 2, 3, or 4. In a preferred embodiment, p is 3; r is 1; s is 3; -[(CH) p O] r -(CH2) s - is intended to be -(CH2)3-O-(CH2)3-.
[0171] In another embodiment, p is 2 or 3; r is 2 or 3; and s is 2 or 3. In a preferred embodiment, p is 2; r is 2; and s is 2; -[(CH) p O] r -(CH2) s - is intended to be -(CH2CH2O)2-(CH2)2-.
[0172] In yet another embodiment, r is 0; s is 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, or 12; -[(CH) p O] r -(CH2) s - is -(CH2) 1-12 -It is designed to be.
[0173] Preferably, in the compound or complex according to the first or second aspect of the present invention, the compound or complex is [ka] wherein Y is a counter anion and q is 0, 1, 2, 3, or 4 (preferably, q is 1). or a metal cation complex thereof, or a pharmaceutically acceptable salt thereof.
[0174] In a particularly preferred embodiment, the first or second aspect of the present invention relates to a compound of formula (VII) or a complex of formula (VIII): [ka] or a pharmaceutically acceptable salt thereof [In the formula, -R 1 is -CH2OR 2 , -CH2SR 2 , -CH2S(O)R 2 , -CH2S(O)2R 2 , -CHN(R 2 )(R 2’ ), -R 2 , -C(O)-OR 3 , -C(O)-SR 3 , -C(O)-N(R 3 )(R 3’ ), -C(S)-OR 3 , -C(S)-SR 3 or -C(S)-N(R 3 )(R 3’ ) [preferably, -R 1 is -C(O)-OR 3 , -C(O)-SR 3 , -C(O)-N(R 3 )(R 3’ ), -C(S)-OR 3 , -C(S)-SR 3 or -C(S)-N(R 3 )(R 3’ ) is selected from; more preferably, -R 1 is -C(O)-N(R 3 )(R 3’ ) is]; -R 2 and -R 3 is -[(CH2) p Q] r -(CH2) s -[N(R 5 )3]Y, -[(CH2) p Q] r -(CH2) s -[P(R 5 )3]Y, -[(CH2) p Q] r -(CH2) s -[R 8 ]Y, -[(CH2) p Q] r -(CH2)s -[N(R 5 )2(R 5’ )], -[(CH2) p Q] r -(CH2) s -[P(R 5 )2(R 5’ )] or -[(CH2) p Q] r -(CH2) s -[R 8’ ] is selected from; -R 2’ and -R 3’ is selected from hydrogen or C1-C6 alkyl [preferably, -R 2’ and -R 3’ is selected from hydrogen or C1-C3 alkyl; more preferably, -R 2’ and -R 3’ is selected from hydrogen or methyl; -R 5 are each independently C1-C4 alkyl, C1-C4 haloalkyl, -(CH2CH2O) n -H, -(CH2CH2O) n and —CH, phenyl, or C-C heteroaryl, where phenyl or C-C heteroaryl optionally comprises one or more (e.g., 1, 2, 3, 4, or 5) C-C alkyl, C-C haloalkyl, —O(C-C alkyl), —O(C-C haloalkyl), halo, —COH, —COZ, —CONH, —O—(CHCHO). n -H or -O-(CH2CH2O) n optionally substituted with -CH3 groups; -R 5’ is C1-C4 alkyl, C1-C4 haloalkyl, -(CH2CH2O) n -H, -(CH2CH2O) n -CH3, phenyl, or C5-C6 heteroaryl, each of which is -CO2 -and the phenyl or C5-C6 heteroaryl is optionally substituted with one or more (e.g., 1, 2, 3, or 4) C1-C6 alkyl, C1-C6 haloalkyl, —O(C1-C6 alkyl), —O(C1-C6 haloalkyl), halo, —CO2H, —CO2Z, —CO2NH2, —O—(CH2CHO) n -H or -O-(CH2CH2O) n may be further substituted with -CH3 groups; -R 8 is one or more (e.g., 1, 2, 3, 4, or 5) C1-C6 alkyl, C1-C6 haloalkyl, -O(C1-C6 alkyl), -O(C1-C6 haloalkyl), halo, -CO2H, -CO2Z, -CO2NH2, -O-(CH2CH2O) n -H or -O-(CH2CH2O) n -[NC5H5] optionally substituted with -CH3 groups; -R 8’ is -CO2 - and optionally substituted with one or more (e.g., 1, 2, 3, or 4) C-C alkyl, C-C haloalkyl, —O(C-C alkyl), —O(C-C haloalkyl), halo, —COH, —COZ, —CONH, —O—(CHCHO) n -H or -O-(CH2CH2O) n -[NC5H5] further substituted with -CH3 groups; Q is O, S, NH, or NMe [preferably Q is O]; Y is a counteranion; Z is a countercation; M 2+ is a metal cation; n is 1, 2, 3, 4, 5 or 6; p is 0, 1, 2, 3 or 4; r is 0, 1, 2, 3, 4, 5, or 6; s is 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 or 12].
[0175] In a particularly preferred embodiment, the first or second aspect of the present invention relates to a compound of formula (VII) or a complex of formula (VIII): [ka] or a pharmaceutically acceptable salt thereof [In the formula, -R 1 is -C(O)-N(R 3 )(R 3’ ) and -R 3 -[(CH2) p Q] r -(CH2) s -[N(R 5 )3]Y, -[(CH2) p Q] r -(CH2) s -[P(R 5 )3]Y, -[(CH2) p Q] r -(CH2) s -[R 8 ]Y, -[(CH2) p Q] r -(CH2) s -[N(R 5 )2(R 5’ )], -[(CH2) p Q] r -(CH2) s -[P(R 5 )2(R 5’ )] or -[(CH2) p Q] r -(CH2) s -[R 8’ ] is selected from; -R 3’ is selected from hydrogen or C1-C3 alkyl (preferably hydrogen or methyl); -R 5 are each independently selected from C1-C3 alkyl or phenyl, and phenyl is optionally selected from C1-C6 alkyl, —O(C1-C6 alkyl), —CO2H, —CO2Z, —CO2NH2, —O—(CH2CH2O) n -H or -O-(CH2CH2O) noptionally substituted with 1, 2, 3, 4, or 5 substituents independently selected from -CH3; -R 5’ is -CO2 - C1-C3 alkyl substituted with -CO2 - phenyl optionally substituted with C1-C6 alkyl, —O(C1-C6 alkyl), —CO2H, —CO2Z, —CO2NH2, —O—(CH2CH2O) n -H or -O-(CH2CH2O) n may be further substituted with 1, 2, 3, or 4 substituents independently selected from -CH3; -R 8 is C1-C6 alkyl, -O(C1-C6 alkyl), -CO2H, -CO2Z, -CO2NH2, -O-(CH2CH2O) n -H or -O-(CH2CH2O) n -[NC5H5] optionally substituted with 1, 2, 3, 4, or 5 substituents independently selected from -CH3; -R 8’ is -CO2 - Substituted with C1-C6 alkyl, -O(C1-C6 alkyl), -CO2H, -CO2Z, -CO2NH2, -O-(CH2CH2O) n -H or -O-(CH2CH2O) n -[NC5H5] optionally further substituted with 1, 2, 3, or 4 substituents independently selected from -CH3; Q is O, S, NH or NMe (preferably O); Y is a counteranion; Z is a countercation; M 2+ is a metal cation; n is 1, 2, 3, 4, 5 or 6; p is 0, 1, 2, 3 or 4; r is 0, 1, 2, 3, 4, 5, or 6; s is 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 or 12].
[0176] In these two preferred embodiments of the previous paragraph, each -R 5 may be the same or different. Preferably, each -R 5 is the same.
[0177] In another preferred embodiment of the first or second aspect of the invention, the compound is a compound of formula (VIIA), (VIIB), (VIIC), (VIID), (VIIE), (VIIF) or (VIIG): [ka] TIFF2024543926000049.tif103159 or a metal cation complex thereof, or a pharmaceutically acceptable salt thereof, wherein: -R 3’ is selected from hydrogen or C1-C3 alkyl (preferably hydrogen or methyl); -R δ is selected from C1-C3 alkyl; -R ε is C1-C6 alkyl, -O(C1-C6 alkyl), -CO2H, -CO2Z, -CO2NH2, -O-(CH2CH2O) n -H or -O-(CH2CH2O) n - selected from CH3; Y is a counteranion; Z is a countercation; n is 1, 2, 3 or 4; p is 0, 1, 2, 3 or 4; r is 0, 1, 2, 3, 4, 5, or 6; s is 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, or 12; t is 0, 1, 2, 3, 4, or 5; and u is 0, 1, 2, 3 and 4.
[0178] The compounds of formula (VIIA), (VIIB), (VIIC), (VIID), (VIIE), (VIIF), (VIIG) and complexes and salts thereof according to the first and second aspects of the present invention comprise a moiety -[(CH2)p O] r -(CH2) s -, wherein p is 0, 1, 2, 3 or 4; r is 0, 1, 2, 3, 4, 5, or 6; s is 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 or 12].
[0179] In one embodiment, p is 2, 3, or 4; r is 1; and s is 2, 3, or 4. In a preferred embodiment, p is 3; r is 1; s is 3; -[(CH) p O] r -(CH2) s - is intended to be -(CH2)3-O-(CH2)3-.
[0180] In another embodiment, p is 2 or 3; r is 2 or 3; and s is 2 or 3. In a preferred embodiment, p is 2; r is 2; and s is 2; -[(CH) p O] r -(CH2) s - is intended to be -(CH2CH2O)2-(CH2)2-.
[0181] In yet another embodiment, r is 0; s is 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, or 12; -[(CH) p O] r -(CH2) s - is -(CH2) 1-12 -It is designed to be.
[0182] Preferably, in the compound or complex according to the first or second aspect of the present invention, the compound or complex is [ka] [In the formula, -R 5 are each independently C1-C4 alkyl, C1-C4 haloalkyl, -(CH2CH2O) n-H, -(CH2CH2O) n -CH3, phenyl or C5-C6 heteroaryl, wherein said phenyl or C5-C6 heteroaryl optionally comprises one or more of C1-C4 alkyl, C1-C4 haloalkyl, -O(C1-C4 alkyl), -O(C1-C4 haloalkyl), halo, -O-(CH2CH2O) n -H or -O-(CH2CH2O) n may be substituted with -CH3 groups; -R 10 are each independently C1-C4 alkyl, C1-C4 haloalkyl, -O(C1-C4 alkyl), -O(C1-C4 haloalkyl), halo, -O-(CH2CH2O) n -H or -O-(CH2CH2O) n -CH3 group; -R 11 each independently represents one or more of C1-C4 alkyl, C1-C4 haloalkyl, -O(C1-C4 alkyl), -O(C1-C4 haloalkyl), halo, -O-(CH2CH2O) n -H or -O-(CH2CH2O) n is phenyl optionally substituted with -CH groups; n is 1, 2, 3 or 4; p is 0, 1, 2, 3 or 4; q is 0, 1, 2, 3, or 4 (preferably q is 1); and Y is a counteranion; or a metal cation complex thereof, or a pharmaceutically acceptable salt thereof.
[0183] Preferably, in the compound or complex according to the first or second aspect of the present invention, the compound or complex is [ka] TIFF2024543926000052.tif217159TIFF2024543926000053.tif209159TIFF2024543926000054.tif184159TIFF2024543926000055.tif192159TIFF2024543926000056.tif129159 or a metal cation complex thereof, or a pharmaceutically acceptable salt thereof.
[0184] In one embodiment, the compound or complex according to the first or second aspect of the present invention is in the form of a pharmaceutically acceptable salt. In one embodiment, the compound or complex is in the form of an inorganic salt, such as a lithium, sodium, potassium, magnesium, calcium, or ammonium salt. In one embodiment, the compound or complex is in the form of a sodium or potassium salt. In one embodiment, the compound is in the form of a sodium salt. In another embodiment, the compound or complex is in the form of an organic salt, such as an amine salt (e.g., a choline or meglumine salt) or an amino acid salt (e.g., an arginine salt).
[0185] In one embodiment, the compound or complex according to the first or second aspect is reduced phyllochlorin in the form of a pharmaceutically acceptable salt. In one embodiment, the compound or complex is reduced phyllochlorin in the form of a pharmaceutically acceptable inorganic salt, such as a lithium, sodium, potassium, magnesium, calcium, or ammonium salt. In one embodiment, the compound or complex is reduced phyllochlorin monosodium or reduced phyllochlorin monopotassium. In one embodiment, the compound or complex is reduced phyllochlorin monosodium.
[0186] The compound or complex according to the first or second aspect of the invention has at least two chiral centres, or the compound or complex of the first or second aspect of the invention is preferably substantially enantiomerically pure, meaning that the compound or complex contains less than 10% of other stereoisomers, preferably less than 5%, preferably less than 3%, preferably less than 2%, preferably less than 1%, preferably less than 0.5%, all by weight as measured by XRPD or SFC.
[0187] Preferably, the compound or complex according to the first or second aspect of the invention has an HPLC purity of greater than 97%, more preferably greater than 98%, more preferably greater than 99%, more preferably greater than 99.5%, more preferably greater than 99.8%, and most preferably greater than 99.9%. As used herein, % HPLC purity is measured by the area normalization method.
[0188] A third aspect of the invention provides a composition comprising a compound or complex according to the first or second aspect of the invention and a pharmaceutically acceptable carrier or diluent.
[0189] In one embodiment, the composition according to the third aspect of the present invention further comprises polyvinylpyrrolidone (PVP). In one embodiment, the composition comprises 0.01 to 10 wt% PVP as a percentage of the total weight of the composition, preferably 0.1 to 5 wt% PVP as a percentage of the total weight of the composition, preferably 0.5 to 5 wt% PVP as a percentage of the total weight of the composition. In one embodiment, the PVP is K30.
[0190] In one embodiment, the composition according to the third aspect of the present invention further comprises dimethyl sulfoxide (DMSO), hi one embodiment, the composition comprises 0.01 to 99 wt% DMSO as a percentage of the total weight of the composition, preferably 40 to 99 wt% DMSO as a percentage of the total weight of the composition, preferably 65 to 99 wt% DMSO as a percentage of the total weight of the composition.
[0191] In one embodiment, the composition according to the third aspect of the invention further comprises an immune checkpoint inhibitor. In one embodiment, the immune checkpoint inhibitor is an inhibitor of PD-1 (programmed cell death protein 1), PD-L1 (programmed death-ligand 1), or CTLA4 (cytotoxic T-lymphocyte-associated protein 4). In one embodiment, the immune checkpoint inhibitor is selected from pembrolizumab, nivolumab, cemiplimab, atezolizumab, avelumab, durvalumab, or ipilimumab.
[0192] Preferably, the compounds or complexes according to the first or second aspect of the invention and the pharmaceutical compositions according to the third aspect of the invention are suitable for use in photodynamic therapy or cytoluminescent therapy.
[0193] Preferably, the compounds or complexes according to the first or second aspect of the invention, and the pharmaceutical compositions according to the third aspect of the invention, are useful for treating atherosclerosis; multiple sclerosis; diabetes; diabetic retinopathy; arthritis; rheumatoid arthritis; fungal, viral, chlamydial, bacterial, nanobacterial or parasitic infections; HIV; AIDS; infection by SARS virus (preferably Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)), Asian (avian) influenza virus, dengue virus, herpes simplex or shingles; hepatitis; viral hepatitis; cardiovascular disease; coronary artery stenosis; carotid artery stenosis; interstitial pneumonia; It is suitable for the treatment of: intermittent claudication; dermatological conditions; acne; psoriasis; diseases characterized by areas of benign or malignant cellular hyperproliferation or angiogenesis; benign or malignant tumors; early stage cancer; cervical dysplasia; soft tissue sarcoma; germ cell tumors; retinoblastoma; age-related macular degeneration; lymphoma; Hodgkin's lymphoma; head and neck cancer; oral cancer; or cancer of the blood, prostate, cervix, uterus, vagina or other female adnexa, breast, nasopharynx, trachea, larynx, bronchi, bronchioles, lung, hollow organs, esophagus, stomach, bile duct, intestine, colon, colorectum, rectum, bladder, ureter, kidney, liver, gallbladder, spleen, brain, lymphatic system, bone, skin, or pancreas.
[0194] Preferably, the compounds or complexes according to the first or second aspect of the invention and the pharmaceutical compositions according to the third aspect of the invention are suitable for the treatment of diseases characterised by areas of benign or malignant cellular hyperproliferation or angiogenesis.
[0195] Preferably, the compounds or complexes according to the first or second aspect of the invention and the pharmaceutical compositions according to the third aspect of the invention are suitable for the treatment of benign or malignant tumours.
[0196] Preferably, the compounds or complexes according to the first or second aspect of the invention, and the pharmaceutical compositions according to the third aspect of the invention, are suitable for the treatment of early stage cancer; cervical dysplasia; soft tissue sarcoma; germ cell tumours; retinoblastoma; age-related macular degeneration; lymphoma; Hodgkin's lymphoma; head and neck cancer; oral cancer; or cancer of the blood, prostate, cervix, uterus, vagina or other female adnexa, breast, nasopharynx, trachea, larynx, bronchi, bronchioles, lung, hollow organs, esophagus, stomach, bile duct, intestine, colon, colorectum, rectum, bladder, ureter, kidney, liver, gallbladder, spleen, brain, lymphatic system, bone, skin or pancreas.
[0197] Preferably, the compounds or complexes according to the first or second aspect of the invention and the pharmaceutical compositions according to the third aspect of the invention are suitable for use in photodynamic diagnosis.
[0198] Preferably, the compounds or complexes according to the first or second aspect of the invention, and the pharmaceutical compositions according to the third aspect of the invention, are useful for treating atherosclerosis; multiple sclerosis; diabetes; diabetic retinopathy; arthritis; rheumatoid arthritis; fungal, viral, chlamydial, bacterial, nanobacterial or parasitic infections; HIV; AIDS; infection by SARS virus (preferably Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)), Asian (avian) influenza virus, dengue virus, herpes simplex or shingles; hepatitis; viral hepatitis; cardiovascular disease; coronary artery stenosis; carotid artery stenosis; interstitial pneumonia; Suitable for detecting intermittent claudication; dermatological conditions; acne; psoriasis; diseases characterized by areas of benign or malignant cellular hyperproliferation or angiogenesis; benign or malignant tumors; early stage cancer; cervical dysplasia; soft tissue sarcoma; germ cell tumors; retinoblastoma; age-related macular degeneration; lymphoma; Hodgkin's lymphoma; head and neck cancer; oral cancer; or cancer of the blood, prostate, cervix, uterus, vagina or other female adnexa, breast, nasopharynx, trachea, larynx, bronchi, bronchioles, lung, hollow organs, esophagus, stomach, bile duct, intestine, colon, colorectum, rectum, bladder, ureter, kidney, liver, gallbladder, spleen, brain, lymphatic system, bone, skin, or pancreas.
[0199] Preferably, the compounds or complexes according to the first or second aspect of the invention and the pharmaceutical compositions according to the third aspect of the invention are suitable for detecting areas affected by benign or malignant cell hyperproliferation or neovascularization.
[0200] Preferably, the compounds or complexes according to the first or second aspect of the invention and the pharmaceutical compositions according to the third aspect of the invention are suitable for the detection of benign or malignant tumours.
[0201] Preferably, the compounds or complexes according to the first or second aspect of the invention, and the pharmaceutical compositions according to the third aspect of the invention, are suitable for the detection of early stage cancer; cervical dysplasia; soft tissue sarcoma; germ cell tumours; retinoblastoma; age-related macular degeneration; lymphoma; Hodgkin's lymphoma; head and neck cancer; oral cancer; or cancer of the blood, prostate, cervix, uterus, vagina or other female adnexa, breast, nasopharynx, trachea, larynx, bronchi, bronchioles, lung, hollow organs, esophagus, stomach, bile duct, intestine, colon, colorectum, rectum, bladder, ureter, kidney, liver, gallbladder, spleen, brain, lymphatic system, bone, skin or pancreas.
[0202] Preferably, the compounds or complexes according to the first or second aspect of the invention, and the pharmaceutical compositions according to the third aspect of the invention, are suitable for the fluorescent or phosphorescent detection of the diseases listed above, preferably for the fluorescent or phosphorescent detection and quantification of said diseases.
[0203] Preferably, the compound or complex according to the first or second aspect of the invention, and the pharmaceutical composition according to the third aspect of the invention, are adapted for administration simultaneously with or before the administration of radiation or sound, preferably before the administration of radiation.
[0204] When the compounds or complexes according to the first or second aspect of the invention, or the pharmaceutical compositions according to the third aspect of the invention, are for use in photodynamic therapy or cytoluminescence therapy, then they are preferably adapted for administration 5 to 100 hours before irradiation, preferably 6 to 72 hours before irradiation, preferably 24 to 48 hours before irradiation.
[0205] When the compounds or complexes according to the first or second aspect of the invention, or the pharmaceutical compositions according to the third aspect of the invention, are for use in photodynamic diagnosis, then they are preferably suitable for administration 3 to 60 hours before irradiation, preferably 8 to 40 hours before irradiation.
[0206] Preferably, the radiation used in photodynamic therapy, cytoluminescence therapy, or photodynamic diagnosis is electromagnetic radiation having a wavelength in the range of 500 nm to 1000 nm, preferably 550 nm to 750 nm, preferably 600 nm to 700 nm, and preferably 640 nm to 670 nm. The electromagnetic radiation can be administered at about 0.1 to 5 W, preferably about 1 W, for about 5 to 60 minutes, preferably about 15 to 20 minutes. In one embodiment of the present invention, two electromagnetic radiation sources (e.g., a laser light and an LED light) are used, both of which are suitable for providing radiation in the wavelength range of 550 nm to 750 nm, preferably 600 nm to 700 nm, and preferably 640 nm to 670 nm. In another embodiment of the present invention, the radiation can be provided by prostate, anal, vaginal, oral, or nasal devices for insertion into body cavities. In another embodiment of the present invention, the radiation can be provided by mediated photoactivation, for example, by inserting a fiber-optic laser into the lung, liver, lymph nodes, or breast using a fine needle. In another embodiment of the invention, illumination may be provided by photoactivation of an endoscope, for example to deliver light to the lungs, stomach, colon, bladder or cervix.
[0207] The pharmaceutical composition according to the third aspect of the present invention may be in a form suitable for oral, parenteral (including intravenous, subcutaneous, intramuscular, intradermal, intratracheal, intraperitoneal, intratumoral, intraarticular, intraperitoneal, intracranial and epidural), transdermal, respiratory (aerosol), rectal, vaginal or topical (including buccal, mucosal and sublingual) administration. The pharmaceutical composition may also be in a form suitable for administration by enema or by injection into a tumor. Preferably, the pharmaceutical composition is in a form suitable for oral, parenteral (such as intravenous, intraperitoneal and intratumoral) or respiratory tract administration, preferably in a form suitable for oral or parenteral administration, preferably in a form suitable for oral administration.
[0208] In one preferred embodiment, the pharmaceutical composition is in a form suitable for oral administration. Preferably, the pharmaceutical composition is provided in the form of tablets, capsules, hard or soft gelatin capsules, caplets, lozenges, or drops, as a powder or granules, or as an aqueous solution, suspension, or dispersion. More preferably, the pharmaceutical composition is provided in the form of an aqueous solution, suspension, or dispersion for oral administration, or in the form of a lyophilized powder that can be mixed with water before administration. Preferably, the pharmaceutical composition is in a form suitable for providing 0.01 to 10 mg / kg / day, preferably 0.1 to 2 mg / kg / day, preferably about 1 mg / kg / day, of the compound or complex according to the first or second aspect of the present invention.
[0209] In another preferred embodiment, the pharmaceutical composition is in a form suitable for parenteral administration. Preferably, the pharmaceutical composition is in a form suitable for intravenous administration. Preferably, the pharmaceutical composition is provided in the form of an aqueous solution for parenteral administration, or in the form of a lyophilized powder that can be mixed with water before administration. Preferably, the pharmaceutical composition is an aqueous solution or suspension having a pH of 6 to 8.5. Preferably, the pharmaceutical composition is in a form suitable for providing 0.01 to 10 mg / kg / day, preferably 0.1 to 2 mg / kg / day, preferably about 1 mg / kg / day, of a compound or complex according to the first or second aspect of the present invention.
[0210] In another preferred embodiment, the pharmaceutical composition is in a form suitable for administration to the respiratory tract. Preferably, the pharmaceutical composition is provided in the form of an aqueous solution, suspension, or dispersion for administration to the respiratory tract, or in the form of a lyophilized powder that can be mixed with water before administration to provide an aqueous solution, suspension, or dispersion for administration to the respiratory tract. Preferably, the pharmaceutical composition is in a form suitable for providing 0.01 to 10 mg / kg / day, preferably 0.1 to 2 mg / kg / day, preferably about 1 mg / kg / day, of a compound or complex according to the first or second aspect of the present invention.
[0211] A fourth aspect of the present invention relates to a method for treating atherosclerosis; multiple sclerosis; diabetes; diabetic retinopathy; arthritis; rheumatoid arthritis; fungal, viral, chlamydial, bacterial, nanobacterial or parasitic infections; HIV; AIDS; infection by SARS virus (preferably Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)), Asian (avian) influenza virus, dengue virus, herpes simplex or shingles; hepatitis; viral hepatitis; cardiovascular disease; coronary artery stenosis; carotid artery stenosis; intermittent claudication; dermatological conditions; acne; psoriasis; benign or malignant cell hyperproliferation or blood clots. There is provided use of a compound or complex according to the first or second aspect of the invention in the manufacture of a medicament for the treatment of a disease characterised by areas of angiogenesis; a benign or malignant tumour; an early stage cancer; cervical dysplasia; soft tissue sarcoma; a germ cell tumour; retinoblastoma; age-related macular degeneration; a lymphoma; Hodgkin's lymphoma; head and neck cancer; oral cancer; or a cancer of the blood, prostate, cervix, uterus, vagina or other female adnexa, breast, nasopharynx, trachea, larynx, bronchi, bronchioles, lung, hollow organ, esophagus, stomach, bile duct, intestine, colon, colorectum, rectum, bladder, ureter, kidney, liver, gallbladder, spleen, brain, lymphatic system, bone, skin or pancreas.
[0212] A fourth aspect of the present invention provides the use of a compound or complex according to the first or second aspect of the present invention in the manufacture of a phototherapeutic agent for use in photodynamic therapy or cytoluminescence therapy, or preferably the phototherapeutic agent is selected from the group consisting of atherosclerosis, multiple sclerosis, diabetes, diabetic retinopathy, arthritis, rheumatoid arthritis, fungal, viral, chlamydial, bacterial, nanobacterial or parasitic infections, HIV, AIDS, SARS virus (preferably Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)), Asian (avian) influenza virus, dengue virus, herpes simplex or shingles infections, hepatitis, viral hepatitis, cardiovascular disease, coronary artery stenosis, carotid artery stenosis, intermittent claudication, dermatological conditions, acne, and psoriasis. ; diseases characterized by areas of benign or malignant cell hyperproliferation or angiogenesis; benign or malignant tumors; early stage cancer; cervical dysplasia; soft tissue sarcoma; germ cell tumors; retinoblastoma; age-related macular degeneration; lymphoma; Hodgkin's lymphoma; head and neck cancer; oral cancer; or cancer of the blood, prostate, cervix, uterus, vagina or other female adnexa, breast, nasopharynx, trachea, larynx, bronchi, bronchioles, lung, hollow organs, esophagus, stomach, bile duct, intestine, colon, colorectum, rectum, bladder, ureter, kidney, liver, gallbladder, spleen, brain, lymphatic system, bone, skin or pancreas.
[0213] Preferably, the medicament or phototherapeutic agent of the fourth aspect of the invention is suitable for the treatment of diseases characterised by areas of benign or malignant cellular hyperproliferation or angiogenesis.
[0214] Preferably, the medicament or phototherapeutic agent according to the fourth aspect of the invention is suitable for the treatment of benign or malignant tumours.
[0215] Preferably, the medicament or phototherapeutic agent according to the fourth aspect of the invention is suitable for the treatment of early stage cancer; cervical dysplasia; soft tissue sarcoma; germ cell tumour; retinoblastoma; age-related macular degeneration; lymphoma; Hodgkin's lymphoma; head and neck cancer; oral cancer; or cancer of the blood, prostate, cervix, uterus, vagina or other female adnexa, breast, nasopharynx, trachea, larynx, bronchi, bronchioles, lung, hollow organs, esophagus, stomach, bile duct, intestine, colon, colorectum, rectum, bladder, ureter, kidney, liver, gallbladder, spleen, brain, lymphatic system, bone, skin or pancreas.
[0216] A fourth aspect of the invention also provides the use of a compound or complex according to the first or second aspect of the invention in the manufacture of a photodiagnostic agent for use in photodynamic diagnosis.
[0217] Preferably, the photodiagnostic agent of the fourth aspect of the present invention is suitable for use in treating atherosclerosis; multiple sclerosis; diabetes; diabetic retinopathy; arthritis; rheumatoid arthritis; fungal, viral, chlamydial, bacterial, nanobacterial or parasitic infections; HIV; AIDS; infection by SARS virus (preferably Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)), Asian (avian) influenza virus, dengue virus, herpes simplex or shingles; hepatitis; viral hepatitis; cardiovascular disease; coronary artery stenosis; carotid artery stenosis; intermittent claudication; dermatological conditions; acne. ; psoriasis; diseases characterized by areas of benign or malignant cellular hyperproliferation or angiogenesis; benign or malignant tumors; early stage cancer; cervical dysplasia; soft tissue sarcoma; germ cell tumors; retinoblastoma; age-related macular degeneration; lymphoma; Hodgkin's lymphoma; head and neck cancer; oral cancer; or cancer of the blood, prostate, cervix, uterus, vagina or other female adnexa, breast, nasopharynx, trachea, larynx, bronchi, bronchioles, lung, hollow organs, esophagus, stomach, bile duct, intestine, colon, colorectum, rectum, bladder, ureter, kidney, liver, gallbladder, spleen, brain, lymphatic system, bone, skin or pancreas.
[0218] Preferably, the photodiagnostic agent according to the fourth aspect of the present invention is suitable for detecting areas affected by benign or malignant cell hyperproliferation or neovascularization.
[0219] Preferably, the photodiagnostic agent according to the fourth aspect of the present invention is suitable for detecting benign or malignant tumors.
[0220] Preferably, the photodiagnostic agent according to the fourth aspect of the present invention is suitable for the detection of early stage cancer; cervical dysplasia; soft tissue sarcoma; germ cell tumour; retinoblastoma; age-related macular degeneration; lymphoma; Hodgkin's lymphoma; head and neck cancer; oral cancer; or cancer of the blood, prostate, cervix, uterus, vagina or other female adnexa, breast, nasopharynx, trachea, larynx, bronchi, bronchioles, lung, hollow organs, esophagus, stomach, bile duct, intestine, colon, colorectum, rectum, bladder, ureter, kidney, liver, gallbladder, spleen, brain, lymphatic system, bone, skin or pancreas.
[0221] Preferably, the photodiagnostic agent of the fourth aspect of the present invention is suitable for fluorescent or phosphorescent detection of said disease, preferably for fluorescent or phosphorescent detection and quantification of said disease.
[0222] Preferably, the medicament, phototherapeutic agent or photodiagnostic agent is adapted for administration simultaneously with or before the administration of radiation or sound, preferably before the administration of radiation.
[0223] If the medicament or phototherapeutic agent is for use in photodynamic therapy or cytoluminescence therapy, then it is preferably adapted for administration 5 to 100 hours before irradiation, preferably 6 to 72 hours before irradiation, preferably 24 to 48 hours before irradiation.
[0224] If the photodiagnostic agent is used for photodynamic diagnosis, then it is preferably adapted for administration 3 to 60 hours before irradiation, preferably 8 to 40 hours before irradiation.
[0225] Preferably, the radiation used in photodynamic therapy, cytoluminescence therapy, or photodynamic diagnosis is electromagnetic radiation having a wavelength in the range of 500 nm to 1000 nm, preferably 550 nm to 750 nm, preferably 600 nm to 700 nm, and preferably 640 nm to 670 nm. The electromagnetic radiation can be administered at about 0.1 to 5 W, preferably about 1 W, for about 5 to 60 minutes, preferably about 15 to 20 minutes. In one embodiment of the present invention, two electromagnetic radiation sources (e.g., a laser light and an LED light) are used, both of which are suitable for providing radiation in the wavelength range of 550 nm to 750 nm, preferably 600 nm to 700 nm, and preferably 640 nm to 670 nm. In another embodiment of the present invention, the radiation can be provided by prostate, anal, vaginal, oral, or nasal devices for insertion into body cavities. In another embodiment of the present invention, the radiation can be provided by mediated photoactivation, for example, by inserting a fiber-optic laser into the lung, liver, lymph nodes, or breast using a fine needle. In another embodiment of the invention, illumination may be provided by photoactivation of an endoscope, for example to deliver light to the lungs, stomach, colon, bladder or cervix.
[0226] A fifth aspect of the present invention provides a method for treating atherosclerosis; multiple sclerosis; diabetes; diabetic retinopathy; arthritis; rheumatoid arthritis; fungal, viral, chlamydial, bacterial, nanobacterial or parasitic infections; HIV; AIDS; infection by SARS virus (preferably Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)), Asian (avian) influenza virus, dengue virus, herpes simplex or shingles; hepatitis; viral hepatitis; cardiovascular disease; coronary artery stenosis; carotid artery stenosis; intermittent claudication; dermatological conditions; acne; psoriasis; benign or non-cancerous conditions. or diseases characterized by areas of malignant cell hyperproliferation or angiogenesis; benign or malignant tumors; early stage cancers; cervical dysplasia; soft tissue sarcoma; germ cell tumors; retinoblastoma; age-related macular degeneration; lymphoma; Hodgkin's lymphoma; head and neck cancer; oral cancer; or cancer of the blood, prostate, cervix, uterus, vagina or other female adnexa, breast, nasopharynx, trachea, larynx, bronchi, bronchioles, lung, hollow organs, esophagus, stomach, bile duct, intestine, colon, colorectum, rectum, bladder, ureter, kidney, liver, gallbladder, spleen, brain, lymphatic system, bone, skin or pancreas. The method comprises administering a therapeutically effective amount of a compound or complex according to the first or second aspect of the invention to a human or animal in need thereof.
[0227] The fifth aspect of the present invention also provides a method for photodynamic or cytoluminescent therapy of a human or animal disease, the method comprising administering to a human or animal in need thereof a therapeutically effective amount of a compound or complex according to the first or second aspect of the present invention. Preferably, the human or animal disease is atherosclerosis; multiple sclerosis; diabetes; diabetic retinopathy; arthritis; rheumatoid arthritis; fungal, viral, chlamydial, bacterial, nanobacterial or parasitic infection; HIV; AIDS; infection by SARS virus (preferably Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)), Asian (avian) influenza virus, dengue virus, herpes simplex or shingles; hepatitis; viral hepatitis; cardiovascular disease; coronary artery stenosis; carotid artery stenosis; intermittent claudication; dermatological conditions; or cutaneous conditions. psoriasis; diseases characterized by areas of benign or malignant cell hyperproliferation or angiogenesis; benign or malignant tumors; early-stage cancer; cervical dysplasia; soft tissue sarcoma; germ cell tumors; retinoblastoma; age-related macular degeneration; lymphoma; Hodgkin's lymphoma; head and neck cancer; oral cancer; or cancer of the blood, prostate, cervix, uterus, vagina or other female adnexa, breast, nasopharynx, trachea, larynx, bronchi, bronchioles, lung, hollow organs, esophagus, stomach, bile duct, intestine, colon, colorectum, rectum, bladder, ureter, kidney, liver, gallbladder, spleen, brain, lymphatic system, bone, skin, or pancreas.
[0228] Preferably, the method of the fifth aspect of the invention is a method of treating areas of benign or malignant cellular hyperproliferation or neovascularization.
[0229] Preferably, the method of the fifth aspect of the invention is a method of treating a benign or malignant tumor.
[0230] Preferably, the method of the fifth aspect of the invention is a method of treating early stage cancer; cervical dysplasia; soft tissue sarcoma; germ cell tumors; retinoblastoma; age-related macular degeneration; lymphoma; Hodgkin's lymphoma; head and neck cancer; oral cancer; or cancer of the blood, prostate, cervix, uterus, vagina or other female adnexa, breast, nasopharynx, trachea, larynx, bronchi, bronchioles, lung, hollow organs, esophagus, stomach, bile duct, intestine, colon, colorectum, rectum, bladder, ureter, kidney, liver, gallbladder, spleen, brain, lymphatic system, bone, skin or pancreas.
[0231] The fifth aspect of the present invention also provides a method for photodynamic diagnosis of a human or animal disease, the method comprising administering to the human or animal a diagnostically effective amount of a compound or complex according to the first or second aspect of the present invention. Preferably, the human or animal disease is atherosclerosis; multiple sclerosis; diabetes; diabetic retinopathy; arthritis; rheumatoid arthritis; fungal, viral, chlamydial, bacterial, nanobacterial or parasitic infection; HIV; AIDS; infection by SARS virus (preferably Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)), Asian (avian) influenza virus, dengue virus, herpes simplex or shingles; hepatitis; viral hepatitis; cardiovascular disease; coronary artery stenosis; carotid artery stenosis; intermittent claudication; dermatological conditions; or cutaneous conditions. The human or animal disease is preferably a cancer of the blood, prostate, cervix, uterus, vagina or other female adnexa, breast, nasopharynx, trachea, larynx, bronchi, bronchioles, lung, hollow organ, esophagus, stomach, bile duct, intestine, colon, colorectum, rectum, bladder, ureter, kidney, liver, gallbladder, spleen, brain, lymphatic system, bone, skin, or pancreas. Preferably, the human or animal disease is characterized by benign or malignant cell hyperproliferation or by areas of angiogenesis. Preferably, the human or animal disease is a benign or malignant tumor. Preferably, the human or animal disease is early stage cancer, cervical dysplasia, soft tissue sarcoma, germ cell tumor, retinoblastoma, age-related macular degeneration, lymphoma, Hodgkin's lymphoma, head and neck cancer, oral cancer, or cancer of the blood, prostate, cervix, uterus, vagina or other female adnexa, breast, nasopharynx, trachea, larynx, bronchi, bronchioles, lung, hollow organs, esophagus, stomach, bile duct, intestine, colon, colorectum, rectum, bladder, ureter, kidney, liver, gallbladder, spleen, brain, lymphatic system, bone, skin or pancreas. Preferably, the method of photodynamic diagnosis is suitable for fluorescent or phosphorescent detection of said disease, preferably fluorescent or phosphorescent detection and quantification of said disease.
[0232] In any of the methods of the fifth aspect of the invention, the human or animal is preferably further subjected to irradiation or sound simultaneously with or after administration of a compound or complex according to the first or second aspect of the invention. Preferably, the human or animal is subjected to irradiation after administration of a compound or complex according to the first or second aspect of the invention.
[0233] If the method is a photodynamic therapy or cytoluminescence therapy method, then the human or animal is preferably irradiated 5 to 100 hours after administration of the compound or complex according to the first or second aspect of the invention, preferably 6 to 72 hours, preferably 24 to 48 hours after administration.
[0234] If the method is a method of photodynamic diagnosis, then the human or animal is preferably irradiated 3 to 60 hours, preferably 8 to 40 hours, after administration of the compound or complex according to the first or second aspect of the invention.
[0235] Preferably, the irradiation is electromagnetic radiation having a wavelength in the range of 500 nm to 1000 nm, preferably 550 nm to 750 nm, preferably 600 nm to 700 nm, and preferably 640 nm to 670 nm. The electromagnetic radiation can be administered at about 0.1 to 5 W, preferably about 1 W, for about 5 to 60 minutes, preferably about 15 to 20 minutes. In one embodiment of the present invention, two electromagnetic radiation sources (e.g., a laser light and an LED light) are used, both radiation sources being suitable for providing irradiation at wavelengths in the range of 550 nm to 750 nm, preferably 600 nm to 700 nm, and preferably 640 nm to 670 nm. In another embodiment of the present invention, irradiation can be provided by prostate, anal, vaginal, oral, or nasal devices for insertion into body cavities. In another embodiment of the present invention, irradiation can be provided by mediated photoactivation, for example, by inserting a fiber-optic laser into the lung, liver, lymph nodes, or breast using a fine needle. In another embodiment of the invention, illumination may be provided by photoactivation of an endoscope, for example to deliver light to the lungs, stomach, colon, bladder or cervix.
[0236] In any of the methods of the fifth aspect of the invention, preferably the human or animal is a human.
[0237] A sixth aspect of the present invention is a method for manufacturing a semiconductor device comprising: (a) a compound or complex according to the first or second aspect of the present invention, and (b) providing a pharmaceutical combination or kit comprising an immune checkpoint inhibitor;
[0238] In one embodiment, the immune checkpoint inhibitor is an inhibitor of PD-1 (programmed cell death protein 1), PD-L1 (programmed death-ligand 1), or CTLA4 (cytotoxic T-lymphocyte-associated protein 4). In one embodiment, the immune checkpoint inhibitor is selected from pembrolizumab, nivolumab, cemiplimab, atezolizumab, avelumab, durvalumab, or ipilimumab.
[0239] Preferably, the combination or kit of the sixth aspect is for use in treating a disease, disorder, or condition, wherein the disease, disorder, or condition is responsive to PD-1, PD-L1, or CTLA4 inhibition. Preferably, the combination or kit of the sixth aspect is for use in treating cancer. In one embodiment, the cancer is melanoma, lung cancer (e.g., non-small cell lung cancer), kidney cancer, bladder cancer, head and neck cancer, or Hodgkin's lymphoma.
[0240] The sixth aspect also provides the use of a combination or kit of the sixth aspect of the invention in the manufacture of a medicament for treating a disease, disorder, or condition responsive to PD-1, PD-L1, or CTLA4 inhibition. The sixth aspect also provides the use of a combination or kit of the sixth aspect of the invention in the manufacture of a medicament for treating cancer. In one embodiment, the cancer is melanoma, lung cancer (e.g., non-small cell lung cancer), kidney cancer, bladder cancer, head and neck cancer, or Hodgkin's lymphoma.
[0241] The sixth aspect of the present invention also provides a method for treating a disease, disorder, or condition responsive to PD-1, PD-L1, or CTLA4 inhibition, comprising administering a therapeutically effective amount of a combination or kit according to the sixth aspect of the present invention to a human or animal in need thereof. The sixth aspect of the present invention also provides a method for treating cancer, comprising administering a therapeutically effective amount of a combination or kit according to the sixth aspect of the present invention to a human or animal in need thereof. In one embodiment, the cancer is melanoma, lung cancer (e.g., non-small cell lung cancer), kidney cancer, bladder cancer, head and neck cancer, or Hodgkin's lymphoma.
[0242] In the case of the combination or kit of the sixth aspect of the invention, the compound or complex according to the first or second aspect of the invention and the immune checkpoint inhibitor may be provided together in one pharmaceutical composition, or may be provided separately in two pharmaceutical compositions, which may be administered at the same time or at different times.
[0243] Preferably, the combination or kit of the sixth aspect is adapted for administration simultaneously with or prior to the administration of irradiation or sound, preferably prior to the administration of irradiation. In one embodiment, the combination or kit of the sixth aspect is suitable for administration 5 to 100 hours prior to irradiation, preferably 6 to 72 hours prior to irradiation, preferably 24 to 48 hours prior to irradiation.
[0244] Preferably, the radiation used in photodynamic therapy or cytoluminescence therapy is electromagnetic radiation having a wavelength in the range of 500 nm to 1000 nm, preferably 550 nm to 750 nm, preferably 600 nm to 700 nm, and preferably 640 nm to 670 nm. The electromagnetic radiation can be administered at about 0.1 to 5 W, preferably about 1 W, for about 5 to 60 minutes, preferably about 15 to 20 minutes. In one embodiment of the present invention, two electromagnetic radiation sources (e.g., a laser light and an LED light) are used, both radiation sources being suitable for providing radiation in the wavelength range of 550 nm to 750 nm, preferably 600 nm to 700 nm, and preferably 640 nm to 670 nm. In another embodiment of the present invention, the radiation can be provided by prostate, anal, vaginal, oral, or nasal devices for insertion into body cavities. In another embodiment of the present invention, the radiation can be provided by mediated photoactivation, for example, by inserting a fiber-optic laser into the lung, liver, lymph nodes, or breast using a fine needle. In another embodiment of the invention, illumination may be provided by photoactivation of an endoscope, for example to deliver light to the lungs, stomach, colon, bladder or cervix.
[0245] For the avoidance of doubt, insofar as is practicable, any embodiment of a given aspect of the invention may be practiced in combination with any other embodiment of the same aspect of the invention. Furthermore, it will be understood that insofar as is practicable, any preferred or optional embodiment of any aspect of the invention shall also be deemed to be a preferred or optional embodiment of any other aspect of the invention.
[0246] Details of the synthesis experiment Synthesis Example 1 - Synthesis of reduced phyllochlorin (compound 1) [ka] A three-necked 250 mL RBF was charged with phyllochlorin (4.0 g, 7.86 mmol, 1 equiv.), 10% Pd / C (200 mg), ethyl acetate (200 mL), methanol (40 mL), and a stir bar (approximately 25 mm). A hydrogen balloon was connected to the flask's mid-joint via a short-length air condenser, and the side arm was connected to a three-way tap. The apparatus was evacuated, then refilled with nitrogen (three times), evacuated, and refilled with hydrogen. The resulting solution was heated and stirred under a hydrogen atmosphere at 35°C overnight. A sample of the mixture was removed, filtered through cotton wool, concentrated under reduced pressure, and analyzed by HPLC, which indicated the reaction was complete. The solution was filtered through Celite® (1 × 4 cm), the Celite® pad was washed with methanol (approximately 10 mL), and the solvent was removed under reduced pressure to give the crude product, which was purified using column chromatography (silica, 4 × 25 cm) eluting with 2–4% MeOH / DCM to give compound 1 (2.35 g, 59%) as a metallic blue / green flaky solid (HPLC purity: 98.8%).
[0247] 1 H NMR (400MHz, CDCl3) δ9.74(s, 1H), 9.56(s, 1H), 8.79(m, 2H), 4.60-4.55(m, 1H), 4.50-4.45(m, 1H), 3.97-3.90(m, 5H), 3.85(q, 2H), 3.62(s, 3H), 3.39(s, 3H), 3.37(s, 3H), 2.55-2.30(m, 2H), 2.12-1.95(m, 2H), 1.79-1.70(m, 9H), -2.25(br s, 1H).
[0248] Synthesis Example 2 - Synthesis of reduced phyllochlorin sodium salt (compound 2) [ka] To a one-necked 25 mL RBF containing reduced phyllochlorin (compound 1) (50 mg, 0.098 mmol, 1 equiv.) and a small stir bar, water (1.5 mL) was added and the suspension was stirred at 400 rpm. Sodium hydroxide (0.103 M, 0.86 mL, 0.088 mmol, 0.9 equiv.) was added, and the mixture was stirred under nitrogen for 15 minutes. The solution was then sonicated for 15 minutes, by which time most of the solid appeared to be soluble. The solution was stirred under nitrogen for an additional 2 hours. The solvent was then removed using a rotary evaporator, and the product was dried on a rotary evaporator at 50 °C under full vacuum for 1 hour to give compound 2 (37 mg, 71%) as a dark green / blue solid (HPLC purity: 94.8%).
[0249] 1 H NMR (400MHz, DMSO-d6) δ9.71(s, 1H), 9.58(s, 1H), 8.98(m, 2H), 4.63-4.52(m, 2H), 3.97-3.90(m, 5H), 3.81(q, 2H), 3.60(s, 3H), 3.3 7(s, 3H), 3.32(s, 3H), 2.47-2.37(m, 2H), 2.11-2.04(m, 1H), 1.84-1.75(m, 1H), 1.72-1.66(m, 9H), -2.34(brs, 1H), -2.39(brs, 1H).
[0250] Synthesis Example 3 - Synthesis of reduced phyllochlorin 2-deoxyglucosamine-propylamide (compound 3) [ka] To a 10 mL RBF containing a stir bar was added reduced phyllochlorin (compound 1) (105.0 mg, 0.2056 mmol, 1 equiv.), PyBOP (117.7 mg, 0.2262 mmol, 1.1 equiv.), DMF (1 mL), and triethylamine (62.7 μL, 0.4523 mmol, 2.2 equiv.). The resulting mixture was stirred (420 rpm) under nitrogen at ambient temperature for 5 minutes, and then a suspension of (D)-glucosamine hydrochloride (48.8 mg, 0.2262 mmol, 1.1 equiv.) in DMF (0.5 mL) was added in one portion, with additional DMF (0.5 mL) used for quantitative transfer. The resulting mixture was stirred for 30 minutes, by which time the reaction was complete as monitored by HPLC. The reaction mixture was concentrated using a rotary evaporator to give a black residue. The crude product was purified by column chromatography using a stepped column (27 / 40 mm), 30 cm silica height, and a gradient of 10% → 15% → 20% MeOH / DCM to give a black solid (158.1 mg) containing compound 3 and triethylammonium impurity. The solid was slurried overnight in distilled water (3 mL), collected on a sinter, and washed with distilled water (2 × 3 mL). After drying in a vacuum oven at 60 °C for 2 hours, compound 3 was obtained as a black solid (96.9 mg, 70%) (HPLC purity: 95.4%).
[0251] 1 H NMR (400MHz, DMSO-d6) δ9.74(s, 1H), 9.60(s, 1H), 9.00(m, 2H), 5.24-4.90(m, 3H), 4.67-4.45(m, 3H), 4.28(dd, 1H), 3.98(m, 5H), 3.82(q, 2H), 3.62(s, 3H), 3.40(s, 3H) ), 3.22-3.15 (m, 2H), 3.14-3.04 (m, 3H), 2.90 (s, 2H), 2.81 (s, 1H), 2.70-2.52 (m, 2H), 2.48-2.35 (m, 1H), 1.81 (m, 1H), 1.76-1.63 (m, 11H), -2.35 (s, 1H), -2.40 (s, 1H). The product in solution exists as a mixture of epimers, giving rise to two sets of signals in an approximately 2:1 ratio.
[0252] Synthesis Example 4 - Synthesis of reduced phyllochlorin β-D-1-thioglucose-N-methylpropylamide (Compound 4) [ka] Step 1: To a solution of (2R,3R,4S,5R,6S)-2-(acetoxymethyl)-6-((3-((tert-butoxycarbonyl)(methyl)amino)propyl)thio)tetrahydro-2H-pyran-3,4,5-triyl triacetate (274 mg, 0.511 mmol, 1.3 equiv) in DCM (4 mL) was added TFA (1 mL). The resulting solution was stirred (420 rpm) at ambient temperature for 1 h and then concentrated on a rotary evaporator. The residue was resuspended and concentrated twice from chloroform (2 × 5 mL) to give a viscous oil, which was dissolved in DCM (2 mL) for the subsequent coupling reaction.
[0253] Step 2: To a 25 mL RBF was added reduced phyllochlorin (compound 1) (200 mg, 0.393 mmol, 1 equiv.), PyBOP (246 mg, 0.472 mmol, 1.2 equiv.), DCM (2 mL), and triethylamine (327 μL, 2.36 mmol, 6 equiv.). The resulting mixture was stirred (420 rpm) under nitrogen at ambient temperature for 30 min, and then a solution of the deprotected amine prepared in Step 1 in DCM (2 mL) was added in one portion and washed with additional DCM (18 mL). The resulting mixture was stirred for 30 min, after which the reaction was monitored by HPLC for completion. The reaction mixture was transferred to a separatory funnel and washed with 1 M HCl (2 × 5 mL) followed by pH 7 buffer (1 × 10 mL). The organic phase was dried (NaSO) and concentrated by rotary evaporation to give a foamy blue-black film. The residue was purified by silica column chromatography (3 × 22 cm). The crude product was dissolved in 1.5% MeOH / DCM and eluted with a gradient of 1.5% to 3% MeOH / DCM to give reduced phyllochlorin β-D-1-thioglucose-N-methylpropylamidoperacetate as a blue / black flaky solid (320 mg).
[0254] Step 3: To a solution of reduced phyllochlorin β-D-1-thioglucose-N-methylpropylamidoperacetate (310 mg, 0.334 mmol, 1 equiv.) in MeOH (5 mL) and DCM (5 mL), NaOMe (4.6 M in MeOH, 0.36 mL, 1.670 mmol, 5 equiv.) was added and the mixture was stirred (420 rpm) under nitrogen for 1 h. TLC analysis showed conversion to the deacetylated product (10% MeOH / DCM, R f (starting material) = 0.80, R f (Product) = 0.30). The reaction was quenched with AcOH (100 mg, 5 eq) and concentrated by rotary evaporation to give a black film. The residue was purified by silica column chromatography (3 x 21 cm). The crude product was dissolved in 5% MeOH / DCM and eluted with a gradient of 5% → 7% → 8% → 10% MeOH / DCM to give compound 4 as a blue / black flaky solid (213 gm).
[0255] 1 H NMR (400MHz, DMSO-d6) δ9.74(s, 1H), 9.60(s, 1H), 9.00(m, 2H), 5.24-4.90(m, 3H), 4.67-4.45(m, 3H), 4.28(dd, 1H), 3.98(m, 5H), 3.82(q, 2H), 3.62(s, 3H), 3.40(s, 3H) ), 3.22-3.15(m, 2H), 3.14-3.04(m, 3H), 2.90(s, 2H), 2.81(s, 2H), 2.75-2.50(m, 3H) ), 2.48-2.30(m, 3H), 1.81(m, 1H), 1.76-1.63(m, 11H), -2.35(s, 1H), -2.40(s, 1H).
[0256] Alternatively, reduced phyllochlorin β-D-1-thioglucose-N-methylpropylamide (compound 4) can be prepared as follows: [ka]
[0257] Step 1: To a 100 mL RBF equipped with a nitrogen inlet and containing a small stir bar, phyllochlorin (2.00 g, 3.93 mmol, 1 equiv.), dichloromethane (50 mL), PyBOP (2.26 mg, 1.1 equiv.), triethylamine (1.64 mL, 3 equiv.), and 3-(methylamino)-propanol (0.42 g, 1.2 equiv.) were added. The mixture was stirred at room temperature for 3 h. Analysis by HPLC indicated the reaction was complete. The reaction mixture was transferred to a separatory funnel and washed with water (2 × 30 mL). The organic layer was dried (NaSO) and concentrated by rotary evaporation to give the crude product as a blue / brown film (5.1 g). The crude mixture was loaded directly onto a silica column and eluted with 1.5–2% MeOH / DCM. f Pure fractions containing a green / blue spot by TLC with 0.30 (5% MeOH / DCM) were combined to give phyllochlorin N-3-hydroxypropyl-N-methylpropylamide (1.29 g, 57%).
[0258] 1 H NMR (400MHz, CDCl3) δ9.75-9.70(m, 2H), 8.85(brs, 1H), 8.16(dd, 1H), 6.38(dd, 1H), 6 .15(dd, 1H), 4.70-4.65(m, 1H), 4.58-4.50(m, 1H), 4.00(s, 3H), 3.89-3.82(m, 3H), 3.6 5(s, 3H), 3.53(s, 3H), 3.37(s, 3H), 3.31-3.15(m, 4H), 2.65-2.53(m, 2H), 2.37-2.22( m, 3H), 2.16(3, 3H), 1.80-1.70(m, 7H), 1.48-1.40(m, 2H), -2.10(s, 1H), -2.22(m, 1H).
[0259] Step 2: A single-necked 50 mL RBF was charged with phyllochlorin N-3-hydroxypropyl-N-methylpropylamide (1.25 g, 2.156 mmol, 1 equiv.), dichloroethane (10 mL), and DMF (1 drop). Thionyl chloride (0.23 mL, 3.233 mmol, 1.5 equiv.) was added, and the resulting solution was stirred (350 rpm) at 40 °C under N2. After 2 h, the flask was heated at 60 °C for an additional 2 h. The reaction was then cooled using an ice / water bath, and pH 7 phosphate buffer (10 mL) was added. The mixture was extracted with DCM (3 × 15 mL), dried (Na2SO4), and the solvent removed under reduced pressure to give approximately 1.4 g of crude product. The remaining blue solid was purified by column chromatography using 2–4% MeOH / DCM, and the fractions containing the first dark band to elute were combined to give phyllochlorin N-3-chloropropyl-N-methylpropylamide as a blue / green solid (0.875 g, 67.8%).
[0260] Step 3: A single-necked 25 mL RBF was charged with phyllochlorin N-3-chloropropyl-N-methylpropylamide (145 mg, 0.242 mmol, 1 equiv.), 2-butanone (5 mL), and sodium iodide (73 mg). The resulting solution was stirred (350 rpm) at 90 °C under N2. After 3 h, TLC indicated the reaction was complete, and the flask was then cooled using an ice / water bath. To the crude iodide was added thioglucose tetraacetate (106 mg, 0.291 mmol, 1.2 equiv.) and DIPEA (38 mg, 0.291 mmol, 1.2 equiv.), and the solution was stirred at 25 °C overnight. TLC analysis indicated the presence of some starting material, and the solution was heated at 50 °C for 3 h. The solvent was removed, and the remaining blue solid was purified by column chromatography using 2-5% MeOH / DCM to isolate the darkest band (R f Fractions containing approximately 0.6% 5% MeOH / DCM) were combined to give phyllochlorin β-1-thioglucose N-methylpropylamidoperacetate as a blue / green solid (145 mg) that was used directly in the next step.
[0261] Step 4: To a solution of phyllochlorin β-1-thioglucose N-methylpropylamidoperacetate (140 mg, 0.1512 mmol, 1 equiv.) in MeOH (2 mL) / DCM (2 mL), NaOMe (4.6 M in MeOH, 0.16 mL, 0.756 mmol, 5 equiv.) was added and the mixture was stirred (250 rpm) under N for 30 min. TLC analysis showed conversion to the deacetylated product (5% MeOH / DCM, R f (starting material) = 0.6, R f (Product) = 0). The reaction was quenched with acetic acid (10 drops) and concentrated by rotary evaporation. The residue was purified by column chromatography (2-8% MeOH / DCM) to elute phyllochlorin β-D-1-thioglucose-N-methylpropylamide as a dark blue solid (30 mg, 16% over two steps from the chloride salt).
[0262] 1 H NMR (400MHz, d6-DMSO) δ9.76(s, 1H), 9.74(s, 1H), 9.10(d, J=5.7Hz, 1H), 9.07(s, 1H), 8.35(dd, J=17.8, 11.6Hz, 1H), 6.45(dd, J=17.8, 1 .6Hz, 1H), 6.18(dd, J=11.6, 1.5Hz, 1H), 5.24-4.89(m, 3H), 4.66(p, J=7.4Hz, 1H), 4.59-4.44(m, 2H), 4.28(dd, J=32.2, 9.6Hz, 1H), 3.98( d. 2.52(m, 1H), 2.42(dt, J=20.1, 5.8Hz, 1H), 1.81(ddd, J=22.3, 14.6, 6.9Hz, 1H), 1.75-1.61(m, 7H), -2.26(s, 1H), -2.42(d, J=2.2Hz, 1H).
[0263] Step 5: A three-necked 250 mL RBF was charged with phyllochlorin β-D-1-thioglucose-N-methylpropylamide (2.10 g, 0.941 mmol, 1 equiv.), 10% Pd / C (300 mg), ethyl acetate (90 mL), methanol (30 mL), and a stir bar. A hydrogen balloon was connected to the flask's mid-joint via a short-length air condenser, and the side arm was connected to a three-way tap. The apparatus was evacuated and then refilled with nitrogen (three times), evacuated, and refilled with hydrogen (twice). The resulting solution was then stirred (350 rpm) under a hydrogen atmosphere at 35°C for 5 hours with heating. The solution was filtered through Celite® (0.5 × 3 cm), washed with methanol (approximately 25 mL), and the solvent was then removed under reduced pressure to give the crude product. The residual crude solid was purified using column chromatography (silica, 4 x 7 cm) eluting with 10% MeOH / DCM to give compound 4 (1.90 g, 95%) as a metallic blue / green solid (HPLC purity: 98.8%).
[0264] 1 H NMR (400MHz, DMSO-d6) δ9.74(s, 1H), 9.61(s, 1H), 9.03-8.97(m, 2H), 5.24-4.88(m, 3H) , 4.68-4.60(m, 1H), 4.58-4.50(m, 2H), 4.28(dd, 1H), 3.99-3.92(m, 5H), 3.82(q, 2H), 3. 62(s, 3H), 3.41(s, 3H), 3.22-3.04(m, 5H), 2.90(s, 2H), 2.81(s, 2H), 2.70-2.52(m, 3H) , 2.48-2.35(m, 3H), 1.90-1.80(m, 1H), 1.76-1.63(m, 11H), -2.34(s, 1H), -2.40(s, 1H).
[0265] Synthesis Example 5 - Synthesis of reduced phyllochlorin β-D-1-glucose-N-methyl-2-ethoxy-N-ethanamine (Compound 5) [ka] Step 1: A solution of N-Cbz-2-(2-methylamino-ethoxy)-ethanol (1.35 g, 5.33 mmol, 1 equiv.) and penta-acetylglucose (2.29 g, 1.1 equiv.) in DCM (30 mL) was cooled in an ice / water bath under nitrogen, and BF EtO (3.78 g, 3.29 mL, 5 equiv.) was added dropwise via syringe. The solution was stirred (420 rpm) at 0-5 °C (external) for 1 h and then at room temperature overnight. Reaction progress was monitored by NMR. Upon completion, the solution was washed with saturated NaHCO (2 × 20 mL), and the combined aqueous washes were then extracted with DCM (20 mL). The combined organic layers were dried (MgSO) and evaporated to give the Cbz-protected PEG-glucose as a pale yellow oil (approximately 4 g), which was partially purified by column chromatography (4 x 25 cm silica) eluting with a gradient of 0.5-3.5% MeOH / DCM. The resulting oil (2.85 g) was used directly in the next step.
[0266] Step 2: To a three-necked 250 mL RBF was added Cbz-protected PEG-glucose (2.85 g), methanol (100 mL), and 10% Pd / C (140 mg, 5 w / w%). A hydrogen balloon was attached to the flask, and the flask was evacuated and refilled with nitrogen three times. The flask was then evacuated and refilled with hydrogen. The solution was stirred at 325 rpm overnight. After evacuating the flask and refilling with nitrogen, the solution was filtered (Celite®), washed with methanol (20 mL), and concentrated under reduced pressure. The concentrated residue was taken up in DCM (25 mL), washed with water (2 × 20 mL), dried (MgSO), and evaporated to give amine PEG-glucose (1.5 g) as a yellow oil, which was used without further purification.
[0267] Step 3: To a 50 mL RBF was added phyllochlorin (1.04 g, 2.05 mmol, 1 equiv.), PyBOP (1.28 g, 2.46 mmol, 1.2 equiv.), DCM (15 mL), and triethylamine (1.92 mL, 13.9 mmol, 6.7 equiv.). The resulting mixture was stirred (250 rpm) under nitrogen at ambient temperature for 30 min, and then amine PEG-glucose in DCM (10 mL) was added in one portion. The resulting mixture was stirred overnight in the dark under nitrogen. The reaction mixture was transferred to a separatory funnel and washed with 1 M HCl (2 × 30 mL) followed by pH 7 buffer (1 × 30 mL). The organic phase was dried (NaSO) and concentrated by rotary evaporation to give a blue / black oil, which was purified by column chromatography (4 × 26 cm silica) eluting with a gradient of 1% → 2.5% MeOH / DCM. Phyllochlorin β-D-1-glucose-N-methylethoxyethylamide tetraacetate (R in 5% MeOH / DCM) f Fractions containing R (approximately 0.4%) were combined to give a blue / black oil (approximately 0.7 g) which was further purified using Biotage autocolumn chromatography. f Approximately 0.4 fractions were combined to give phyllochlorin β-D-1-glucose-N-methylethoxyethylamide tetraacetate (0.38 g), which was deprotected in the next step without further purification.
[0268] Step 4: To a solution of phyllochlorin β-D-1-glucose-N-methylethoxyethylamide tetraacetate (350 mg, 0.372 mmol, 1 equiv.) in MeOH (5 mL) and DCM (5 mL), NaOMe (4.6 M in MeOH, 0.40 mL, 1.862 mmol, 5 equiv.) was added and the mixture was stirred (420 rpm) under nitrogen for 1 h. TLC analysis showed conversion to the deacetylated product (10% MeOH / DCM, R f (starting material) = 0.85, R f(Product) = 0.25). The reaction was quenched with AcOH (112 mg, 1.862 mmol, 5 equiv.) and concentrated by rotary evaporation to give a black film, which was purified by column chromatography (3 x 21 cm silica) eluting with a gradient of 3-10% MeOH / DCM to give phyllochlorin β-D-1-glucose-N-methyl-2-ethoxy-N-ethanamine as a blue / black solid (204 mg, 71%) (HPLC purity: 91%).
[0269] 1 H NMR (400MHz, DMSO-d6) δ9.75(s, 1H), 9.73(s, 1H), 9.10(s, 1H), 9.06(s, 1H), 8.33(dd, 1H), 6.44(d, 1H), 6.18(d, 1H), 5.30-4.70(br m, 3H), 4.65(m, 1H), 4.60-4.53(m, 2H), 4.13(m, 1H), 3.98(d, 3H), 3.81( m, 4H), 3.68-3.62(m, 2H), 3.62(s, 3H), 3.54(d, 3H), 3.50-3.30(m, 14H) , 3.18-3.05(m, 4H), 3.00-2.94(m, 3H), 2.88-2.78(m, 2H), 2.55-2.45(m , 1H), 2.45-2.38(m, 1H), 1.75-1.65(m, 7H), -2.25(s, 1H), -2.42(s, 1H).
[0270] Step 5: A three-necked 100 mL RBF was charged with phyllochlorin β-D-1-glucose-N-methyl-2-ethoxy-N-ethanamine (80 mg, 0.104 mmol, 1 equiv.), 10% Pd / C (10 mg), methanol (4 mL), ethyl acetate (12 mL), and a stir bar (approximately 15 mm). A hydrogen balloon was connected to the flask's mid-joint via a short-length air condenser, and the side arm was attached to a three-way tap. The apparatus was evacuated and then refilled with nitrogen (three times), evacuated, and refilled with hydrogen (twice). The resulting solution was stirred (525 rpm) under a hydrogen atmosphere at room temperature overnight. A sample of the mixture was removed, filtered through cotton wool, concentrated under reduced pressure, and analyzed by HPLC, which indicated the reaction was complete. The solution was filtered through Celite® (1 × 3 cm), the Celite® pad was washed with methanol (approximately 3 mL), and the solvent was removed under reduced pressure to give the crude product as a dark blue / green solid, which was purified using column chromatography (silica, 3 × 16 cm) eluting with 5–11% MeOH / DCM to give compound 5 as a dark blue / green solid (62 mg, 78%) (HPLC purity: 94.1%).
[0271] 1 H NMR (400MHz, DMSO-d6) δ9.74(s, 1H), 9.61(s, 1H), 9.02(s, 1H), 8.99(s, 1H), 5.05-4.87(br m, 3H), 4.61(m, 1H), 4.58-4.45(m, 2H), 4.12(m, 2H), 3.96(m, 5H), 3.81(m, 3H), 3.67-3.60(m, 5H), 3.62(s, 3H), 3.58-3.50(m, 2H), 3.50-3. 37(m, 12H), 3.18(s, 3H), 3.15-3.10(m, 1H), 3.08-3.00(m, 2H), 2.95( m, 3H), 2.83(s, 2H), 1.75-1.65(m, 10H), -2.35(s, 1H), -2.40(s, 1H).
[0272] Synthesis Example 6 - Synthesis of reduced phyllochlorin methyl ester (compound 6) [ka] To a 10 mL RBF under nitrogen was added reduced phyllochlorin (compound 1) (250 mg, 0.4895 mmol, 1 equiv.), potassium carbonate (81.2 mg, 0.5875 mmol, 1.2 equiv.), and DMF (3 mL). Methyl iodide (39.6 μL, 0.6364 mmol, 1.3 equiv.) was then added, and the resulting mixture was stirred (420 rpm) for 6 h, by which time the reaction was complete as monitored by HPLC. DCM (3 mL) was added, and the solution was stirred for 15 min before being filtered through a pad of Celite®, washing with additional DCM (2 × 3 mL) until the filtrate was colorless. The solvent was removed on a rotary evaporator to give a nearly black syrup, which was then dissolved in EtOAc (12.5 mL), washed with water (3 × 10 mL), dried (NaSO), and concentrated under reduced pressure to give the crude product as a dark blue / green solid (241.1 mg). The crude product was purified by Biotage autocolumn chromatography to give compound 6 as a black / green solid (151.6 mg).
[0273] 1 H NMR (400MHz, CDCl3) δ9.73(s, 1H), 9.56(s, 1H), 8.82(s, 1H), 8.78(s, 1H), 4.5 5(d, J=9.1Hz, 1H), 4.49(q, J=7.3Hz, 1H), 3.97(s, 3H), 3.95(d, J=7.7Hz, 2H), 3.85(q, J=7.6Hz, 2H), 3.64(d, J=1.0Hz, 3H), 3.57(s, 3H), 3.41(s, 3H), 3.38( s, 3H), 2.62-2.43(m, 2H), 2.17-1.99(m, 2H), 1.82-1.71(m, 9H), -2.19(s, 2H).
[0274] Synthesis Example 7 - Synthesis of reduced phyllochlorin N-(2-(2-hydroxyethoxy)ethyl)-N-methylpropylamide (Compound 7) [ka] Step 1: To a 100 mL RBF equipped with a nitrogen inlet and containing a stir bar, phyllochlorin (2.00 g, 3.93 mmol, 1 equiv.), dichloromethane (40 mL), PyBOP (2.46 g, 4.72 mmol, 1.2 equiv.), and triethylamine (0.87 mL, 3 equiv.) were added. The mixture was stirred at room temperature for 30 min, and then 2-(2-methylaminoethoxy)ethanol (0.61 g, 1.3 equiv.) in DCM (5 mL) was added in one portion. The mixture was stirred at room temperature overnight. Analysis by HPLC indicated the reaction was complete. The reaction mixture was transferred to a separatory funnel and washed with 1 M HCl (2 × 50 mL) followed by pH 7 buffer (2 × 50 mL). The organic layer was dried (NaSO) and concentrated by rotary evaporation to give the crude product as a blue / green film (4.2 g), which was purified by column chromatography (5 x 25 cm silica) eluting with 1-3% MeOH / DCM. Pure fractions by TLC (R in 5% MeOH / DCM) were f 0.40) were combined to give phyllochlorin N-(2-(2-hydroxyethoxy)ethyl)-N-methylpropylamide (1.40 g, 58%) (HPLC purity: 94.4%).
[0275] 1 H NMR (400MHz, CDCl3) δ9.72(m, 2H), 8.87-8.82(m, 1H), 8.16(dd, 1H), 6.39(dd, 1H), 6.15(dd, 1H), 4.7 2-4.65(m, 1H), 4.59-4.50(m, 1H), 4.01(s, 3H), 3.85(q, 2H), 3.65(s, 3H), 3.60-3.55(m, 2H), 3.53(s , 3H), 3.41-3.38(m, 2H), 3.37(s, 3H), 3.35-3.30(m, 2H), 2.76-2.71(m, 1H), 2.65-2.50(m, 4H), 2.50 -2.40(m, 1H), 2.38-2.30(m, 3H), 2.30-2.20(m, 2H), 1.90-1.80(m, 1H), 1.80-1.73(m, 7H), -2.09(br s, 1H), -2.22(br s, 1H).
[0276] Step 2: A three-necked 100 mL RBF was charged with phyllochlorin N-(2-(2-hydroxyethoxy)ethyl)-N-methylpropylamide (100 mg, 0.164 mmol, 1 equiv.), 10% Pd / C (10 mg), ethyl acetate (20 mL), and a stir bar (approximately 15 mm). A hydrogen balloon was connected to the flask's mid-joint via a short-length air condenser, and the side arm was connected to a three-way tap. The apparatus was evacuated and then refilled with nitrogen (three times), evacuated, and refilled with hydrogen (twice). The resulting solution was then stirred (550 rpm) under a hydrogen atmosphere at 30° C. for 90 minutes with heating. The solution was filtered through Celite® (0.5 × 3 cm), washed with ethyl acetate (approximately 10 mL), and the solvent was then removed under reduced pressure to give the crude product (approximately 0.15 g). The residual solid was purified using column chromatography (silica, 3 × 19 cm) eluting with 3–4% MeOH / DCM to give compound 7 (84 mg, 84%) as a metallic blue / green flaky solid (HPLC purity: 97.7%).
[0277] 1 H NMR (400MHz, CDCl3) δ9.73(s, 1H), 9.56(s, 1H), 8.82(brs, 1H), 8.79(m, 1H), 4.70-4.62(m, 1 H), 4.55-4.47(m, 1H), 4.00(m, 3H), 3.95(q, 2H), 3.86(q, 2H), 3.64(s, 3H), 3.60-3.56(m, 2H) , 3.43-3.37(m, 9H), 3.35-3.30(m, 1H), 2.70-2.66(m, 1H), 2.65-2.50(m, 4H), 2.42-2.35(m, 1H), 2.33(s, 2H), 2.30-2.15(m, 2H), 1.90-1.80(m, 1H), 1.80-1.73(m, 10H), -2.18(brm, 2H).
[0278] Synthesis Example 8 - Synthesis of reduced phyllochlorin β-D-1-thioglucose-N-methylpropylamide zinc complex (compound 8) [ka] To a 25 mL one-necked RBF was added reduced phyllochlorin β-D-1-thioglucose-N-methylpropylamide (compound 4) (50 mg, 0.0658 mmol, 1 equiv.) and DCM (2 mL). A solution of zinc acetate (24 mg, 0.1316 mmol, 2 equiv.) in methanol (1 mL) was added, and the mixture was stirred under nitrogen in the dark for 2 h. The solution was then diluted with DCM (20 mL), washed with water (3 × 25 mL), dried (NaSO), and concentrated to give compound 8 (57 mg, quantitative) (HPLC purity: 99.3%) as a blue solid.
[0279] 1 H NMR (400MHz, CDCl3) δ9.45(brs, 1H), 9.37(brs, 1H), 8.65(brs, 1H), 8.51(brs, 1H), 4. 15-4.00(brm, 2H), 3.90-3.70(brm, 4H), 3.60-3.50(brm, 3H), 3.45-3.30(brm, 9H), 3.2 0(brm, 1H), 3.15-3.00(brm, 1H), 2.80-2.45(brm, 2H), 2.40-2.20(brm, 4H), 2.15-2.0 0(brm, 3H), 1.95-1.70(brm, 12H), 1.60(brm, 2H), 1.50(brs, 4H), 1.00-1.20(brm, 3H).
[0280] Synthesis Example 9 - Synthesis of reduced phyllochlorin β-D-glucosyl-N-methylpropylamide (Compound 9) [ka] Step 1: A 250 mL three-neck RBF equipped with an internal thermometer, nitrogen inlet, and rubber septum was charged with tert-butyl (3-hydroxypropyl)(methyl)carbamate (2.68 g, 14.17 mmol, 1.05 equiv.), a stir bar, 2,3,4,6-tetra-O-benzoyl-α-D-glucopyranosyl trichloroacetimidate (10.00 g, 13.5 mmol, 1 equiv.), dry DCM (100 mL), and crushed 4A molecular sieves (5.0 g). The resulting suspension was placed under a nitrogen atmosphere and stirred (420 rpm) for 0.5 h before being cooled to −15 °C (internal temperature) using an EtOH / ice / NaCl bath. A solution of TMSOTf (0.2 M in DCM, 3.3 mL, 0.67 mmol) was added dropwise over 1 min and stirring was continued at low temperature for 0.5 h, at which point TLC analysis indicated the reaction was complete (25% EtOAc / hexane, R f (starting material) = 0.4, R f (product) = 0.2, visualized by UV). The reaction was quenched with triethylamine (8 drops), filtered through Celite®, and washed with additional DCM. The filtrate was concentrated to give the crude glycosylated product as a yellow syrup (15.4 g), which was dissolved in a minimal amount of DCM, and the solution was purified by column chromatography (4 x 22 cm silica) using a gradient solvent of 25 to 35% EtOAc in hexanes to give 2,3,4,6-tetra-O-benzoyl-β-D-glucopyranose-N-Boc-N-methylproproxyamine as a colorless syrup (7.95 g, 77%) (R in 35% EtOAc in hexanes). f 0.4).
[0281] 1H NMR (400MHz, CDCl3) δ8.05-7.99(m, 2H), 7.98-7.93(m, 2H), 7.92-7.88(m, 2H), 7.86-7.79(m, 2H), 7.59-7.46( m, 3H), 7.46-7.24(m, 9H), 5.90(dd, J=9.7, 9.7Hz, 1H), 5.68(dd, J=9.7, 9.7Hz, 1H), 5.52(dd, J=9.7, 7.8Hz, 1H) , 4.84(d, J=7.8Hz, 1H), 4.64(dd, J=12.2, 3.2Hz, 1H), 4.49(dd, J=12.2, 5.2Hz, 1H), 4.20-4.13(m, 1H), 3.95(d dd, J=9.7, 5.2, 3.2Hz, 1H), 3.61-3.50(m, 1H), 3.24-2.99(m, 2H), 2.66(s, 3H), 1.82-1.68(m, 2H), 1.39(s, 9H).
[0282] Step 2: To a 500 mL RBF containing 2,3,4,6-tetra-O-benzoyl-β-D-glucopyranose-N-Boc-N-methylproproxyamine conjugate (7.95 g, 10.35 mmol, 1 equiv.) was added DCM (50 mL) and a stir bar. The mixture was stirred briefly (250 rpm) until a solution formed, after which TFA (10 mL) was added. The mixture was stirred for 0.5 h and analyzed by TLC (30% EtOAc / hexane, R f (starting material) = 0.4, R f (Product) = 0), visualized by UV. The reaction was concentrated by rotary evaporation and then reconcentrated from CHCl3 (2 x 30 mL) to give 2,3,4,6-tetra-O-benzoyl-β-D-glucopyranose-N-methylproproxyammonium trifluoroacetate as a light syrup (11.0 g), which was used without further purification.
[0283] 1H NMR (400MHz, CDCl3) δ8.69(br s, 1H), 8.15(br s, 1H), 8.08-8.02(m, 2H), 7.99-7.88(m, 4H), 7.87-7.80(m, 2H), 7.67(br s, 1H), 7.63-7.48(m, 3H), 7.52-7.24(m, 9H), 5.99(dd, J=9.8, 9.8Hz, 1H), 5.71(dd, J=9 .8, 9.8Hz, 1H), 5.38(dd, J=9.8, 7.8Hz, 1H), 4.82(d, J=7.8Hz, 1H), 4.74(dd, J=12.3, 2. 8Hz, 1H), 4.47(dd, J=12.3, 5.0Hz, 1H), 4.22-4.06(m, 2H), 3.73(app.p, J=5.1Hz, 1H), 3 .31-3.18(m, 1H), 3.14-3.01(m, 1H), 2.79(t, J=5.3Hz, 3H), 2.04(app.p, J=5.4Hz, 2H).
[0284] Step 3: A 500 mL RBF was charged with a stir bar, phyllochlorin (4.05 g, 7.96 mmol, 1 equiv.), and DCM (60 mL). 2,3,4,6-tetra-O-benzoyl-β-D-glucopyranose-N-methylpropyloxyammonium trifluoroacetate conjugate (6.91 g, 10.35 mmol, 1.3 equiv.) was dissolved in DCM (20 mL) and transferred to the RBF. Triethylamine (6.62 mL, 47.8 mmol, 6 equiv.) was added, followed by PyBOP (4.97 g, 9.55 mmol, 1.2 equiv.), and the mixture was stirred for 0.5 h. TLC analysis indicated consumption of starting material and presence of product (5% MeOH / DCM, R f (phyllochlorin) = 0.25, R f(Product) = 0.95, visualized by UV). The mixture was transferred to a separatory funnel and washed with 1 M HCl (2 × 75 mL), then with pH 7 phosphate buffer (100 mL), then dried (NaSO) and concentrated by rotary evaporation to give the crude product as a green film (16.3 g). The crude product was purified by Biotage automated column chromatography (0–2% MeOH / DCM) to give phyllochlorin β-D-glucosyl-N-methylpropylamidotetrabenzoate as a green film (4.75 g, 52%) (HPLC purity: 95.9%).
[0285] Step 4: To a 500 mL RBF containing phyllochlorin β-D-glucosyl-N-methylpropylamidotetrabenzoate (4.65 g, 4.01 mmol, 1 equiv.) was added DCM (50 mL), MeOH (50 mL), and a stir bar. The mixture was stirred briefly (300 rpm) until a dark solution formed, whereupon a solution of NaOMe (4.6 M in MeOH, 0.44 mL, 2.01 mmol, 0.5 equiv.) was added and the mixture was stirred for 2 h. TLC analysis at this point indicated complete reaction (10% MeOH / DCM, R f (starting material) = 0.95, R f (Product) = 0). The reaction mixture was concentrated, and the residue was purified by Biotage autocolumn chromatography (5–12% MeOH / DCM) to give phyllochlorin β-D-glucosyl-N-methylpropylamide as a blue / green flaky solid (2.34 g, 79%) (HPLC purity: 99.4%).
[0286] Step 5: A three-necked 250 mL RBF equipped with a stopper and a three-way tap connected to a nitrogen line / vacuum pump was charged with phyllochlorin β-D-glucosyl-N-methylpropylamide (2.25 g, 3.03 mmol, 1 equiv.), a stir bar, and acetone (100 mL). The mixture was stirred briefly until a dark green solution formed, and then 10% Pd / C (100 mg) was added under positive nitrogen pressure. A hydrogen balloon was connected to the flask's mid-joint via a short-length air condenser, and a side arm was attached to the three-way tap. The apparatus was evacuated and then refilled with nitrogen (three times), evacuated, and refilled with hydrogen (twice). The resulting solution was then stirred (550 rpm) under a hydrogen atmosphere at 30 °C for 5 h with heating. The reaction mixture was filtered through a small plug of Celite® and washed with acetone. The filtrate was concentrated to give the crude hydrogenated compound as a blue-green film (2.30 g). The crude material was purified by Biotage autocolumn chromatography to give compound 9 as a black solid (2.02 g, 89%) (HPLC purity: 99.7%).
[0287] 1 H NMR (400MHz, CD3OD) δ9.65(brs, 1H), 9.49(m, 1H), 8.91(m, 1H), 8.87(m, 1H), 4.59(m , 2H), 3.95(m, 3H), 3.47(m, 2H), 3.73(m, 3H), 6.63(m, 1H), 3.55(m, 4H), 3.48(m, 3H), 3.26(m, 5H), 3.20-3.03(m, 4H), 2.87(m, 1H), 2.78(m, 1H), 2.58(s, 1H), 2.55-2.40( m, 2H), 2.39(s, 2H), 2.20-1.95(m, 2H), 1.80-1.68(m, 9H), 1.47(m, 1H), 1.20(m, 1H).
[0288] Synthesis Example 10 - Synthesis of reduced phyllochlorin N-meglumine-propylamide (Compound 10) [ka] Step 1: To a 50 mL RBF was added phyllochlorin (0.50 g, 0.983 mmol, 1 equiv.), DMTMM (0.30 g, 1.081 mmol, 1.1 equiv.), DCM (15 mL), and meglumine (0.23 g, 1.179 mmol, 1.2 equiv.). The resulting mixture was stirred under nitrogen at ambient temperature for 1 h. Additional meglumine (0.10 g, 0.51 mmol, 0.5 equiv.) was added, and the solution was stirred for an additional 3 h. The reaction mixture was transferred to a separatory funnel, diluted with chloroform (30 mL), and washed with 0.5 M HCl (50 mL). The aqueous layer was re-extracted with chloroform, and the combined organics were washed with pH 7 buffer. The organic phase was dried (Na2SO4) and concentrated by rotary evaporation to give a blue / black film which was purified by column chromatography (silica) using a gradient of 5% MeOH / DCM (50 mL), then 7% MeOH / DCM (100 mL), then 9% MeOH / DCM (100 mL), then 10% MeOH / DCM (200 mL) to give phyllochlorin N-meglumine-propylamide as a dark blue / green solid (432 mg, 64%).
[0289] 1 H NMR (400MHz, d6-DMSO) δ9.74(s, 1H), 9.72(s, 1H), 9.11(s, 1H), 9.07(s, 1H), 8.34(dd, 1H), 6.44(d, 1H), 6.17(d, 1H), 5.10&4.75(2 xd, 1H), 4.65-4.40(m, 5H), 4.30(m, 1H), 4.00(m, 3H), 3.90(m, 1H), 3.80( m, 2H), 3.68(m, 1H), 3.62(s, 3H), 3.60-3.50(m, 5H), 3.50-3.40(m, 2H), 3. 30-3.08(m, 1H), 3.00(s, 1H), 2.90(s, 2H), 2.86-2.60(m, 1H), 2.45-2.35( m, 1H), 1.75-1.65(m, 6H), 1.75-1.50(m, 1H), -2.26(s, 1H), -2.42(s, 1H).
[0290] Step 2: A three-necked 50 mL RBF was charged with phyllochlorin N-meglumine-propylamide (200 mg, 0.292 mmol, 1 equiv.), 10% Pd / C (25 mg), methanol (4 mL), ethyl acetate (4 mL), and a stir bar. A hydrogen balloon was connected to the flask's mid-joint via a short-length air condenser, and the side arm was connected to a three-way tap. The apparatus was evacuated and then refilled with nitrogen (three times), evacuated, and refilled with hydrogen (twice). The resulting solution was then stirred (500 rpm) under a hydrogen atmosphere at 30 °C for 4 h with heating. The solution was filtered through Celite® (0.5 × 1.5 cm), washed with methanol (approximately 10 mL), and the solvent was then removed under reduced pressure to give compound 10 as a metallic blue / green solid (190 mg, 95%) (HPLC purity: 99.4%).
[0291] 1 H NMR (400MHz, DMSO-d6) δ9.74(s, 1H), 9.61(s, 1H), 9.02(s, 1H), 8.99(s, 1H), 5.10&4.75(2 xm, 1H), 4.65-4.40(m, 5H), 4.40-4.30(m, 1H), 4.10(m, 1H), 4.00-3.88(m, 6 H), 3.80(m, 2H), 3.70-3.50(m, 7H), 3.40(s, 3H), 3.18(s, 3H), 3.00&2.90(2 xs, 3H), 2.86-2.60(m, 1H), 2.50-2.38(m, 1H), 1.75-1.65(m, 9H), 1.65-1.50(m, 1H), -2.35(s, 1H), -2.40(s, 1H).
[0292] Synthesis Example 11 - Synthesis of reduced phyllochlorin ((3-(3-(methylamino)propoxy)propyl)triphenylphosphonium chloride propylamide (Compound 11) [ka] Step 1: A 500 mL three-necked RBF was charged with bis(3-chloropropyl)ether (20.00 g, 70.15 mmol, 1.66 equiv), triphenylphosphine (18.40 g, 70.15 mmol, 1 equiv), sodium iodide (7.01 g, 46.77 mmol, 0.66 equiv), and acetonitrile (340 mL). The reaction was stirred at 90 °C for 72 h. The reaction flask was then cooled to room temperature, and the suspension was filtered through a 2 cm plug of Celite®, washing with an additional 250 mL of acetonitrile. The pale yellow solution was then evaporated to dryness, leaving a dark yellow oil (44.40 g). The crude oil was first purified by column chromatography (column length: 12 cm; column width: 9 cm; mobile phase: 6% MeOH in DCM; fraction size: approximately 75 mL; loading method: dissolved in 20 mL of mobile phase; R f (Protrusion)=0.35, R f The product was purified by rotary evaporation (dimer = 0.06, visualized by UV). The product-containing fractions were concentrated by rotary evaporation, and the resulting crude product was loaded onto a second column (column length: 7 cm; column width: 9 cm; loading method: dissolved in 10 mL of DCM). The column was first run with DCM and then switched to 10% MeOH in DCM to give 3-(3-chloropropoxy)propyl)triphenyl-phosphonium chloride as a faintly red solid (18.74 g, 62%) (mp: 131-134 °C).
[0293] 1 H NMR (400MHz, CDCl3) δ7.87-7.76(m, 9H), 7.75-7.63(m, 6H), 3.93-3.80(m, 2H), 3.75(td, J=5.7, 1.3Hz, 2H), 3.58(q, J=6.3Hz, 4H), 2.05-1.88(m, 4H).
[0294] Step 2: A 50 mL pressure vessel fitted with a Teflon insert was charged with (3-(3-chloropropoxy)propyl)triphenylphosphonium chloride (3.00 g, 6.92 mmol, 1 equiv.), methylamine (40% w / w in HO, 5.99 mL, 69.23 mmol, 10 equiv.), and potassium iodide (11.5 mg, 69.22 μmol, 0.01 equiv.). The vessel was then heated to 45 °C, and the mixture was left stirring for 24 h (500 rpm). The progress of the reaction was followed by NMR. The reaction mixture was then diluted with HO (60 mL) and extracted with DCM (3 × 60 mL). The combined organic layers were dried over MgSO, filtered, and concentrated by rotary evaporation to give (3-(3-(methylamino)propoxy)propyl)triphenylphosphonium chloride as a viscous light beige syrup (2.96 g, quantitative, approximately 63% pure by NMR analysis), mp: 131-134 °C.
[0295] 1 H NMR (400MHz, CDCl3) δ7.87-7.75(m, 9H), 7.75-7.65(m, 6H), 3.98-3.85(m, 2H), 3.74(t, J=5.2Hz, 2H), 3.55( t, J=6.1Hz, 2H), 2.70(t, J=6.8Hz, 2H), 2.43(s, 3H), 1.94(ddt, J=16.5, 8.7, 5.6Hz, 2H), 1.86-1.77(m, 2H).
[0296] Step 3: To a 50 mL RBF equipped with a nitrogen inlet and containing a small stir bar, phyllochlorin (500 mg, 0.983 mmol, 1 equiv.), dichloromethane (20 mL), 4-(4,6-dimethoxy-1,3,5-triazin-2-yl)-4-methyl-morpholinium chloride (DMTMM) (354 mg, 1.28 mmol, 1.3 equiv.), and (3-(3-(methylamino)propoxy)propyl)triphenyl-phosphonium chloride (504 mg, 1.18 mmol, 1.2 equiv.) were added. The mixture was stirred at 25 °C for 1 h, at which point HPLC analysis indicated that approximately 6% of the phyllochlorin was still present in the reaction mixture. After stirring for an additional 1 h, DMTMM (53 mg, 0.197 mmol, 0.2 equiv.) and (3-(3-(methylamino)propoxy)propyl)triphenylphosphonium chloride (133 mg, 0.197 mmol, 0.2 equiv.) were added, and the reaction mixture was stirred at 25 °C for 1 h. The reaction mixture was then diluted with DCM (50 mL) and washed with 0.1 M HCl (50 mL) followed by HO (50 mL). The organic layer was then dried over NaSO, filtered on a sintered glass frit, and concentrated by rotary evaporation to give the crude product as a dark blue solid. The crude mixture was directly loaded onto a silica column (4 × 20 cm, pre-equilibrated with 1% MeOH in DCM) and eluted with 1% to 5% MeOH in DCM. f Fractions (5% MeOH in DCM) containing a green / blue spot by TLC = 0.42 were collected, concentrated by rotary evaporation, and then dried in a vacuum oven at 60 °C for 2 h to give phyllochlorin ((3-(3-(methylamino)propoxy)propyl)triphenyl-phosphonium chloride propylamide) as a dark blue solid (407 mg, 45%) (HPLC purity: 95.4%).
[0297] 1H NMR (400MHz, CDCl3) δ9.75-9.62(m, 2H), 8.91-8.78(m, 2H), 8.15(m, 1H), 7.64(m, 4H), 7.51-7.40(m, 8H), 7.39-7.31(m, 2H) , 6.36(m, 1H), 6.13(dd, J=11.5, 1.5Hz, 1H), 4.66-4.47(m, 2H), 3.98(s, 1H), 3.95(s, 2H), 3.89-3.77(m, 2H), 3.74-3.66(m, 1 H), 3.63(t, J=1.2Hz, 3H), 3.58(m, 1H), 3.52(d, J=2.9Hz, 3H), 3.36(s, 2H), 3.34-3.28(m, 3H), 3.15-3.03(m, 1H), 2.90-2.78 (m, 1H), 2.72(s, 1H), 2.57(s, 2H), 2.54-2.37(m, 1H), 2.18-1.96(m, 1H), 1.85-1.69(m, 5H), 1.62(m, 6H), 1.43-1.29(m, 1H).
[0298] Step 4: A three-necked 50 mL RBF was charged with phyllochlorin ((3-(3-(methylamino)propoxy)propyl)triphenylphosphonium chloride propylamide (60 mg, 0.065 mmol, 1 equiv.), 10% Pd / C (10 mg), methanol (4 mL), ethyl acetate (4 mL), and a stir bar. A hydrogen balloon was connected to the flask's mid-joint via a short-length air condenser, and the side arm was connected to a three-way tap. The apparatus was evacuated and then refilled with nitrogen (3 times), evacuated and refilled with hydrogen (2 times). The resulting solution was then stirred (450 rpm) under a hydrogen atmosphere for 3 hours. The solution was filtered through Celite® (0.5 × 1.5 cm), washed with methanol (approximately 10 mL), and the solvent was then removed under reduced pressure to give compound 11 as a dark green solid (62 mg, quantitative) (HPLC purity: 96.1%).
[0299] 1H NMR (400MHz, CDCl3) δ9.73-9.69(m, 1H), 9.55-9.42(m, 1H), 8.80-8.77(m, 2H), 7.68-7.61(m, 4H), 7.49-7.41(m, 9H), 7.39-7.34(m, 2H), 4.62-4.45(m, 2H), 3.96-3.90(m, 5H), 3.88-3.80(m, 2H), 3.75-3.66(m, 1H), 3.62(s, 3H), 3.57(td , 1H), 3.39(m, 3H), 3.37(m, 2H), 3.32-3.28(m, 5H), 3.09(m, 1H), 2.88-2.80(m, 1H), 2.71(s, 1H), 2.53(s, 2H), 2.50-2 .40(m, 2H), 2.12-1.95(m, 2H), 1.82-1.70(m, 10H), 1.60(m, 5H), 1.42-1.28(m, 2H), -2.18(brs, 1H), -2.19(brs, 1H).
[0300] Synthesis Example 12 - Synthesis of reduced phyllochlorin N-(2-(2-(2-hydroxyethoxy)ethoxy)ethyl)-N-methyl-3-amide (Compound 12) [ka] Step 1: To a 50 mL RBF equipped with a nitrogen inlet and containing a small stir bar, phyllochlorin (500 mg, 0.983 mmol, 1 equiv.), dichloromethane (15 mL), PyBOP (563 mg, 1.1 equiv.), triethylamine (409 μL, 3 equiv.), and 2-(2-(2-(methylamino)ethoxy)ethoxy)ethanol (193 mg, 1.2 equiv.) were added. The mixture was stirred at room temperature for 1 h. Analysis by HPLC indicated the reaction was complete. The reaction mixture was transferred to a separatory funnel and washed with water (2 × 10 mL). The organic layer was dried (NaSO) and concentrated by rotary evaporation to give the crude product as a blue / brown film (1.10 g). The crude mixture was loaded directly onto a silica column and eluted with 3–7% MeOH / DCM. TLC (R in 5% MeOH / DCM) indicated the reaction was complete. fThe pure fractions containing the green / blue compound from 0.20) were combined to give phyllochlorin N-(2-(2-(2-hydroxyethoxy)ethoxy)ethyl)-N-methyl-3-amide.
[0301] 1 H NMR (400MHz, CDCl3) δ9.71(m, 2H), 8.83(m, 2H), 8.16(dd, 1H), 6.38(dd, 1H), 6. 13(dd, 1H), 4.66(m, 1H), 4.54(m, 1H), 4.01(s, 3H), 3.84(q, 2H), 3.63(s, 3H), 3 .55-3.50(m, 4H), 3.47-3.30(m, 10H), 3.04(m, 1H), 2.77-2.50(m, 6H), 2.40-2. 20(m, 4H), 1.93-1.35(m, 1H), 1.30-1.22(m, 6H), -2.10(br, 1H), -2.24(br, 1H).
[0302] Step 2: A three-necked 100 mL RBF was charged with phyllochlorin N-(2-(2-(2-hydroxyethoxy)ethoxy)ethyl)-N-methyl-3-amide (500 mg, 0.765 mmol, 1 equiv.), 10% Pd / C (25 mg), ethyl acetate (15 mL), MeOH (5 mL), and a stir bar (approximately 15 mm). A hydrogen balloon was connected to the flask's mid-joint via a short-length air condenser, and the side arm was connected to a three-way tap. The apparatus was evacuated and then refilled with nitrogen (three times), evacuated, and refilled with hydrogen (twice). The resulting solution was then stirred (500 rpm) under a hydrogen atmosphere at 30 °C for 2 h with heating. The solution was filtered through Celite® (0.5 × 2 cm), washed with ethyl acetate (approximately 10 mL), and then the solvent was removed under reduced pressure to give compound 12 as a dark green solid (507 mg, quantitative) (HPLC purity: 98.7%).
[0303] 1H NMR (400MHz, CDCl3) δ9.73(m, 2H), 8.83(brs, 1H), 8.78(s, 1H), 4.68-4.62(m, 1H), 4.57-4.4 9(m, 1H), 4.00(s, 3H), 3.96(q, 2H), 3.86(q, 2H), 3.65(s, 3H), 3.51(m, 1H), 3.46(m, 1H), 3.45 -3.38(m, 9H), 3.37-3.34(m, 2H), 3.00(m, 1H), 2.72-2.68(m, 1H), 2.67(s, 1H), 2.65-2.50(m , 3H), 2.40(s, 2H), 2.38-2.20(m, 3H), 1.94-1.84(m, 1H), 1.81-1.74(m, 9H), -2.15(brm, 2H).
[0304] Synthesis Example 13 - Synthesis of reduced phyllochlorin N-(2-(2-(2-pyridiniumethoxy)ethoxy)ethyl)-N-methyl-3-amido chloride (Compound 13) [ka] Step 1: A single-necked 50 mL RBF was charged with reduced phyllochlorin N-(2-(2-(2-hydroxyethoxy)ethoxy)ethyl)-N-methyl-3-amide (compound 12) (200 mg, 0.305 mmol, 1 equiv.), dichloroethane (4 mL), and thionyl chloride (54 mg, 0.457 mmol, 1.5 equiv.). The resulting solution was cooled using a water bath and stirred (350 rpm) under a nitrogen atmosphere. DMF (1 drop) was added, and the mixture was stirred at room temperature for 1 h and then heated at 40 °C for an additional 1 h. The reaction was then cooled using an ice / water bath, and pH = 7 phosphate buffer (10 mL) and water (10 mL) were added. The mixture was then extracted with DCM (2 × 15 mL), dried (NaSO), and the solvent was removed under reduced pressure to give the crude product (0.6 g) as a dark green oil. The residue was purified by column chromatography (3 × 18 cm) eluting with a gradient of 2–4% MeOH / DCM. Fractions containing the major dark green spot (Rf = 0.5 in 5% MeOH / DCM) were combined to give reduced phyllochlorin N-(2-(2-(2-chloroethoxy)ethoxy)ethyl)-N-methyl-3-amide (compound 13A) as a dark green solid (157 mg, 76%).
[0305] 1 H NMR (400MHz, CDCl3) δ9.71(m, 1H), 9.53(m, 1H), 8.81(brs, 1H), 8.76(s, 1H), 4.64(m, 1H), 4.51(m, 1H) , 4.00(m, 3H), 3.94(m, 2H), 3.86(q, 2H), 3.64(s, 3H), 3.57(m, 1H), 3.47(m, 2H), 3.45-3.39(m, 5H), 3. 38-3.34(m, 5H), 3.18(t, 1H), 3.03(t, 1H), 2.73-2.65(m, 3H), 2.62-2.50(m, 2H), 2.44(s, 2H), 2.42-2 .35(m, 2H), 2.31-2.17(m, 2H), 1.95-1.86(m, 1H), 1.80-1.73(m, 9H), -2.14(brs, 1H), -2.17(brs, 1H).
[0306] Step 2: Reduction. To a sealed tube (2.5 × 20 cm with a Teflon screw cap) containing phyllochlorin N-(2-(2-(2-chloroethoxy)ethoxy)ethyl)-N-methyl-3-amide (compound 13A) (0.100 g, 0.148 mmol, 1 equiv.) and a stir bar was added MeCN (5 mL), pyridine (117 mg, 1.483 mmol, 10 equiv.), and NaI (44 mg, 0.297 mmol, 2 equiv.). The tube was flushed with nitrogen, and after sealing, the dark green mixture was stirred (300 rpm) at 95 °C for 17 h. The mixture was cooled, diluted with DCM (25 mL), washed with 0.1 M HCl (20 mL), pH = 7 phosphate buffer (20 mL), dried (NaSO), and concentrated by rotary evaporation to give the crude product as a dark green oil. The residue was purified by column chromatography (3 × 15 cm) eluting with a gradient of 3–8% MeOH / DCM. Fractions containing the major dark green spot (Rf<0.1 in 5% MeOH / DCM) were combined to give compound 13 as a dark green solid (38 mg, 34%) (HPLC purity: 96.9%).
[0307] 1 H NMR (400MHz, CDCl3) δ9.68(d, 1H), 9.51(s, 1H), 8.80(m, 2H), 7.43(d, 1H), 6.95-6.75(m, 2H), 6.33(t, 1H) , 6.21(t, 1H), 4.63-4.48(m, 2H), 3.98-3.91(m, 5H), 3.82(m, 2H), 3.63(s, 3H), 3.41(m, 3H), 3.37(m, 3H), 3 .32(m, 1H), 3.27-3.18(m, 2H), 3.10-3.02(m, 3H), 3.0-2.95(m, 1H), 2.83-2.76(m, 2H), 2.60(m, 3H), 2.55 -2.40(m, 3H), 2.35-2.20(m, 2H), 2.18-2.00(m, 2H), 1.81-1.67(m, 13H), -2.33(brs, 1H), -2.44(brs, 1H).
[0308] Synthesis Example 14 - Synthesis of reduced phyllochlorin N-methyl-N-3,6,9,12,15,18-hexaoxanonadecylpropylamide (Compound 14) [ka] To a 50 mL RBF equipped with a nitrogen inlet and containing a small stir bar, reduced phyllochlorin (compound 1) (100 mg, 0.194 mmol, 1 equiv.), dichloromethane (4 mL), 4-(4,6-dimethoxy-1,3,5-triazin-2-yl)-4-methyl-morpholinium chloride (DMTMM) (81 mg, 0.294 mmol, 1.5 equiv.), and N-methyl-2,5,8,11,14,17-hexaoxanonadecane-19-amine (91 mg, 0.294 mmol, 1.5 equiv.) were added. The mixture was stirred at room temperature for 2 h and monitored by HPLC. The reaction mixture was transferred to a separatory funnel, diluted with DCM (20 mL), and washed with 0.5 M HCl (20 mL) and pH 7 phosphate buffer (20 mL). The organic layer was dried (NaSO) and concentrated by rotary evaporation to give the crude product as a dark green film (0.40 g). The residue was purified by column chromatography (3 × 16 cm) eluting with a gradient of 2–3% MeOH / DCM. Fractions containing the major dark green spot (Rf = 0.25 in 5% MeOH / DCM) were combined to give compound 14 as a dark green oil (164 mg, quantitative) (HPLC purity: 94.4%).
[0309] 1 H NMR (400MHz, CDCl3) δ9.72(m, 1H), 9.55(m, 1H), 8.82(s, 1H), 8.78(s, 1H), 4.65(m, 1H), 4.52(m, 1H), 4.00(m, 3 H), 3.98-3.91(m, 4H), 3.90-3.78(m, 3H), 3.70-3.60(m, 8H), 3.58-3.52(m, 7H), 3.50-3.43(m, 12H), 3.42-3.36 (m, 9H), 3.34(m, 4H), 3.22(m, 2H), 2.97(m, 1H), 2.93-2.89(m, 1H), 2.86-2.78(m, 1H), 2.74(s, 1H), 2.65-2.50( m, 1H), 2.46(s, 2H), 2.45-2.34(m, 1H), 2.25-2.12(m, 1H), 2.06-1.85(m, 1H), 1.80-1.72(m, 9H), -2.18(s, 2H).
[0310] Synthesis Example 15 - Synthesis of reduced phyllochlorin 2-deoxy-D-mannosamine-propylamide (Compound 15) [ka] To a 25 mL RBF containing a stir bar was added reduced phyllochlorin (compound 1) (100 mg, 0.196 mmol, 1 equiv.), DMTMM (70 mg, 0.255 mmol, 1.3 equiv.), DMF (1.5 mL), triethylamine (26 mg, 0.255 mmol, 1.3 equiv.), and (D)-mannosamine hydrochloride (55 mg, 0.255 mmol, 1.3 equiv.). The resulting mixture was stirred for 1 h. The reaction mixture was concentrated using a rotary evaporator to give a black residue. The residue was purified by column chromatography (3 × 14 cm) eluting with a gradient of 5–12% MeOH / DCM. Fractions containing a major dark green spot (Rf = 0.2 in 10% MeOH / DCM) were combined to give compound 15 as a dark green solid (97 mg, 73%).
[0311] 1 H NMR (400MHz, DMSO-d6) δ9.73(s, 1H), 9.60(s, 1H), 9.02(s, 1H), 8.98(m, 1H), 7.52&7.18(2 xd, 1H), 6.60&6.46(2 xd, 1H), 4.92(m, 1H), 4.72-4.50(m, 4H), 4.32-4.25(m, 1H), 4.01-3.90 (m, 6H), 3.87-3.80(m, 3H), 3.78-3.70(m, 1H), 3.65-3.60(m, 4H), 3.58- 3.52(m, 2H), 2.68-2.55(m, 1H), 2.45-2.37(m, 1H), 2.35-2.28(m, 1H), 2.20-2.08(m, 1H), 1.85-1.60(m, 1H), -2.34(brs, 1H), -2.40(brs, 1H).
[0312] Synthesis Example 16 - Synthesis of reduced phyllochlorin N-(2-(2-(2-triphenylphosphoniumethoxy)ethoxy)ethyl)-N-methyl-3-amido chloride (Compound 16) [ka] Step 1: A single-necked 50 mL RBF was charged with phyllochlorin N-(2-(2-(2-hydroxyethoxy)ethoxy)ethyl)-N-methyl-3-amide (1.20 g, 1.84 mmol, 1 equiv.), dichloroethane (10 mL), and DMF (1 drop) and cooled using a water bath. Thionyl chloride (328 mg, 2.76 mmol, 1.5 equiv.) was dissolved in dichloroethane (2 mL), and the thionyl chloride solution was added to the reaction over 1 min. The resulting solution was stirred at room temperature under a nitrogen atmosphere with HPLC monitoring for 2 h. The reaction was then cooled using an ice / water bath, and pH 7 phosphate buffer (30 mL) and water (30 mL) were added. The mixture was then extracted with DCM (2 × 30 mL), dried (NaSO), and the solvent removed under reduced pressure to give 2.07 g of crude product. The residual blue-green crude product was purified by column chromatography (4 x 18 cm silica) using 1-2% MeOH in DCM as eluent. R by TLC (5% MeOH / DCM eluent) f The fractions containing the spot at 0.7 were combined to give phyllochlorin N-(2-(2-(2-chloroethoxy)ethoxy)ethyl)-N-methyl-3-amide as a dark blue-green solid (924 mg, 75%) (HPLC purity: 97.2%).
[0313] 1H NMR (400MHz, CDCl3) δ9.71(m, 2H), 8.86(m, 2H), 8.17(dd, 1H), 6.38(dd, 1H), 6.15(dd, 1H), 4.66(m, 1H) ), 4.54(m, 1H), 4.01(m, 3H), 3.86(q, 2H), 3.64(m, 3H), 3.59-3.50(m, 4H), 3.48-3.45(m, 2H), 3.44-3. 39(m, 2H), 3.40-3.30(m, 5H), 3.22(t, 1H), 3.09(t, 1H), 2.77-2.65(m, 3H), 2.62-2.50(m, 2H), 2.48-2 .43(m, 2H), 2.43-2.15(m, 2H), 1.98-1.83(m, 1H), 1.80-1.72(m, 6H), -2.07(brs, 1H), -2.21(brs, 1H).
[0314] Step 2: To a sealed tube (2.5 x 20 cm with a Teflon screw cap) containing phyllochlorin N-(2-(2-(2-chloroethoxy)ethoxy)ethyl)-N-methyl-3-amide (150 mg, 0.223 mmol, 1 equiv.) and a stir bar, MeCN (5 mL), triphenylphosphine (64 mg, 0.245 mmol, 1.1 equiv.), and sodium iodide (40 mg, 0.266 mmol, 1.2 equiv.) were added. The tube was flushed with nitrogen, and after sealing, the dark green mixture was stirred (300 rpm) at 90 °C for 70 h under HPLC monitoring. The mixture was cooled, transferred to a RBF, and concentrated by rotary evaporation to give a dark green oil. The residue was purified by column chromatography (3 x 16 cm) using a gradient of 2–4% MeOH / DCM. Fractions containing the major dark green spot (Rf=0.1 in 5% MeOH / DCM) were combined to give phyllochlorin N-(2-(2-(2-triphenylphosphoniumethoxy)ethoxy)ethyl)-N-methyl-3-amido chloride (125 mg, 60%) (HPLC purity: 96.2%) as a dark green solid.
[0315] 1H NMR (400MHz, CDCl3) δ9.69(m, 2H), 8.84(m, 2H), 8.14(m, 1H), 7.55(m, 6H), 7.44(m, 5H), 7.23(m, 2H), 7.06(m, 2H), 6.3 5(dd, 1H), 6.13(m, 1H), 4.63(m, 1H), 4.53(m, 1H), 3.99(m, 3H), 3.82(q, 2H), 3.78-3.68(m, 2H), 3.63(m, 4H), 3.58-3.5 0(m, 4H), 3.36-3.32(m, 3H), 3.23-3.10(m, 1H), 3.08(m, 2H), 3.00(m, 1H), 2.72-2.59(m, 3H), 2.58-2.45(m, 2H), 2.45 -2.38(m, 1H), 2.37(s, 2H), 2.32-2.14(m, 3H), 1.97-1.88(m, 1H), 1.80-1.68(m, 6H), -2.11(brs, 1H), -2.23(brs, 1H).
[0316] Step 3: A three-necked 50 mL RBF was charged with phyllochlorin N-(2-(2-(2-triphenylphosphoniumethoxy)ethoxy)ethyl)-N-methyl-3-amido chloride (80 mg, 0.086 mmol, 1 equiv.), 10% Pd / C (10 mg), ethyl acetate (3 mL), MeOH (3 mL), and a stir bar. A hydrogen balloon was connected to the flask's mid-joint via a short-length air condenser, and the side arm was connected to a three-way tap. The apparatus was evacuated and then refilled with nitrogen (3 times), evacuated, and refilled with hydrogen (2 times). The resulting solution was then stirred (450 rpm) under a hydrogen atmosphere at 30 °C for 22 h with heating. The solution was filtered through Celite® (0.5 × 2 cm), washed with methanol (approximately 10 mL), and then the solvent was removed under reduced pressure to give compound 16 as a dark green solid (63 mg, 79%) (HPLC purity: 95.5%).
[0317] 1H NMR (400MHz, CDCl3) δ9.69(m, 1H), 9.50(m, 1H), 8.79(m, 2H), 7.54(m, 5H), 7.44(m, 5H), 7.23( m, 2H), 7.01(m, 2H), 4.63(m, 1H), 4.52(m, 1H), 3.98(m, 3H), 3.92(m, 2H), 3.82(m, 2H), 3.75-3. 48(m, 6H), 3.40(s, 3H), 3.36-3.33(m, 3H), 3.23-2.97(m, 5H), 2.78-2.57(m, 3H), 2.55-2.35(m , 4H), 2.38(m, 2H), 2.35-2.07(m, 5H), 1.98-1.88(m, 1H), 1.80-1.68(m, 12H), -2.18(brs, 2H).
[0318] Synthesis Example 17 - Synthesis of reduced phyllochlorin β-D-1-thioglucose-N-methylpropylamide sulfoxide (Compound 17) [ka] Step 1: To a single-necked 25 mL RBF was added phyllochlorin β-D-1-thioglucose-N-methylpropylamide (100 mg, 0.132 mmol, 1 equiv.), urea-hydrogen peroxide (18.6 mg, 0.198 mmol, 1.5 equiv.), and acetic acid (1.5 mL). The solution was stirred at 55 °C (external temperature, oil bath) for 2 h. The acetic acid was removed under reduced pressure (rotary evaporator, 40 °C, full vacuum) leaving a dark green viscous oil. The crude product was purified by silica column chromatography (3 x 20 cm) using 10-16% MeOH / DCM. The product-containing fractions (R in 10% MeOH / DCM) were f 0.3) were combined to give phyllochlorin β-D-1-thioglucose-N-methylpropylamide sulfoxide as a dark green / blue flaky solid (91 mg, 89%).
[0319] 1H NMR (400MHz, d6-DMSO) δ9.76-9.72(m, 2H), 9.11-9.05(m, 2H), 8.35(dd, 1H), 6.44(dd, 1H), 6.18(dd, 1H), 5.70-5.30(m , 1H), 5.24-5.02(m, 2H), 4.80-4.60(m, 2H), 4.60-4.52(m, 1H), 4.31-4.10(m, 1H), 3.99-3.95(m, 3H), 3.81(q, 2H), 3.7 5-3.65(m, 1H), 3.62(s, 3H), 3.55(s, 3H), 3.51-3.39(m, 3H), 3.33(s, 3H), 3.17(m, 1H), 3.16-2.97(m, 2H), 2.90(m, 2H) , 2.84(s, 1H), 2.82-2.55(m, 2H), 2.47-2.38(m, 1H), 1.99-1.75(m, 2H), 1.73-1.66(m, 7H), -2.25(s, 1H), -2.43(s, 1H).
[0320] Step 2: A three-necked 50 mL RBF was charged with phyllochlorin β-D-1-thioglucose-N-methylpropylamide sulfoxide (75 mg, 0.097 mmol, 1 equiv.), 10% Pd / C (10 mg), ethyl acetate (3 mL), MeOH (2 mL), and a stir bar. A hydrogen balloon was connected to the flask's mid-joint via a short-length air condenser, and the side arm was connected to a three-way tap. The apparatus was evacuated and then refilled with nitrogen (three times), evacuated, and refilled with hydrogen (twice). The resulting solution was then stirred (500 rpm) under a hydrogen atmosphere at 35 °C for 4 h with heating. The solution was filtered through Celite® (0.5 × 2 cm), washed with ethyl acetate (approximately 10 mL), and the solvent was then removed under reduced pressure to give compound 17 as a dark green solid (67 mg, 89%) (HPLC purity: 98.3%).
[0321] 1H NMR (400MHz, DMSO-d6) δ9.73 (s, 1H), 9.60 (s, 1H), 9.02-8.98 (m, 2H), 5.70-5.30 (m, 1H), 5.69-5.28 (m, 1H), 5.22 -5.00(m,2H),4.80-4.60(m,2H),4.53(m,1H),4.30-4.20(m,1H),3.99-3.93(m,5H),3.81(q,2H),3.75-3.65(m,1 H), 3.61 (s, 3H), 3.55-3.40 (m, 3H), 3.40 (m, 4H), 3.33 (s, 3H), 3.25 (m, 1H), 3.13-3.00 (m, 2H), 2.90 (m, 2H), 2.86 ( s, 1H), 2.82-2.60 (m, 2H), 2.47-2.35 (m, 1H), 1.99-1.75 (m, 2H), 1.74-1.66 (m, 10H), -2.33 (s, 1H), -2.38 (s, 1H).
[0322] Synthesis Example 18 - Synthesis of Reduced Fuserulin 3-Aminolin (Compound 18)
change
[0323] 1 H NMR (400MHz, CDCl3) δ-2.22(br, 1H), -2.10(br, 1H), 1.72-1.80(m, 6H), 2.20-2.10(m, 1H), 2.10-2.00(m, 1H), 2.48-2.62(m, 2H), 3.38(s, 3H), 3.53(s, 3H), 3.58(s, 3H), 3.64(s, 3H), 3.84(q, 2H), 3.98(s, 3H), 4.50( q, 1H), 4.56(d, 1H), 6.13(dd, 1H), 6.37(dd, 1H), 8.16(dd, 1H), 8.83(br s, 2H), 9.71(br s, 2H).
[0324] Step 2: To a two-necked 500 mL RBF was added lithium aluminum hydride (670 mg, 16.8 mmol, 5 equiv.) and THF (200 mL). The solution was stirred (350 rpm) and cooled under nitrogen using an ice / water bath for 10 minutes. Phyllochlorin methyl ester (1.75 g, 3.35 mmol, 1 equiv.) was added in small portions over 5 minutes. After 30 minutes, additional lithium aluminum hydride (670 mg, 16.8 mmol, 5 equiv.) was added, and stirring was continued for 90 minutes, during which time the reaction warmed slightly. TLC analysis indicated the reaction was complete. The flask was cooled (ice / water bath), and water (1.3 mL) was added, followed by 4 M NaOH (1.3 mL). After stirring for 10 minutes, additional water (4.0 mL) was added, and the solution was warmed to room temperature and stirred for 15 minutes. Sodium sulfate was added, and the mixture was stirred for 10 minutes before being filtered and rinsed with DCM until no further color eluted. The solvent was then removed under reduced pressure to give approximately 2.3 g of crude product (still containing some solvent). HPLC analysis at this stage indicated a purity of 97.3% for the crude product. The crude material was purified by column chromatography (silica, 4 x 11 cm, 2-4% MeOH / DCM) to give 3-hydroxypropyl phyllochlorin as a dark blue / green solid (1.60 g, 97%) (HPLC purity: 97.6%).
[0325] 1 H NMR (400MHz, CDCl3) δ9.72(m, 2H), 8.88(s, 1H), 8.84(m, 1H), 8.16(dd, 1H), 6.48(dd, 1H), 6.14(dd, 1H), 4.51(m, 2H), 3.94(s, 3H), 3.85(q, 2H), 3.63 (s, 3H), 3.60-3.50(m, 5H), 3.38(s, 3H), 2.21-2.612(m, 1H), 1.85-1.72(m , 8H), 1.52-1.40(m, 2H), 1.12-1.05(m, 1H), -2.10(br, 1H), -2.22(br, 1H).
[0326] Step 3: A single-necked 25 mL RBF was charged with 3-hydroxypropyl phyllochlorin (0.50 g, 1.01 mmol, 1 equiv.), dichloroethane (4 mL), and thionyl chloride (200 mg, 1.68 mmol, 1.65 equiv.). The resulting solution was cooled using an ice / water bath and stirred (350 rpm) under a nitrogen atmosphere. DMF (1 drop) was added, and the mixture was stirred at room temperature for 1 h and then at 40 °C for an additional 1 h, at which point HPLC analysis indicated the reaction was complete. The reaction was then cooled using an ice / water bath, and pH 7 phosphate buffer (10 mL) was added. The mixture was extracted with DCM (2 × 15 mL), dried (NaSO), and concentrated under reduced pressure to give the crude chloride. Column chromatography (3 × 10 cm silica) using 1% MeOH / DCM afforded 3-chloropropyl phyllochlorin as a dark blue / green solid (450 mg, 87%).
[0327] 1 H NMR (400MHz, CDCl3) δ9.71(m, 2H), 8.85(s, 1H), 8.84(m, 1H), 8.17(dd, 1H), 6.37(dd, 1 H), 6.13(dd, 1H), 4.51(m, 2H), 3.96(s, 3H), 3.84(q, 2H), 3.64(s, 3H), 3.53(s, 3H), 3.4 9-3.42(m, 2H), 3.38(s, 3H), 2.35-2.25(m, 1H), 2.08-1.95(m, 1H), 1.94-1.85(m, 1H), 1 .80-1.72(m, 6H), 1.71-1.60(m, 1H), 1.04-1.01(m, 3H), -2.10(br, 1H), -2.23(br, 1H).
[0328] Step 4: To a 100 mL RBF was added 3-chloropropyl phyllochlorin (3.14 g, 6.12 mmol, 1 equiv.) and DMF (30 mL). Sodium azide (477 mg, 7.34 mmol, 1.2 equiv.) was then added, and the resulting mixture was stirred at 60 °C overnight. An additional portion of sodium azide (119 mg, 1.84 mmol, 0.3 equiv.) was added, and the reaction was stirred at 60 °C for an additional 3 h, by which time it was complete as monitored by HPLC. The solvent was removed by rotary evaporation to give the crude product as a dark residue. The crude product was purified by column chromatography using a stepped column (40 / 57 mm), 35 cm silica height, and a mobile phase of 0-5% MeOH in DCM. Product-containing fractions were combined to give 3-azidopropyl phyllochlorin as a blue / black solid (878 mg, 28%).
[0329] 1 H NMR (400MHz, CDCl3) δ9.73(d, J=2.8Hz, 2H), 8.87(s, 1H), 8.84(s, 1H), 8.16(dd, J=17.8, 11.5Hz, 1H), 6 .37(dd, J=17.8, 1.5Hz, 1H), 6.14(dd, J=11.6, 1.5Hz, 1H), 4.57-4.48(m, 2H), 3.96(s, 3H), 3.85(q, J=7. 6Hz, 2H), 3.65(d, J=1.0Hz, 3H), 3.54(s, 3H), 3.37(s, 3H), 3.21(t, J=6.5Hz, 2H), 2.27-2.16(m, 1H), 1. 90-1.81(m, 1H), 1.79(d, J=7.3Hz, 3H), 1.75(t, J=7.6Hz, 3H), 1.52(s, 2H), -2.11(s, 1H), -2.22(s, 1H).
[0330] Step 5: A 10 mL RBF was charged with 3-azidopropyl phyllochlorin (628 mg, 1.21 mmol, 1 equiv.), THF (2 mL), and water (0.4 mL). Triphenylphosphine (380 mg, 1.45 mmol, 1.2 equiv.) was then added in one portion, and the resulting mixture was stirred for 3 h, by which time the reaction was complete as monitored by TLC. The solvent was removed by rotary evaporation. The residue was dissolved in DCM (10 mL), dried over Na2SO4, filtered, and concentrated to a dark residue, which was purified by column chromatography using a step column (27 / 40 mm), 30 cm silica height, and a gradient of 10% to 60% MeOH / DCM. The main product fractions were combined to give 3-aminopropyl phyllochlorin as a blue / black solid (393 mg, 66%).
[0331] 1 H NMR (400MHz, d6-DMSO) δ9.76(d, J=8.4Hz, 2H), 9.12(s, 1H), 9.09(d, J=1.8Hz, 1H), 8.36(dd, J=17.9, 11.6Hz, 1H), 7.10(s, 2H), 6.46(dd, J=17.8, 1.6Hz, 1H), 6.19(dd, J=11.6, 1.5Hz, 1H), 4.59(d, J=7.6 Hz, 3H), 3.94(s, 3H), 3.83(q, J=7.6Hz, 2H), 3.64(s, 3H), 3.56(s, 3H), 2.75(s, 1H), 2.70-2.58(m, 1H) ), 2.19-2.06(m, 1H), 1.87-1.64(m, 9H), 1.23(d, J=9.5Hz, 1H), -2.27(s, 1H), -2.43(d, J=2.2Hz, 1H).
[0332] Step 6: A three-necked 50 mL RBF was charged with 3-aminopropyl phyllochlorin (60 mg, 0.122 mmol, 1 equiv.), 10% Pd / C (10 mg), ethyl acetate (2 mL), THF (3 mL), and a stir bar. A hydrogen balloon was connected to the flask's mid-joint via a short-length air condenser, and the side arm was connected to a three-way tap. The apparatus was evacuated and then refilled with nitrogen (three times), evacuated, and refilled with hydrogen (twice). The resulting solution was then stirred (500 rpm) under a hydrogen atmosphere at 35 °C for 2 h with heating. The solution was filtered through Celite® (0.5 × 2 cm), washed with ethyl acetate (approximately 10 mL), and the solvent was then removed under reduced pressure to give compound 18 as a dark green solid (48 mg, 80%) (HPLC purity: 93.1%).
[0333] 1 H NMR (400MHz, CDCl3) δ9.73(s, 1H), 9.55(s, 1H), 8.84-8.76(m, 2H), 4.51-4.40(m, 2H), 3.99-3.93(m, 2H), 3.92-3.84(m, 5H), 3.64(m, 3H), 3.45- 3.38(m, 6H), 2.62-2.54(m, 1H), 2.53-2.45(m, 1H), 2.30-1.98(m, 4H), 1 .97-1.85(m, 1H), 1.82-1.75(m, 9H), 1.70-1.62(m, 2H), -2.15(brs, 2H).
[0334] Synthesis Example 19 - Synthesis of reduced phyllochlorin N-2-hydroxyethyl-N-methylpropylamide (Compound 19) [ka] Step 1: To a 250 mL RBF equipped with a nitrogen inlet and containing a small stir bar was added phyllochlorin (3.00 g, 5.90 mmol, 1 equiv.), dichloromethane (70 mL), PyBOP (3.30 g, 1.1 equiv.), triethylamine (2.46 mL, 3 equiv.), and 2-(methylamino)-ethanol (0.53 g, 1.2 equiv.). The mixture was stirred at room temperature for 3 hours. Analysis by TLC indicated the reaction was complete. The reaction mixture was transferred to a separatory funnel and washed with water (2 × 30 mL). The organic layer was dried (NaSO), filtered through Celite®, and concentrated by rotary evaporation to give the crude product as a blue / brown film (6.0 g). The crude product was loaded directly onto a silica column and eluted with 1–3% MeOH / DCM. Pure fractions containing a green / blue spot by TLC (R in 5% MeOH / DCM) were collected. f 0.40) were combined to give phyllochlorin N-2-hydroxyethyl-N-methylpropylamide (0.62 g, 25%).
[0335] 1 H NMR (400MHz, CDCl3) δ9.78-9.70(m, 2H), 8.85(m, 2H), 8.20-8.10(m, 1H), 6.38(d, 1 H), 6.14(d, 1H), 4.70-4.65(m, 1H), 4.58-4.50(m, 1H), 4.01(m, 3H), 3.89-3.82(m, 2 H), 3.65(s, 3H), 3.53(s, 3H), 3.37(m, 4H), 3.31-3.22(m, 1H), 3.14-3.08(m, 2H), 2 .65-2.51(m, 3H), 2.37-2.22(m, 3H), 2.09(s, 2H), 1.88-1.70(m, 8H), 1.62-1.50(br s, 2H), -2.05--2.32(m, 2H).
[0336] Step 2: A three-necked 100 mL RBF was charged with phyllochlorin N-2-hydroxyethyl-N-methylpropylamide (200 mg, 0.354 mmol, 1 equiv.), 10% Pd / C (15 mg), ethyl acetate (20 mL), and a stir bar (approximately 15 mm). A hydrogen balloon was connected to the flask's mid-joint via a short-length air condenser, and the side arm was connected to a three-way tap. The apparatus was evacuated and then refilled with nitrogen (three times), evacuated, and refilled with hydrogen (twice). The resulting solution was then stirred (600 rpm) under a hydrogen atmosphere at 30°C for 2 hours with heating. The reaction progress was monitored by HPLC. The solution was filtered through Celite® (0.5 × 3 cm), washed with ethyl acetate (approximately 20 mL), and the solvent was then removed under reduced pressure to give 202 mg of crude product. The residual solid was purified by passing through a silica gel plug (3×3 cm) eluting with 5% MeOH / DCM to give compound 19 as a dark blue solid (162 mg, 81%) (HPLC purity: 98.7%).
[0337] 1 H NMR (400MHz, CDCl3) δ9.85(s, 1H), 9.73(s, 1H), 9.55(s, 1H), 8.96-8.85(m, 1H), 8.83-8.80(m, 1H), 8.77(s, 1H), 4.8 2-4.70(m, 1H), 4.69-4.63(m, 1H), 4.61-4.55(m, 1H), 4.50(q, J=7.3Hz, 1H), 4.07-4.01(m, 2H), 3.98(s, 3H), 3.97-3. 91(m, 2H), 3.85(q, J=7.5Hz, 2H), 3.68-3.62(m, 4H), 3.41(d, J=3.6Hz, 6H), 3.38(s, 5H), 3.31-3.23(m, 1H), 3.14-3. 07(m, 2H), 2.63(s, 1H), 2.53(s, 2H), 2.48-2.18(m, 2H), 2.08(s, 3H), 1.90-1.69(m, 11H), 1.56(s, 4H), -2.19(s, 2H).
[0338] Synthesis Example 20 - Synthesis of reduced phyllochlorin 3-hydroxypropyl (compound 20) [ka] A three-necked 100 mL RBF was charged with 3-hydroxypropyl phyllochlorin (100 mg, 0.202 mmol, 1 equiv.), 10% Pd / C (10 mg), ethyl acetate (20 mL), and a stir bar (approximately 15 mm). A hydrogen balloon was connected to the flask's mid-joint via a short-length air condenser, and the side arm was connected to a three-way tap. The apparatus was evacuated and then refilled with nitrogen (three times), evacuated, and refilled with hydrogen (twice). The resulting solution was then stirred (600 rpm) under a hydrogen atmosphere at 30° C. for 2 hours with heating. The solution was filtered through Celite® (1 × 3 cm), washed with ethyl acetate (approximately 10 mL), and the solvent was then removed under reduced pressure to give 170 mg of crude product. The crude product was purified by passing through a silica gel plug (3×3 cm) eluting with 5% MeOH / DCM to give compound 20 (94 mg, 94%) as a dark blue solid (HPLC purity: 98.2%).
[0339] 1 H NMR (400MHz, CDCl3) δ9.73(s, 1H), 9.56(s, 1H), 8.84-8.74(m, 2H), 4.51(q, J=7.2Hz, 2H), 3.99-3.91(m, 5H), 3.85(q, J=7.6Hz, 2H), 3.66-3.62(m, 3 H), 3.57-3.45(m, 2H), 3.41(s, 3H), 3.38(s, 3H), 2.23-2.12(m, 1H), 1.86- 1.71(m, 10H), 1.52(s, 2H), 1.47-1.33(m, 1H), 1.10(s, 1H), -2.20(s, 2H).
[0340] Synthesis Example 21 - Synthesis of reduced phyllochlorin ((methylamino)-10-decyl)triphenylphosphonium chloride propylamide (Compound 21) [ka] Step 1: To a 50 mL RBF equipped with a nitrogen inlet and containing a small stir bar, phyllochlorin (227 mg, 0.446 mmol, 1 equiv.), dichloromethane (15 mL), DMTMM (160 mg, 0.580 mmol, 1.3 equiv.), and (10-(methylamino)decyl)triphenyl-phosphonium chloride (417 mg, 0.891 mmol, 2 equiv.) were added. The mixture was stirred at room temperature for 1 h. The reaction mixture was then concentrated by rotary evaporation to give the crude product as a dark blue viscous syrup. The crude mixture was directly loaded onto a silica column (4 x 20 cm, pre-equilibrated with 1% MeOH in DCM) and eluted with 1% to 3% MeOH in DCM. f Fractions containing a green / blue spot by TLC at pH = 0.37 (5% MeOH in DCM) were combined and concentrated by rotary evaporation to give a dark blue solid (422 mg). The compound was then dissolved in DCM (50 mL) and washed with 0.1 M HCl (50 mL) followed by HO (50 mL). The organic layer was then dried over NaSO, filtered on a sintered glass frit, and concentrated by rotary evaporation. The residue was dried in a vacuum oven at 60 °C for 2 hours to give phyllochlorin ((methylamino)-10-decyl)triphenylphosphonium chloride propylamide as a dark blue solid (278 mg, 65%) (HPLC purity: 94.5%).
[0341] 1H NMR (400MHz, CDCl3) δ9.73-9.64(m, 2H), 8.87-8.77(m, 2H), 8.21-8.08(m, 1H), 7.85-7.66(m, 10H), 7.65-7.57(m, 6H), 6.36(dd, J=17.8, 6 .3, 1.6Hz, 1H), 6.12(dd, J=11.5, 6.8, 1.5Hz, 1H), 4.65-4.48(m, 2H), 4.00(d, J=7.6Hz, 3H), 3.88-3.77(m, 2H), 3.62(s, 3H), 3.52(d, J=5.0 Hz, 3H), 3.35(d, J=7.3Hz, 3H), 3.22-3.14(m, 1H), 2.71(s, 1H), 2.66-2.51(m, 1H), 2.46(s, 2H), 2.15-2.06(m, 1H), 2.06-1.95(m, 1H), 1.80 -1.69(m, 6H), 1.68-1.58(m, 3H), 1.58-1.43(m, 4H), 1.37-0.99(m, 7H), 0.98-0.78(m, 2H), 0.75-0.63(m, 1H), -2.08(s, 1H), -2.21(s, 1H).
[0342] Step 2: A three-necked 100 mL RBF was charged with phyllochlorin ((methylamino)-10-decyl)triphenylphosphonium chloride propylamide (70 mg, 0.0729 mmol, 1 equiv.), 10% Pd / C (10 mg), ethyl acetate (7 mL), methanol (7 mL), and a stir bar (approximately 15 mm). A hydrogen balloon was connected to the flask's mid-joint via a short-length air condenser, and the side arm was connected to a three-way tap. The apparatus was evacuated and then refilled with nitrogen (three times), evacuated, and refilled with hydrogen (twice). The resulting solution was then stirred (600 rpm) under a hydrogen atmosphere at 30° C. for 2 hours with heating. The solution was filtered through Celite® (1 × 3 cm), washed with methanol (approximately 10 mL), and the solvent was then removed under reduced pressure to give 81 mg of crude product. The residual solid was purified by passing through a plug of silica gel (3×3 cm) eluting with 5% MeOH / DCM to give compound 21 (60 mg, 86%) as a dark blue solid (HPLC purity: 95.0%).
[0343] 1 H NMR (400MHz, CDCl3) δ9.70(d, J=7.0Hz, 1H), 9.53(d, J=8.5Hz, 1H), 8.85-8.71(m, 2H), 7.86-7.67(m, 9H), 7.67-7.58(m, 6H), 4.62(d , J=9.1, 2.8Hz, 1H), 4.56-4.44(m, 1H), 3.99(d, J=6.9Hz, 3H), 3.97-3.89(m, 1H), 3.84(p, J=7.5Hz, 2H), 3.67-3.49(m, 3H), 3.38(dd , J=12.2, 5.4Hz, 6H), 3.22-3.13(m, 1H), 2.71(s, 1H), 2.64(t, J=7.6Hz, 1H), 2.60-2.50(m, 1H), 2.44(s, 2H), 2.17-2.04(m, 1H), 2.0 4-1.91(m, 1H), 1.80-1.68(m, 9H), 1.62(s, 5H), 1.52(s, 4H), 1.37-1.01(m, 8H), 0.99-0.82(m, 1H), 0.78-0.65(m, 1H), -2.19(s, 2H).
[0344] Synthesis Example 22 - Synthesis of reduced phyllochlorin N-3-hydroxypropyl-N-methylpropylamide (Compound 22) [ka] To a 25 mL RBF containing a stir bar was added reduced phyllochlorin (compound 1) (100 mg, 0.196 mmol, 1 equiv.), DMTMM (71 mg, 0.255 mmol, 1.3 equiv.), DCM (4 mL), and 3-(methylamino)-1-propanol (26 mg, 0.294 mmol, 1.5 equiv.). The resulting mixture was stirred for 1 h, at which point HPLC analysis indicated the reaction was complete. The reaction mixture was diluted with DCM (20 mL) and then washed with saturated aqueous NaHCO (2 × 20 mL) and brine (20 mL). The organic layer was then dried over NaSO, filtered on a sintered glass frit, and concentrated by rotary evaporation to give the crude product as a dark blue solid. The residue was subjected to column chromatography (graduated column, silica gel, 4 × 8 cm, then 2 × 15 cm) using 1–1.5% MeOH in DCM as the eluent. Product (major dark green spot, R in 5% MeOH / DCM) f =0.43) were combined and the solvent was removed by rotary evaporation to give compound 22 as a dark blue solid (39 mg, 34%) (HPLC purity: 96.9%).
[0345] 1 H NMR (400MHz, CDCl3) δ9.84-9.72(m, 1H), 9.67-9.50(m, 1H), 8.88-8.67(m, 2H), 4.76-4.61(m , 1H), 4.51(q, J=7.3Hz, 1H), 4.05-3.91(m, 5H), 3.91-3.80(m, 2H), 3.68-3.62(m, 3H), 3.39( d, J=10.6Hz, 6H), 3.32-3.11(m, 3H), 2.63-2.49(m, 1H), 2.45(s, 1H), 2.27(d, J=9.1Hz, 1H), 2.14(s, 2H), 1.93-1.69(m, 10H), 1.55(s, 2H), 1.46-1.38(m, 2H), 1.26(s, 1H), -2.18(s, 2H).
[0346] Synthesis Example 23 - Synthesis of reduced phyllochlorin N-5-hydroxypentyl-N-methylpropylamide (Compound 23) [ka] To a 25 mL RBF containing a stir bar was added reduced phyllochlorin (compound 1) (100 mg, 0.196 mmol, 1 equiv.), DMTMM (71 mg, 0.255 mmol, 1.3 equiv.), DCM (4 mL), and 3-(methylamino)-1-propanol (34 mg, 0.294 mmol, 1.5 equiv.). The resulting mixture was stirred for 1 h, at which point HPLC analysis indicated the reaction was complete. The reaction mixture was diluted with DCM (20 mL) and then washed with saturated aqueous NaHCO (2 × 20 mL) and brine (20 mL). The organic layer was then dried over NaSO, filtered on a sintered glass frit, and concentrated by rotary evaporation to give the crude product as a dark blue solid. The crude product was subjected to column chromatography (graduated column, silica gel, 4 × 8 cm, then 2 × 15 cm) using 1–1.5% MeOH in DCM as the eluent. Product (major dark green spot, R in 5% MeOH / DCM) f =0.36) were combined and the solvent was removed by rotary evaporation to give compound 23 as a dark blue solid (57 mg, 48%) (HPLC purity: 97.6%).
[0347] 1 H NMR (400MHz, CDCl3) δ9.74(s, 1H), 9.56(s, 1H), 8.88-8.73(m, 2H), 4.76-4.60(m, 1H), 4.57-4.41(m, 1H), 3.99 (s, 3H), 3.96-3.91(m, 2H), 3.85(q, J=7.5Hz, 2H), 3.63(s, 3H), 3.52(t, J=6.5Hz, 1H), 3.40(s, 3H), 3.38(s, 3H) , 3.17-3.04(m, 1H), 2.55(s, 2H), 2.43(s, 1H), 2.23(s, 2H), 2.11-1.98(m, 2H), 1.80-1.68(m, 9H), 1.56(s, 5H), 1.52-1.41(m, 1H), 1.40-1.14(m, 3H), 0.59-0.45(m, 1H), 0.29-0.15(m, 1H), 0.12--0.03(m, 2H), -2.21(s, 2H).
[0348] Synthesis Example 24 - Synthesis of reduced phyllochlorin 2-deoxy-D-galactosamine-propylamide (Compound 24) [ka] Step 1: To a 25 mL RBF containing a stir bar, phyllochlorin (250 mg, 0.491 mmol, 1 equiv.), DMTMM (149 mg, 0.541 mmol, 1.1 equiv.), DMF (3 mL), triethylamine (75 μL, 0.541 mmol, 1.1 equiv.), and (D)-(+)-galactosamine hydrochloride (116 mg, 0.541 mmol, 1.1 equiv.) were added. The resulting mixture was stirred for 30 min, at which point HPLC analysis indicated that approximately 4% of the phyllochlorin remained. Additional DMTMM (14 mg, 0.1 equiv.), triethylamine (7 μL, 0.1 equiv.), and (D)-(+)-galactosamine hydrochloride (11 mg, 0.1 equiv.) were added, and the solution was stirred for an additional 30 min. The reaction mixture was concentrated by rotary evaporation to yield a black residue. The residue was subjected to column chromatography. The column was eluted using a gradient of 10% MeOH / DCM (300 mL), then 15% MeOH / DCM, then 20% MeOH / DCM (300 mL). The product-containing fractions were combined and the solvent was removed by rotary evaporation. The solid was dried under vacuum at 60°C to give phyllochlorin 2-deoxy-D-galactosamine-propylamide as a dark blue solid (275 mg, 84%).
[0349] 1H NMR (400MHz, d6-DMSO) δ9.74(d, J=6.2Hz, 2H), 9.13-8.95(m, 2H), 8.33(dd, J=17.8, 11.6Hz, 1H ), 7.66(dd, J=36.3, 8.5Hz, 1H), 6.50-6.33(m, 1H), 6.27-6.07(m, 2H), 4.92(t, J=3.9Hz, 1H), 4. 72-4.22 (m, 5H), 4.00-3.90 (m, 3H), 3.88-3.67 (m, 4H), 3.62 (d, J = 0.9 Hz, 4H), 3.55 (s, 4H), 3.33 (s, 24H), 2.53-2.47 (m, 4H), 2.20-1.99 (m, 1H), 1.84-1.62 (m, 8H), -2.25 (s, 1H), -2.41 (s, 1H). The product exists as a mixture of epimers, giving rise to two sets of signals in an approximately 3:1 ratio.
[0350] Step 2: A three-necked 100 mL RBF was charged with phyllochlorin 2-deoxy-D-galactosamine-propylamide (100 mg, 0.149 mmol, 1 equiv.), 10% Pd / C (10 mg), THF (15 mL), and a stir bar (approximately 15 mm). A hydrogen balloon was connected to the flask's mid-joint via a short-length air condenser, and the side arm was connected to a three-way tap. The apparatus was evacuated and then refilled with nitrogen (three times), evacuated, and refilled with hydrogen (twice). The resulting solution was then stirred (600 rpm) under a hydrogen atmosphere at 30° C. for 2 hours with heating. The solution was filtered through Celite® (1 × 3 cm), washed with THF (approximately 10 mL), and the solvent was then removed under reduced pressure to give 152 mg of crude product. The residual solid was purified by passing through a plug of silica gel (3×3 cm) eluting with 10% MeOH / DCM to give compound 24 (66 mg, 66%) as a dark blue solid (HPLC purity: 96.3%).
[0351] 1H NMR (400MHz, DMSO-d6) δ9.73(s, 1H), 9.61(s, 1H), 9.05-8.92(m, 2H), 7.67(dd, J=26.0, 8.6Hz, 1H), 6.51-6.33(m , 1H), 6.24(dd, J=4.4, 1.2Hz, 1H), 4.91(t, J=3.9Hz, 1H), 4.69-4.40(m, 3H), 4.37-4.21(m, 1H), 4.16-4.02(m, 1H) , 4.02-3.90(m, 4H), 3.86(s, 1H), 3.84-3.73(m, 2H), 3.69(q, J=4.4, 3.9Hz, 1H), 3.62(d, J=1.0Hz, 3H), 3.56-3.4 8(m, 1H), 3.42(s, 3H), 3.17(d, J=3.4Hz, 1H), 2.18-2.08(m, 1H), 1.78-1.59(m, 10H), -2.34(s, 1H), -2.40(s, 1H).
[0352] Synthesis Example 25 - Synthesis of reduced phyllochlorin(6-hexyl)triphenylphosphonium chloride propylamide (Compound 25) [ka] Step 1: To a 25 mL RBF was added phyllochlorin (100 mg, 0.1966 mmol, 1 equiv.), 4-(4,6-dimethoxy-1,3,5-triazin-2-yl)-4-methylmorpholin-4-ium chloride (DMTMM) (76 mg, 0.2752 mmol, 1.4 equiv.), DCM (5 mL), triethylamine (44 μL, 0.3145 mmol, 1.6 equiv.), and (6-aminohexyl)triphenylphosphonium chloride hydrochloride (120 mg, 0.2752 mmol, 1.4 equiv.). The resulting mixture was stirred (420 rpm) under nitrogen at ambient temperature for 30 min. The reaction mixture was concentrated using a rotary evaporator, and the crude residue was purified by column chromatography (silica, 5–7% MeOH / DCM) to give phyllochlorin(6-hexyl)triphenylphosphonium chloridepropylamide as a dark blue / green solid (180 mg, quantitative).
[0353] 1H NMR (400MHz, CDCl3) δ9.67(m, 2H), 8.89(s, 1H), 8.78(s, 1H), 8.14(dd, 1H), 7.83(t, 1H) ), 7.62(m, 6H), 7.48(m, 9H), 6.35(d, 1H), 6.10(d, 1H), 4.70(q, 1H), 4.51(m, 1H), 3.98 (m, 7H), 3.82(q, 2H), 3.60(s, 3H), 3.49(m, 5H), 3.35(s, 3H), 3.26(m, 2H), 2.88(m, 1H) , 2.61-2.48(m, 2H), 1.90-1.80(m, 1H), 1.78-1.70(m, 6H), 1.60-1.40(m, 8H), -2.11(br s, 1H), -2.24(br s, 1H).
[0354] Step 2: A three-necked 100 mL RBF was charged with phyllochlorin(6-hexyl)triphenylphosphonium chloride propylamide (60 mg, 0.0675 mmol, 1 equiv.), 10% Pd / C (10 mg), ethyl acetate (7 mL), methanol (7 mL), and a stir bar (approximately 15 mm). A hydrogen balloon was connected to the flask's mid-joint via a short-length air condenser, and the side arm was connected to a three-way tap. The apparatus was evacuated and then refilled with nitrogen (three times), evacuated, and refilled with hydrogen (twice). The resulting solution was then stirred (600 rpm) under a hydrogen atmosphere while heating (heat block) to 30 °C for 4 h. The solution was filtered through Celite® (1 × 3 cm), washed with methanol (approximately 10 mL), and the solvent was then removed under reduced pressure to give compound 25 as a dark blue solid (24 mg, 40%) (HPLC purity: 91.1%).
[0355] 1H NMR (400MHz, CDCl3) δ9.67(s, 1H), 9.50(s, 1H), 8.77(d, J=25.9Hz, 2H), 7.89-7.61(m, 8H), 7.59-7.39(m, 9H) , 4.66(s, 1H), 4.51(d, J=10.3Hz, 1H), 4.01-3.87(m, 6H), 3.83(q, J=7.5Hz, 2H), 3.66-3.48(m, 5H), 3.44-3.33 (m, 7H), 3.32-3.29(m, 1H), 3.28-3.16(m, 3H), 2.77(s, 1H), 2.65-2.51(m, 1H), 2.46(s, 1H), 1.99(s, 1H), 1.73 (q, J=7.7Hz, 10H), 1.46(d, J=37.3Hz, 10H), 1.32-1.16(m, 2H), 0.95-0.76(m, 2H), 0.06(s, 1H), -2.24(s, 1H).
[0356] Synthesis Example 26 - Synthesis of reduced phyllochlorin lysyl-lysyl-lysyl-lysyl-lysyldimethylamidopropylamidopentahydrochloride (Compound 26) Synthesis of H-(Lys(Boc))5-NMe2 [ka] Step 1: To a 500 mL RBF was added Fmoc-Lys(Boc)-OH (20.0 g, 42.7 mmol, 1 equiv.), DMTMM (14.19 g, 51.2 mmol, 1.2 equiv.), DCM (200 mL), triethylamine (5.62 g, 55.5 mmol, 1.3 equiv.), and dimethylamine hydrochloride (4.17 g, 51.2 mmol, 1.2 equiv.). The resulting mixture was stirred (420 rpm) in the dark under nitrogen at ambient temperature for 1 h. The reaction mixture was transferred to a separatory funnel and washed with 0.5 M HCl (100 mL) and water (100 mL). The organic layer was dried (MgSO4) and concentrated by rotary evaporation to give a pale yellow oil (25.32 g). The oil was subjected to column chromatography (9 × 18 cm). The crude product was dissolved in 2% MeOH / DCM and eluted with a gradient of 2-4% MeOH / DCM. Two major fractions containing the product were collected (major UV-active spot, R in 5% MeOH / DCM).f =0.5), and combined after concentration by rotary evaporation to give (S)-(9H-fluoren-9-yl)methyl tert-butyl (6-(dimethylamino)-6-oxohexane-1,5-diyl)dicarbamate as a pale yellow solid (17.47 g, 83%).
[0357] 1 H NMR (400MHz, CDCl3) δ7.76(d, 2H), 7.60(m, 2H), 7.39(t, 2H), 7.30(t, 2H), 5.77(d, 1H), 4.67(m, 1H), 4.59(m, 1H), 4 .36(m, 2H), 4.20(t, 1H), 3.15-3.08(m, 4H), 2.97(s, 3H), 1.78-1.68(m, 1H), 1.64-1.47(m, 3H), 1.46-1.37(m, 11H).
[0358] Step 2: A 250 mL RBF equipped with a stir bar and an air condenser was loaded with (S)-(9H-fluoren-9-yl)methyl tert-butyl (6-(dimethylamino)-6-oxohexane-1,5-diyl)dicarbamate (12.00 g, 24.2 mmol, 1 equiv.). Piperidine (14.7 mL) and DMF (58.8 mL) were added to the RBF, and the resulting solution was stirred at room temperature for 30 min. The solvent was then removed by rotary evaporation (65 °C, 1 mbar). The residue was dissolved in DCM (200 mL), and the DCM solution was then washed with 2% w / w aqueous NaHCO (2 × 200 mL) and brine (200 mL). The organic layer was then dried over MgSO, filtered on a sintered glass frit, and concentrated by rotary evaporation to give the crude product as a thick, pale yellow syrup (10.70 g). The crude product was purified by column chromatography (6 × 20 cm silica gel, eluent gradient = 1:1:98 EtN:MeOH:DCM to 1:3:96 EtN:MeOH:DCM to 1:5:94 EtN:MeOH:DCM, R f=0.26 in 5% MeOH in DCM, visualized by ninhydrin staining / heating). The product-containing fractions were then combined and concentrated by rotary evaporation to give (S)-tert-butyl (5-amino-(6-dimethylamino)-6-oxohexyl)carbamate as a pale yellow, highly viscous syrup (2.98 g, 45%).
[0359] 1 H NMR (400MHz, CDCl3) δ4.59(s, 1H), 3.65(dd, J=7.5, 4.5Hz, 1H), 3.10(dd, J=13. 3, 6.7Hz, 2H), 3.02(s, 3H), 2.96(s, 3H), 1.67-1.54(m, 1H), 1.52-1.31(m, 13H).
[0360] Step 3: A 100 mL one-neck RBF equipped with a stir bar and an air condenser was loaded with Fmoc-Lys(Boc)-OH (3.81 g, 8.14 mmol, 1 equiv.), (S)-tert-butyl (5-amino-(6-dimethylamino)-6-oxohexyl)carbamate (2.47 g, 9.04 mmol, 1.11 equiv.), DMTMM (2.93 g, 10.6 mmol, 1.3 equiv.), and DCM (30 mL). The reaction mixture was stirred at room temperature for 1 h and monitored by TLC. DCM (100 mL) was added to the reaction mixture, and the reaction mixture was then washed with saturated aqueous NaHCO3 (2 x 100 mL) and brine (100 mL). The organic phase was dried over MgSO4, filtered, and the solvent was then removed by rotary evaporation to give the crude product (9.47 g) as a colorless solid. The crude product was purified by column chromatography (2–5% MeOH in DCM, 6 × 20 cm silica gel, R f Purification by HPLC (HPLC = 0.5, visualized by UV) gave Fmoc-(Lys(Boc))2-NMe2 as a colorless solid (5.81 g, 99%) (mp: 69-73 °C).
[0361] 1H NMR (400MHz, CDCl3) δ7.80-7.71(m, 2H), 7.60(d, J=7.5Hz, 2H), 7.43-7.37(m, 2H), 7.31(tdd, J=7.4, 2.1, 1.2Hz, 2H), 6.82(d, J=8.0Hz, 1H), 5.56(s, 1H), 4.94-4.85( m, 1H), 4.79(s, 1H), 4.71(s, 1H), 4.38(d, J=7.1Hz, 2H), 4.21(q, J=8.6, 7.9Hz, 2H) , 3.18-3.00(m, 6H), 2.97(d, J=4.9Hz, 3H), 1.88-1.55(m, 3H), 1.54-1.19(m, 26H).
[0362] Step 4: A 100 mL RBF equipped with a stir bar and air condenser was loaded with Fmoc-(Lys(Boc))2-NMe2 (6.00 g, 8.29 mmol, 1 equiv.). Piperidine (7.35 mL) and DMF (29.4 mL) were added to the RBF, and the resulting solution was stirred at room temperature for 30 min. The solvent was then removed by rotary evaporation (65 °C, 1 mbar). The residue was dissolved in DCM (100 mL), and the DCM solution was then washed with 2% w / w aqueous NaHCO3 (2 × 100 mL) and brine (100 mL). The organic layer was then dried over MgSO4, filtered on a sintered glass frit, and concentrated by rotary evaporation to give the crude product as a thick, pale yellow syrup (7.39 g). The crude product was purified by column chromatography (6 × 20 cm silica gel, eluent gradient = 1:1:98 EtN:MeOH:DCM to 1:3:96 EtN:MeOH:DCM to 1:5:94 EtN:MeOH:DCM, R f =0.26 in 5% MeOH in DCM, visualized by ninhydrin staining / heating). The product-containing fractions were then combined and concentrated by rotary evaporation to give H-(Lys(Boc))-NMe as a pale yellow, highly viscous syrup (3.15 g, 76%).
[0363] 1H NMR (400MHz, CDCl3) δ7.81(d, J=8.6Hz, 1H), 4.88(td, J=8.3, 4.7Hz, 1H), 4.68(s, 2H), 3.32(d d, J=7.8, 4.6Hz, 1H), 3.13-3.01(m, 7H), 2.94(s, 3H), 1.84-1.66(m, 1H), 1.64-1.28(m, 26H).
[0364] Step 5: A 50 mL one-neck RBF equipped with a stir bar and air condenser was loaded with Fmoc-Lys(Boc)-OH (1.90 g, 4.06 mmol, 1 equiv.), H-(Lys(Boc))2-NMe2 (2.26 g, 4.51 mmol, 1.11 equiv.), DMTMM (1.46 g, 5.28 mmol, 1.3 equiv.), and DCM (20 mL). The reaction mixture was stirred at room temperature for 1 h and monitored by TLC. DCM (50 mL) was added to the reaction mixture, which was then washed with saturated aqueous NaHCO3 (2 x 50 mL) and brine (50 mL). The organic phase was dried over MgSO4, filtered, and the solvent was removed by rotary evaporation to give the crude product (5.23 g) as a faintly beige solid. The crude product was purified by column chromatography (2–5% MeOH in DCM, 6 × 20 cm silica gel, R f =0.43, visualized by UV) to give Fmoc-(Lys(Boc))3-NMe2 as a faintly beige solid (4.07 g, quantitative), mp: 100-101 °C.
[0365] 1 H NMR (400MHz, CDCl3) δ7.75(d, J=7.5Hz, 2H), 7.59(d, J=7.5Hz, 2H), 7.38(t, J= 7.5Hz, 2H), 7.29(t, J=7.6Hz, 2H), 7.11-6.76(m, 2H), 5.78(s, 1H), 5.01-4.65( m, 4H), 4.49-4.28(m, 2H), 4.20(t, J=7.2Hz, 2H), 3.06(q, J=9.6, 7.4Hz, 11H), 2.94(d, J=2.4Hz, 4H), 2.01(s, 1H), 1.91-1.62(m, 2H), 1.41(d, J=7.3Hz, 46H).
[0366] Step 6: A 100 mL RBF equipped with a stir bar and air condenser was loaded with Fmoc-(Lys(Boc))3-NMe2 (3.87 g, 4.06 mmol, 1 equiv.). Piperidine (5.00 mL) and DMF (20.0 mL) were added to the RBF, and the resulting solution was stirred at room temperature for 30 min. The solvent was then removed by rotary evaporation (65 °C, 1 mbar). The residue was dissolved in DCM (100 mL), and the DCM solution was then washed with 2% w / w aqueous NaHCO3 (2 × 100 mL) and brine (100 mL). The organic layer was then dried over MgSO4, filtered on a sintered glass frit, and concentrated by rotary evaporation to give the crude product as a thick, pale yellow syrup (4.27 g). The crude product was purified by column chromatography (6 × 20 cm silica gel, eluent gradient = 1:2:97 EtN:MeOH:DCM to 1:4:95 EtN:MeOH:DCM to 1:6:93 EtN:MeOH:DCM, R f =0.26 in 5% MeOH in DCM, visualized by ninhydrin staining / heating). The product-containing fractions were then combined and concentrated by rotary evaporation to give H-(Lys(Boc))3-NMe2 as a pale yellow, highly viscous syrup (2.56 g, 87%).
[0367] 1 H NMR (400MHz, CDCl3) δ7.73(d, J=7.5Hz, 1H), 6.90(d, J=8.0Hz, 1H), 4.84(dd, J=10.5, 5.8Hz, 3H), 4.74(s, 1H), 4.35(td, J=8.0, 5.6Hz, 1H), 3.37(dd, J=7.8, 4.5Hz, 1H), 3.15-2.99(m, 9H), 2.94(s, 3H), 1.87-1.60(m, 3H), 1.59-1.23(m, 38H).
[0368] Step 7: A 100 mL one-neck RBF equipped with a stir bar and air condenser was loaded with Fmoc-Lys(Boc)-OH (1.22 g, 2.61 mmol, 1 equiv.), H-(Lys(Boc))3-NMe2 (2.12 g, 2.90 mmol, 1.11 equiv.), DMTMM (938 mg, 3.39 mmol, 1.3 equiv.), and DCM (20 mL). The reaction mixture was stirred at room temperature for 1 h and monitored by TLC. DCM (50 mL) was added to the reaction mixture, which was then washed with saturated aqueous NaHCO3 (2 × 50 mL) and brine (50 mL). The organic phase was dried over MgSO4, filtered, and the solvent was removed by rotary evaporation to give the crude product (4.32 g) as a faintly beige solid. The crude product was purified by column chromatography (3–6% MeOH in DCM, 6 × 20 cm silica gel, R f =0.35, visualized by UV) to give Fmoc-(Lys(Boc))4-NMe2 as a faintly beige solid (3.14 g, quantitative), mp: 152-158 °C.
[0369] 1 H NMR (400MHz, CDCl3) δ7.75(d, J=7.5Hz, 2H), 7.60(d, J=7.4Hz, 2H), 7.39(t, J=7.5Hz, 2H), 7.29(t, J=7.5Hz, 2H), 6.39-5.78(m, 2H), 5.1 5-4.78(m, 4H), 4.61-4.27(m, 6H), 4.20(t, J=7.2Hz, 1H), 3.27-2.99(m, 13H), 2.97-2.85(m, 3H), 1.99-1.61(m, 7H), 1.60-1.10(m, 56H).
[0370] Step 8: A 100 mL RBF equipped with a stir bar and air condenser was loaded with Fmoc-(Lys(Boc))-NMe (3.08 g, 2.61 mmol, 1 equiv.). Piperidine (5.00 mL) and DMF (20.0 mL) were added to the RBF, and the resulting solution was stirred at room temperature for 30 min. The solvent was then removed by rotary evaporation (65 °C, 1 mbar). The residue was dissolved in DCM (100 mL), and the DCM solution was then washed with 2% w / w aqueous NaHCO (2 × 100 mL) and brine (100 mL). The organic layer was then dried over MgSO, filtered on a sintered glass frit, and concentrated by rotary evaporation to give the crude product as a colorless solid (4.15 g). The crude product was purified by column chromatography (4 × 20 cm silica gel, eluent gradient = 1:2:97 EtN:MeOH:DCM to 1:4:95 EtN:MeOH:DCM to 1:6:93 EtN:MeOH:DCM, R f =0.26 in 5% MeOH in DCM, visualized by ninhydrin staining / heating). The product-containing fractions were then combined and concentrated by rotary evaporation to give H-(Lys(Boc))-NMe as a colorless solid (2.08 g, 83%) (mp: 57-63 °C).
[0371] 1 H NMR (400MHz, CDCl3) δ7.77(s, 1H), 7.06-6.83(m, 2H), 5.13-4.68(m, 5H), 4.51-4.31(m, 2H), 3.41-3.31(m, 1H), 3.16-2.99(m, 11H), 2.93(s, 3H), 1.98-1.60(m, 2H), 1.59-1.22(m, 58H).
[0372] Step 9: A 100 mL one-neck RBF equipped with a stir bar and air condenser was loaded with Fmoc-Lys(Boc)-OH (439 mg, 0.937 mmol, 1 equiv.), H-(Lys(Boc))-NMe (1.00 g, 1.04 mmol, 1.11 equiv.), DMTMM (338 mg, 1.22 mmol, 1.3 equiv.), and DCM (7 mL). The reaction mixture was stirred at room temperature for 1 h and monitored by TLC. DCM (50 mL) was added to the reaction mixture, which was then washed with saturated aqueous NaHCO (2 × 50 mL) and brine (50 mL). The organic phase was dried over MgSO and filtered, and the solvent was removed by rotary evaporation to give the crude product (1.39 g) as a faintly beige solid. The crude product was purified by column chromatography (2–6% MeOH in DCM, 4 × 20 cm silica gel, R f Purification by HPLC (HPLC = 0.30, visualized by UV) gave Fmoc-(Lys(Boc))5-NMe2 as a faintly beige solid (1.14 g, 86%) (mp: 200-204 °C).
[0373] 1 H NMR (400MHz, CDCl3) δ9.13(s, 1H), 8.84(s, 1H), 7.74(d, J=7.6Hz, 2H), 7.60(d, J=7.5Hz, 2H), 7.38(t, J=7.5Hz, 2H), 7.29(d, J=7.5Hz, 2H), 7.21 -6.83(m, 2H), 6.24-5.67(m, 2H), 5.18-4.72(m, 3H), 4.70-4.11(m, 5H), 3.33-2.66(m, 18H), 2.10(s, 2H), 2.00-1.60(m, 7H), 1.57-1.02(m, 74H).
[0374] Step 10: A 50 mL RBF equipped with a stir bar and air condenser was loaded with Fmoc-(Lys(Boc))5-NMe2 (1.09 g, 0.774 mmol, 1 equiv.). Piperidine (2.00 mL) and DMF (8.00 mL) were added to the RBF, and the resulting solution was stirred at room temperature for 30 min. The solvent was then removed by rotary evaporation (65 °C, 1 mbar). The residue was dissolved in DCM (30 mL), and the DCM solution was then washed with 2% w / w aqueous NaHCO3 (2 × 30 mL) and brine (30 mL). The organic layer was then dried over MgSO4, filtered on a sintered glass frit, and concentrated by rotary evaporation to give the crude product as a colorless solid (1.40 g). The crude product was purified by column chromatography (4 × 20 cm silica gel, eluent gradient = 1:2:97 EtN:MeOH:DCM to 1:4:95 EtN:MeOH:DCM, R f The product was purified by HPLC using a 5% COOH column (H = 0.25, 5% MeOH in DCM, visualized by ninhydrin staining / heating). The product-containing fractions were then combined and concentrated by rotary evaporation to give H-(Lys(Boc))5-NMe2 as a colorless solid (853 mg, 93%) (mp: 157-175 °C).
[0375] 1 H NMR (400MHz, CDCl3) δ8.83(d, J=47.0Hz, 1H), 8.27(s, 1H), 7.83(s, 1H), 7.21-6.84(m, 2H), 6.10(s, 1H), 6.00-5.70(m, 1H), 5. 26-4.63(m, 2H), 4.63-4.07(m, 2H), 3.50-3.18(m, 1H), 3.18-2.96(m, 9H), 2.93(s, 3H), 1.92-1.61(m, 4H), 1.60-1.17(m, 63H).
[0376] Synthesis of reduced phyllochlorin lysyl-lysyl-lysyl-lysyl-lysyldimethylamidopropylamidopentahydrochloride (compound 26) [ka] Step 1: To a 25 mL RBF containing a stir bar, phyllochlorin (143 mg, 0.281 mmol, 1 equiv.), DMTMM (101 mg, 0.365 mmol, 1.3 equiv.), DMF (7 mL), and H-(Lys(Boc))5-NMe2 (400 mg, 0.472 mmol, 1.2 equiv.) were added. The resulting mixture was stirred for 1 h while monitoring by HPLC. The reaction mixture was diluted with DCM (13 mL) and then washed with saturated aqueous NaHCO3 (2 × 20 mL) and brine (20 mL). The organic layer was then dried over Na2SO4, filtered on a sintered glass frit, and concentrated by rotary evaporation to give the crude product as a dark blue solid. The crude product was subjected to column chromatography (silica gel, 4 × 20 cm) using an eluent gradient of 2–6% MeOH in DCM, with the gradient beginning at 2% MeOH when the first light blue-green band eluted from the column. Product (major dark green spot, R in 5% MeOH / DCM) f Fractions containing 5-(Lys(Boc))-NMe were combined and the solvent removed by rotary evaporation. The solid was dried in a vacuum oven at 60 °C for 3 h to give phyllochlorin-(Lys(Boc))5-NMe2 as a dark blue solid (378 mg, 80%).
[0377] 1 H NMR (400MHz, CDCl3) δ9.70(d, J=3.3Hz, 2H), 8.83(d, J=4.0Hz, 2H), 8.16(dd, J=17.9, 11.6Hz, 1H), 7.13-6.65(m , 1H), 6.36(d, J=17.8Hz, 1H), 6.13(dd, J=11.5, 1.5Hz, 1H), 6.07-5.70(m, 1H), 5.20-4.64(m, 3H), 4.66-4.16(m, 3H), 3.96(d, J=4.0Hz, 3H), 3.84(q, J=7.5Hz, 2H), 3.79(s, 0H), 3.63(s, 3H), 3.53(s, 2H), 3.36(s, 3H), 3.18-2. 70(m, 8H), 2.48(s, 1H), 2.39-2.01(m, 1H), 1.96-1.55(m, 12H), 1.53-0.81(m, 66H), -2.12(s, 1H), -2.24(s, 2H).
[0378] Step 2: To a 50 mL RBF containing a stir bar and an air condenser was added phyllochlorin-(Lys(Boc))5-NMe2 (442 mg, 0.305 mmol, 1 equiv.) and 4 M HCl in 1,4-dioxane (10 mL). The mixture was stirred at room temperature for 2 h. An additional portion of 4 M HCl in 1,4-dioxane (10 mL) was added, and the reaction was stirred for an additional 4 h, after which the solvent was removed by rotary evaporation. The residue was dried overnight in a vacuum oven at 60 °C to give phyllochlorin lysyl-lysyl-lysyl-lysyl-lysyldimethylamidopropylamide pentahydrochloride as a dark blue solid (312 mg, 135%).
[0379] 1 H NMR (400MHz, CD3OD) δ10.14(s, 1H), 10.09(s, 1H), 9.49(s, 1H), 9.32-9.26(m, 1H), 8.40-8.26(m, 3H), 8.19(dd, J=16.5, 7.5Hz, 2H), 6.45(dd, J =17.8, 1.3Hz, 1H), 6.35(dd, J=11.7, 1.3Hz, 1H), 4.84-4.74(m, 2H), 4.72(s, 1H), 4.51(s, 1H), 4.42-4.25(m, 3H), 4.13(d, J=4.9Hz, 4H), 3.97(p , J=7.2Hz, 2H), 3.91-3.78(m, 3H), 3.78-3.70(m, 23H), 3.70-3.62(m, 3 9H), 3.61-3.54(m, 12H), 3.51(s, 1H), 3.43(s, 3H), 3.35(s, 1H), 3.12(s , 3H), 3.00-2.84(m, 17H), 2.82-2.71(m, 1H), 2.63-2.52(m, 1H), 2.42-2 .31(m, 1H), 2.19-2.12(m, 1H), 2.01-1.60(m, 38H), 1.60-1.35(m, 23H).
[0380] Step 3: A three-necked 100 mL RBF was charged with phyllochlorin lysyl-lysyl-lysyl-lysyl-lysyldimethylamidopropylamide pentahydrochloride (50 mg, 0.0368 mmol, 1 equiv.), 10% Pd / C (10 mg), methanol (15 mL), and a stir bar (approximately 15 mm). A hydrogen balloon was connected to the flask's mid-joint via a short-length air condenser, and the side arm was connected to a three-way tap. The apparatus was evacuated and then refilled with nitrogen (three times), evacuated, and refilled with hydrogen (twice). The resulting solution was then heated under a hydrogen atmosphere at 30 °C for 2 h with stirring (600 rpm). After filtering the solution through a 0.45 μm syringe filter and then a 0.20 μm syringe filter, the solvent was removed under reduced pressure to give compound 26 as a dark blue solid (26 mg, 52%).
[0381] 1 H NMR (400MHz, CD3OD) δ10.19(s, 1H), 10.05(s, 1H), 9.40(s, 1H), 9.26(s, 1H), 4.40-4.23(m, 5H), 4.1 6-4.07(m, 5H), 4.02(m, 2H), 3.90-3.78(m, 2H), 3.77-3.70(m, 13H), 3.70-3.62(m, 19H), 3.61-3.55 (m, 5H), 3.53(s, 2H), 3.49(s, 3H), 3.11(d, J=2.1Hz, 4H), 3.00-2.85(m, 16H), 2.80-2.68(m, 1H), 2. 63-2.50(m, 1H), 2.40-2.26(m, 1H), 2.16(t, J=6.8Hz, 1H), 2.01-1.58(m, 22H), 1.58-1.35(m, 14H).
[0382] Synthesis Example 27 - Synthesis of reduced phyllochlorin 3-triphenylphosphonium propyl iodide (compound 27) [ka] Step 1: To a 50 mL RBF equipped with a reflux condenser and stir bar containing 3-chloropropyl phyllochlorin (300 mg, 0.585 mmol, 1 equiv.) was added acetone (15 mL) and NaI (263 mg, 1.754 mmol, 3 equiv.). The solution was heated at 65 °C under nitrogen with HPLC monitoring. After 4 h, additional NaI (263 mg, 1.754 mmol, 3 equiv.) was added and heating continued for a total of 30 h. The mixture was cooled and the acetone removed by rotary evaporation. The residue was diluted with DCM (25 mL), washed with water (25 mL), dried (NaSO), and concentrated by rotary evaporation to give the crude product as a dark green oil. The residue was purified by column chromatography (3 × 20 cm) using a gradient of 0–0.5% MeOH / DCM. The major dark green spot (R in DCM) f =0.50) were combined to give phyllochlorin 3-propyl iodide as a dark green solid (270 mg, 76%) (HPLC purity: 93.3%), which was used directly in the next step.
[0383] Step 2: To a sealed tube (2.5 x 20 cm with a Teflon screw cap) containing phyllochlorin 3-propyl iodide (120 mg, 0.198 mmol, 1 equiv.) and a stir bar, MeCN (7 mL) and PPh3 (57 mg, 0.218 mmol, 1.1 equiv.) were added. The tube was flushed with nitrogen and, after sealing, the dark green mixture was stirred (300 rpm) at 90 °C for 20 h. The mixture was cooled, transferred to a RBF, and the solvent was removed by rotary evaporation to remove MeCN, yielding the crude product as a dark green oil. The residue was purified by column chromatography (3 x 13 cm) using 2-4% MeOH / DCM. The major dark green spot (R in 5% MeOH / DCM) f =0.15) were combined to give phyllochlorin 3-triphenylphosphonium propyl iodide as a dark green solid (120 mg, 70%) (HPLC purity: 97.6%).
[0384] 1H NMR (400MHz, CDCl3) δ9.73(m, 2H), 8.82(s, 1H), 8.69(s, 1H), 8.18(dd, 1H), 7.02(m, 3H), 6. 60(m, 6H), 6.40(m, 7H), 6.19(d, 1H), 4.72(m, 1H), 4.50(m, 1H), 3.94(s, 3H), 3.88(q, 2H), 3 .68(s, 3H), 3.48(s, 3H), 3.39(s, 3H), 3.20(m, 1H), 2.72(m, 1H), 2.61(m, 1H), 2.08(m, 1H), 1.80-1.71(m, 6H), 1.25-1.10(m, 1H), 0.40-0.30(m, 1H), -2.25(brs, 1H), -2.35(brs, 1H).
[0385] Step 3: A three-necked 50 mL RBF was charged with phyllochlorin 3-triphenylphosphonium propyl iodide (50 mg, 0.058 mmol), 10% Pd / C (10 mg), ethyl acetate (3 mL), MeOH (2 mL), and a stir bar. A hydrogen balloon was connected to the flask's mid-joint via a short-length air condenser, and the side arm was connected to a three-way tap. The flask was evacuated and refilled with nitrogen (three times), then evacuated and refilled with hydrogen (twice). The reaction mixture was then stirred under a hydrogen atmosphere at 30 °C for 3 h while heating. The flask was evacuated and refilled with nitrogen (three times). The reaction mixture was then filtered through Celite® (0.5 × 2 cm), washing with MeOH (approximately 5 mL). The solvent was then removed under reduced pressure to give a dark green residue. The residue was purified by column chromatography (3 × 14 cm) eluting with 2–4% MeOH / DCM. The major dark green spot (R in 5% MeOH / DCM) f =0.25) were combined to give compound 27 as a dark green solid (37 mg, 74%).
[0386] 1H NMR (400MHz, CDCl3) δ9.72(s, 1H), 9.53(s, 1H), 8.78(s, 1H), 8.61(s, 1H), 7.01(m, 3H), 6.59(m , 6H), 6.37(m, 6H), 4.69(m, 1H), 4.45(m, 1H), 3.96(q, 2H), 3.91-3.83(m, 5H), 3.65(s, 3H), 3.39 (s, 3H), 3.36(s, 3H), 3.18-3.08(m, 1H), 2.72-2.62(m, 1H), 2.61-2.52(m, 1H), 2.10-1.98(m, 1H) ), 1.84-1.70(m, 6H), 1.32-1.10(m, 3H), 0.90-0.82(m, 1H), 0.41-0.30(m, 1H), -2.30(brm, 2H).
[0387] Synthesis Example 28 - Synthesis of reduced phyllochlorin N-(2-(2-(2-picolinethoxy)ethoxy)ethyl)-N-methyl-3-amido chloride (Compound 28) [ka] Step 1: To a 50 mL RBF equipped with a nitrogen inlet and containing a small stir bar, phyllochlorin (500 mg, 0.983 mmol, 1 equiv.), dichloromethane (15 mL), PyBOP (563 mg, 1.1 equiv.), triethylamine (409 μL, 3 equiv.), and 2-(2-(2-(methylamino)ethoxy)ethoxy)ethanol (193 mg, 1.2 equiv.) were added. The mixture was stirred at room temperature for 1 h. Analysis by HPLC indicated the reaction was complete. The reaction mixture was transferred to a separatory funnel and washed with water (2 × 10 mL). The organic layer was dried (NaSO) and concentrated by rotary evaporation to give the crude product as a blue / brown film (1.10 g). The crude mixture was loaded directly onto a silica column and eluted with 3–7% MeOH / DCM. TLC (R in 5% MeOH / DCM) indicated the reaction was complete. f Pure fractions containing the green / blue compound with a chromatogram of 0.0001 were combined to give phyllochlorin N-(2-(2-(2-hydroxyethoxy)ethoxy)ethyl)-N-methyl-3-amide.
[0388] 1H NMR (400MHz, CDCl3) δ9.71(m, 2H), 8.83(m, 2H), 8.16(dd, 1H), 6.38(dd, 1H), 6. 13(dd, 1H), 4.66(m, 1H), 4.54(m, 1H), 4.01(s, 3H), 3.84(q, 2H), 3.63(s, 3H), 3 .55-3.50(m, 4H), 3.47-3.30(m, 10H), 3.04(m, 1H), 2.77-2.50(m, 6H), 2.40-2. 20(m, 4H), 1.93-1.35(m, 1H), 1.30-1.22(m, 6H), -2.10(br, 1H), -2.24(br, 1H).
[0389] Step 2: A 50 mL RBF was charged with phyllochlorin N-(2-(2-(2-hydroxyethoxy)ethoxy)ethyl)-N-methyl-3-amide (1.20 g, 1.84 mmol, 1 equiv.), dichloroethane (10 mL), and DMF (1 drop) and cooled using a water bath. Thionyl chloride (328 mg, 2.76 mmol, 1.5 equiv.) was dissolved in dichloroethane (2 mL), and the thionyl chloride solution was added to the reaction over 1 min. The resulting solution was stirred at room temperature under a nitrogen atmosphere with HPLC monitoring for 2 h. The reaction was then cooled using an ice / water bath, and pH 7 phosphate buffer (30 mL) and water (30 mL) were added. The mixture was then extracted with DCM (2 × 30 mL), dried (NaSO), and the solvent was removed under reduced pressure to give 2.07 g of crude product. The residual blue-green crude product was purified by column chromatography (4 x 18 cm silica) using 1-2% MeOH in DCM as eluent. R by TLC (5% MeOH / DCM eluent) f The fractions containing the spot at 0.7 were combined to give phyllochlorin N-(2-(2-(2-chloroethoxy)ethoxy)ethyl)-N-methyl-3-amide as a dark blue-green solid (924 mg, 75%) (HPLC purity: 97.2%).
[0390] 1H NMR (400MHz, CDCl3) δ9.71(m, 2H), 8.86(m, 2H), 8.17(dd, 1H), 6.38(dd, 1H), 6.15(dd, 1H), 4.66(m, 1H) ), 4.54(m, 1H), 4.01(m, 3H), 3.86(q, 2H), 3.64(m, 3H), 3.59-3.50(m, 4H), 3.48-3.45(m, 2H), 3.44-3. 39(m, 2H), 3.40-3.30(m, 5H), 3.22(t, 1H), 3.09(t, 1H), 2.77-2.65(m, 3H), 2.62-2.50(m, 2H), 2.48-2 .43(m, 2H), 2.43-2.15(m, 2H), 1.98-1.83(m, 1H), 1.80-1.72(m, 6H), -2.07(brs, 1H), -2.21(brs, 1H).
[0391] Step 3: To a sealed tube (2.5 x 20 cm with a Teflon screw cap) containing phyllochlorin N-(2-(2-(2-chloroethoxy)ethoxy)ethyl)-N-methyl-3-amide (0.400 g, 0.595 mmol, 1 equiv.) and a stir bar, MeCN (10 mL), 4-picoline (277 mg, 2.975 mmol, 5 equiv.), and NaI (178 mg, 1.190 mmol, 2 equiv.) were added. The tube was flushed with nitrogen, and after sealing, the dark green mixture was stirred (300 rpm) at 90 °C for 40 h. The mixture was cooled, diluted with DCM (25 mL), washed with 0.1 M HCl (20 mL), dried (NaSO), and concentrated by rotary evaporation to give the crude product as a dark green oil. The residue was purified by column chromatography (3 x 18 cm) using 5–8% MeOH / DCM. The major dark green spot (R in 5% MeOH / DCM) f Fractions containing <0.1% methyl phosphate were combined to give phyllochlorin N-(2-(2-(2-picolinethoxy)ethoxy)ethyl)-N-methyl-3-amido chloride as a dark green solid (207 mg, 45%) (HPLC purity: 96.9%).
[0392] 1H NMR (400MHz, CDCl3) δ9.70(m, 2H), 8.88(m, 2H), 8.14(m, 1H), 7.39(d, 1H), 6.91(d, 1H), 6.48(dd , 1H), 6.20(m, 2H), 5.99(m, 1H), 4.66-4.53(m, 2H), 3.99(m, 3H), 3.84(m, 2H), 3.67(s, 3H), 3.54( m, 3H), 3.42(m, 1H), 3.36(m, 4H), 3.30-3.23(m, 2H), 3.20(m, 1H), 3.15-2.95(m, 4H), 2.88(m, 1H) ), 2.66(m, 3H), 2.62-2.30(m, 4H), 2.28-1.85(m, 3H), 1.80-1.71(m, 6H), -2.22--2.49(brm, 2H).
[0393] Step 4: A three-necked 50 mL RBF was charged with phyllochlorin N-(2-(2-(2-picolinethoxy)ethoxy)ethyl)-N-methyl-3-amido chloride (60 mg, 0.0 mmol), 10% Pd / C (10 mg), ethyl acetate (3 mL), MeOH (2 mL), and a stir bar. A hydrogen balloon was connected to the flask's mid-joint via a short-length air condenser, and the side arm was connected to a three-way tap. The flask was evacuated and refilled with nitrogen (3 times), then evacuated and refilled with hydrogen (2 times). The reaction mixture was then stirred under a hydrogen atmosphere while heating to 30 °C. After 4 days, an additional portion of 10% Pd / C (10 mg) was added, and stirring under hydrogen was continued overnight. The flask was evacuated and refilled with nitrogen (3 times). The reaction mixture was then filtered through Celite® (0.5 × 2 cm), washing with MeOH (approximately 5 mL). The solvent was then removed under reduced pressure to give a dark green residue. The residue was purified by column chromatography (3 x 15 cm) eluting with 3-7% MeOH / DCM. The major dark green spot (R in 5% MeOH / DCM) f =0.10) were combined to give compound 28 as a dark green solid (37 mg, 62%).
[0394] 1H NMR (400MHz, CDCl3) δ9.68(m, 1H), 9.51(m, 1H), 8.82(m, 1H), 8.78(m, 1H), 7.13(d, 1H), 6.70(d, 1H) , 6.00(d, 1H), 5.86(d, 1H), 4.62-4.49(m, 2H), 3.97(m, 5H), 3.83(m, 2H), 3.64(s, 3H), 3.41(m, 3H), 3 .38(m, 3H), 3.30-3.20(m, 3H), 3.18-3.02(m, 4H), 2.98-2.75(m, 2H), 2.71(s, 2H), 2.66(s, 1H), 2.59 (m, 2H), 2.40-2.15(m, 3H), 2.10-1.98(m, 1H), 1.80-1.70(m, 10H), -2.30(brs, 1H), -2.44(brm, 1H).
[0395] Synthesis Example 29 - Synthesis of reduced phyllochlorin N-methyl-N-(2-methoxy)ethylpropylamide (Compound 29) [ka] A 25 mL RBF was charged with reduced phyllochlorin (compound 1) (150 mg, 0.293 mmol, 1 equiv.), DMTMM (121 mg, 0.440 mmol, 1.5 equiv.), DCM (10 mL), and 2-methoxy-N-methylethan-1-amine (39 mg, 0.440 mmol, 1.5 equiv.). The reaction mixture was stirred under nitrogen at ambient temperature for 2 h. The reaction mixture was transferred to a separatory funnel, diluted with DCM (15 mL), and washed with 0.5 M HCl (20 mL). The aqueous layer was re-extracted with DCM (2 × 5 mL). The combined organic layers were washed with pH 7 phosphate buffer (20 mL), dried (NaSO), and concentrated by rotary evaporation to give a blue-black film. The residue was purified by column chromatography (4 × 18 cm) using 0.5–2% MeOH / DCM loaded as a solution in eluent. The major dark green band (R in 5% MeOH / DCM) f =0.50) were combined and concentrated by rotary evaporation to give compound 29 as a dark green solid (145 mg, 85%).
[0396] 1H NMR (400MHz, CDCl3) δ9.72(m, 1H), 9.52(m, 1H), 8.88(s, 1H), 8.75(s, 1H), 4.62(m, 1H), 4.50(m, 1H), 4.05-3.82(m, 9H), 3.80-3.68(m, 8H), 3.64(s, 3H), 3.57(m, 3H), 3.42(m, 3) H), 3.40-3.35(m, 8H), 3.22(s, 3H), 3.17(m, 1H), 2.92(m, 1H), 2.88-2.75(m, 2H), 2.62- 2.42(m, 2H), 2.22-2.10(m, 1H), 2.10-1.75(m, 1H), 1.81-1.72(m, 9H), -2.21(brs, 2H).
[0397] Synthesis Example 30 - Synthesis of reduced phyllochlorin N-(2-methoxy)ethylpropylamide (Compound 30) [ka] A 50 mL RBF was charged with reduced phyllochlorin (compound 1) (150 mg, 0.294 mmol, 1 equiv.), DMTMM (122 mg, 0.441 mmol, 1.5 equiv.), DCM (6 mL), and 2-methoxyethylamine (33 mg, 0.441 mmol, 1.5 equiv.). The reaction mixture was stirred under nitrogen at ambient temperature for 5 h. The reaction mixture was transferred to a separatory funnel, diluted with DCM (15 mL), and washed with 0.5 M HCl (20 mL). The aqueous layer was re-extracted with DCM (2 × 5 mL). The combined organic layers were washed with pH 7 phosphate buffer (20 mL), dried (NaSO), and concentrated by rotary evaporation to give a blue-black film. The residue was purified by column chromatography (3 × 16 cm) eluting with 0.5–2% MeOH / DCM. The major dark green spot (R in 5% MeOH / DCM) was f =0.40) were combined to give compound 30 as a dark green solid (83 mg, 50%).
[0398] 1H NMR (400MHz, CDCl3) δ9.73(s, 1H), 9.55(s, 1H), 8.84-8.76(m, 2H), 5.06(m, 1H), 4.61(m, 1H), 4.48(m, 1H), 4.07(s, 3H), 3.97(m, 6H), 3.87( q, 2H), 3.65(s, 3H), 3.40(m, 6H), 3.20-3.03(m, 3H), 3.00(s, 3H), 2.5 8-2.48(m, 1H), 2.22-2.08(m, 2H), 1.83-1.73(m, 9H), -2.16(brs, 2H).
[0399] Synthesis Example 31 - Synthesis of reduced phyllochlorin N-lysyldimethylamidopropylamide hydrochloride (Compound 31) [ka] Step 1: A 50 mL RBF containing a stir bar was charged with reduced phyllochlorin (compound 1) (200 mg, 0.392 mmol, 1 equiv.), DMTMM (141 mg, 0.510 mmol, 1.3 equiv.), DCM (7 mL), and H-Lys(Boc)-NMe (128 mg, 0.470 mmol, 1.2 equiv.). The reaction mixture was stirred at 25 °C for 1 h, and the progress of the reaction was monitored by HPLC. The reaction mixture was diluted with DCM (13 mL) and then washed with saturated aqueous NaHCO (2 × 20 mL) and brine (20 mL). The organic layer was then dried (NaSO), filtered over a sintered glass frit, and concentrated by rotary evaporation to give a dark blue residue. The residue was purified by column chromatography (4 x 20 cm) eluting with 1-3% MeOH / DCM, with the gradient starting at 1% MeOH when the first light blue-green band eluted from the column. f Fractions containing methyl methyl ether (C = 0.49) were combined and the solvent removed by rotary evaporation to give reduced phyllochlorin-Lys(Boc)-NMe2 as a dark blue solid (171 mg, 57%).
[0400] 1H NMR (400MHz, CDCl3) δ9.69(s, 1H), 9.52(s, 1H), 8.79(dd, J=2.1, 1.1Hz, 1H), 8.74(s, 1H), 5.96(d, J=8.0Hz, 1H), 4.69(td , J=7.9, 4.7Hz, 1H), 4.59-4.53(m, 1H), 4.45(q, J=7.2Hz, 1H), 4.37(s, 1H), 3.97-3.89(m, 5H), 3.83(q, J=7.6Hz, 2H), 3.6 2(s, 3H), 3.41(s, 3H), 3.36(s, 3H), 2.95(s, 3H), 2.83(s, 5H), 2.51-2.41(m, 1H), 2.32-2.22(m, 1H), 2.21-2.09(m, 1H), 1 .74(dt, J=11.0, 7.7Hz, 10H), 1.47-1.36(m, 1H), 1.29(s, 9H), 1.24-1.12(m, 2H), 1.07-0.92(m, 1H), -2.07--2.40(m, 2H).
[0401] Step 2: A 25 mL RBF containing a stir bar, an air condenser, and a drying tube packed with silica beads was charged with reduced phyllochlorin-Lys(Boc)-NMe (153 mg, 0.200 mmol, 1 equiv.), DCM (5 mL), and TFA (2 mL). The reaction mixture was stirred at 25 °C for 2 h, and the progress of the reaction was monitored by HPLC. The reaction mixture was concentrated by rotary evaporation to remove DCM and bulk TFA. The residue was then redissolved in DCM (20 mL) and washed with saturated aqueous NaHCO (2 × 30 mL). The organic layer was then washed with HO (20 mL), dried (NaSO), filtered through a sintered glass funnel, and concentrated by rotary evaporation. HCl (0.1017 M in HO, 1.47 mL, 0.150 mmol, 0.75 equiv.) was then added to the residue, followed by HO (30 mL). The mixture was then sonicated at 30° C. for 30 minutes, at which point the pH of the mixture was 4.31. The mixture was then passed through a 0.2 μm syringe filter and lyophilized overnight to give compound 31 as a pale green solid (141 mg, quantitative).
[0402] 1H NMR (400MHz, DMSO-d6) δ9.85(s, 1H), 9.74(s, 1H), 9.09(s, 2H), 8.20(d, J=8.2Hz, 1H), 7.80(s, 3H), 4.69(td, J=8.4, 5.4Hz, 1H), 4.62(q, J=7.1Hz, 1H), 4.54(dd, J=10.0, 2.8Hz, 1H), 3.99(q, J=7.7Hz, 2H), 3.94(s, 3H), 3. 86(q, J=7.6Hz, 2H), 3.64(s, 3H), 3.44(s, 3H), 3.05(s, 3H), 2.82(s, 3H), 2.72-2.61(m, 2H), 2.60-2.52(m, 1H) , 2.44-2.32(m, 1H), 2.15-2.02(m, 1H), 1.84-1.63(m, 9H), 1.61-1.34(m, 3H), 1.28-1.13(m, 2H), -2.58(s, 2H).
[0403] Synthesis Example 32 - Synthesis of reduced phyllochlorin N-lysyl-lysyldimethylamidopropylamide dihydrochloride (Compound 32) [ka] Step 1: A 25 mL RBF containing a stir bar was charged with reduced phyllochlorin (compound 1) (300 mg, 0.587 mmol, 1 equiv.), DMTMM (211 mg, 0.763 mmol, 1.3 equiv.), DCM (7 mL), and H-(Lys(Boc))2-NMe2 (351 mg, 0.700 mmol, 1.2 equiv.). The reaction mixture was stirred at 25 °C for 1 h, and the reaction progress was monitored by HPLC. The reaction mixture was diluted with DCM (25 mL) and then washed with saturated aqueous NaHCO3 (2 × 30 mL) and brine (30 mL). The organic layer was then dried (Na2SO4), filtered over a sintered glass frit, and concentrated by rotary evaporation to give a dark blue residue. The residue was purified by column chromatography (4 x 20 cm) eluting with 2-4% MeOH / DCM, with the gradient starting at 1% MeOH when the first light blue-green band eluted from the column. The dark green spot (R in 5% MeOH / DCM) f=0.34), and the solvent was removed by rotary evaporation to give reduced phyllochlorin-(Lys(Boc))2-NMe2 as a dark blue solid (434 mg, 74%).
[0404] 1 H NMR (400MHz, CDCl3) δ9.70(s, 1H), 9.52(s, 1H), 8.82-8.78(m, 1H), 8.76(s, 1H), 6.61(d, J=8.1Hz, 1H), 5.52(s, 1H), 4.75-4.67(m, 1H), 4 .66-4.61(m, 1H), 4.61-4.54(m, 1H), 4.48(q, J=7.2Hz, 1H), 4.03-3.90(m, 5H), 3.84(q, J=7.6Hz, 2H), 3.63(d, J=1.0Hz, 3H), 3.41(s, 3H) , 3.37(s, 3H), 2.96(s, 3H), 2.95-2.90(m, 2H), 2.87(s, 3H), 2.84-2.71(m, 1H), 2.52-2.41(m, 1H), 2.25(t, J=16.0Hz, 3H), 1.80-1.71(m, 9H), 1.68(s, 3H), 1.51-1.39(m, 1H), 1.36(s, 9H), 1.29(s, 9H), 1.26-1.15(m, 1H), 1.11-0.95(m, 2H), 0.87(s, 2H), -2.09--2.29(m, 2H).
[0405] Step 2: A 25 mL RBF containing a stir bar, an air condenser, and a drying tube packed with silica beads was charged with reduced phyllochlorin-(Lys(Boc))2-NMe2 (200 mg, 0.201 mmol, 1 equiv.), DCM (5 mL), and TFA (2 mL). The reaction mixture was stirred at 25 °C for 2 h, and the progress of the reaction was monitored by HPLC. The reaction mixture was concentrated by rotary evaporation to remove DCM and bulk TFA. The residue was then redissolved in DCM (30 mL) and washed with saturated aqueous NaHCO3 (2 × 30 mL). The organic layer was then washed with HO (20 mL), dried (Na2SO4), filtered through a sintered glass funnel, and concentrated by rotary evaporation. HCl (0.1017 M in HO, 3.17 mL, 0.322 mmol, 1.6 equiv.) was then added to the residue, followed by HO (30 mL). The mixture was then sonicated at 30° C. for 30 minutes, at which point the pH of the mixture was 3.17. The mixture was then passed through a 0.2 μm syringe filter and lyophilized overnight to give compound 32 as a dark blue solid (146 mg, quantitative).
[0406] 1 H NMR (400MHz, DMSO-d6) δ9.98(s, 1H), 9.88(s, 1H), 9.30-9.10(m, 2H), 8.24(d, J=7.8Hz, 1H), 8.15-7.87( m, 7H), 4.75-4.57(m, 3H), 4.24(td, J=8.3, 4.9Hz, 1H), 4.03(d, J=7.8Hz, 2H), 3.98(s, 2H), 3.90(t, J=7.7 Hz, 1H), 3.67(s, 3H), 2.98(s, 3H), 2.75(s, 3H), 2.73-2.60(m, 2H), 2.45-2.35(m, 0H), 2.21-2.08(m, 1H), 1.78(d, J=7.1Hz, 3H), 1.71(t, J=7.5Hz, 3H), 1.67-1.43(m, 11H), 1.42-1.14(m, 6H), -2.61--3.13(m, 2H).
[0407] Synthesis Example 33 - Synthesis of reduced phyllochlorin N-lysyl-lysyl-lysyl-dimethylamidopropylamide trihydrochloride (Compound 33) [ka] Step 1: A 50 mL RBF containing a stir bar was charged with reduced phyllochlorin (compound 1) (500 mg, 0.979 mmol, 1 equiv.), DMTMM (351 mg, 1.27 mmol, 1.3 equiv.), DCM (15 mL), and H-(Lys(Boc))3-NMe2 (854 mg, 1.17 mmol, 1.2 equiv.). The reaction mixture was stirred at 25 °C for 1 h, at which point HPLC analysis indicated the reaction was complete. The reaction mixture was diluted with DCM (25 mL) and then washed with saturated aqueous NaHCO3 (2 x 40 mL) and brine (40 mL). The organic layer was then dried (Na2SO4), filtered over a sintered glass frit, and concentrated by rotary evaporation to give a dark blue residue. The residue was purified by column chromatography (5 x 20 cm) eluting with 2-6% MeOH / DCM, starting with a gradient of 1% MeOH when the first light blue-green band eluted from the column. f Fractions containing (C = 0.34) were combined and the solvent removed by rotary evaporation to give reduced phyllochlorin-(Lys(Boc))3-NMe2 as a dark blue solid (1.12 g, 94%).
[0408] 1 H NMR (400MHz, CDCl3) δ9.70(s, 1H), 9.52(s, 1H), 8.79(s, 1H), 8.75(s, 1H), 6.92-6.64(m, 2H), 5.77(s, 1H), 4.9 0-4.68(m, 4H), 4.62-4.43(m, 2H), 4.26(s, 1H), 4.12-3.98(m, 1H), 3.97-3.89(m, 6H), 3.84(q, J=7.6Hz, 2H), 3. 63(s, 3H), 3.42(s, 3H), 3.37(s, 3H), 3.09-2.76(m, 14H), 2.56-2.40(m, 1H), 2.35-2.17(m, 2H), 1.82(s, 3H), 1 .79-1.70(m, 9H), 1.63-1.48(m, 1H), 1.41-1.27(m, 35H), 1.23-1.07(m, 12H), 1.02-0.87(m, 2H), -2.20(s, 2H).
[0409] Step 2: A 25 mL RBF containing a stir bar, an air condenser, and a drying tube packed with silica beads was charged with reduced phyllochlorin-(Lys(Boc))3-NMe2 (200 mg, 0.164 mmol, 1 equiv.), DCM (5 mL), and TFA (2 mL). The reaction mixture was stirred at 25 °C for 2 h, and the reaction progress was monitored by HPLC. The reaction mixture was concentrated by rotary evaporation to remove DCM and bulk TFA. The residue was then redissolved in DCM (40 mL) and washed with saturated aqueous NaHCO3 (40 mL), resulting in an emulsion. EtOH (15 mL) was added to the emulsion in approximately 2 mL portions, gently swirling the mixture with each addition to aid in the separation of the DCM and aqueous layers. The aqueous layer was then extracted with DCM (30 mL), forming an emulsion. EtOH (5 mL) was added to the emulsion to aid in the separation of the DCM and aqueous layers. The organic layers were combined and washed with HO (50 mL) to give an emulsion. Brine (50 mL) and then MeOH (50 mL) were added to the emulsion, and the DCM layer was collected, dried (NaSO), filtered through a sintered glass funnel, and concentrated by rotary evaporation to give the free base intermediate (96 mg). HCl (0.1017 M in HO, 2.43 mL, 0.247 mmol, 1.51 equiv) was then added to the residue, followed by HO (30 mL). The mixture was then sonicated at 30 °C for 30 minutes, at which point the pH of the mixture was 2.16. The mixture was then passed through a 0.2 μm syringe filter and lyophilized overnight to give compound 33 as a dark blue solid (88 mg, 52%).
[0410] 1H NMR (400MHz, DMSO-d6) δ10.20(s, 1H), 10.12(s, 1H), 9.41(s, 1H), 9.34(s, 1H), 8.34(d, J=7.7Hz, 1H), 8.29-8.08(m, 10H), 8.03(d , J=8.0Hz, 1H), 4.76(q, J=7.3Hz, 1H), 4.69(dd, J=9.9, 2.7Hz, 1H), 4.60(td, J=8.3, 4.9Hz, 1H), 4.25(dtd, J=26.2, 8.4, 5.4Hz, 2H) ), 4.15-3.93(m, 6H), 3.71(s, 3H), 3.48(s, 4H), 3.46(s, 3H), 2.93(s, 3H), 2.76(s, 3H), 2.75-2.59(m, 8H), 2.47-2.36(m, 1H), 2.2 3-2.10(m, 1H), 1.81(d, J=7.1Hz, 3H), 1.70(t, J=7.5Hz, 3H), 1.66-1.45(m, 12H), 1.43-1.16(m, 6H), -3.05(s, 1H), -3.39(s, 1H).
[0411] Synthesis Example 34 - Synthesis of reduced phyllochlorin ((methylamino)-3-propyl)triphenylphosphonium bromidopropylamide (Compound 34) [ka] A 25 mL RBF was charged with reduced phyllochlorin (compound 1) (100 mg, 0.197 mmol, 1 equiv.), DMTMM (82 mg, 0.295 mmol, 1.5 equiv.), DCM (5 mL), TEA (34 mg, 0.295 mmol, 1.7 equiv.), and (3-(methylamino)propyl)triphenylphosphonium bromide hydrobromide (146 mg, 0.295 mmol, 1.5 equiv.). The reaction mixture was stirred under nitrogen at ambient temperature for 2 h. The reaction mixture was transferred to a separatory funnel, diluted with DCM (10 mL), and washed with 0.5 M HCl (10 mL). The aqueous layer was re-extracted with DCM (2 × 5 mL). The combined organic layers were washed with pH 7 phosphate buffer (10 mL), dried (NaSO), and concentrated by rotary evaporation to give a blue-black film. The residue was purified by column chromatography (3 x 16 cm) eluting with 3-6% MeOH / DCM. The major dark green spot (R in 7% MeOH / DCM) f =0.20) were combined to give compound 34 as a dark green solid (105 mg, 59%).
[0412] 1 H NMR (400MHz, CDCl3) δ9.70(s, 1H), 9.52(s, 1H), 8.79-8.75(m, 2H), 7.71-7.64(m, 6H) ), 7.62-7.58(m, 3H), 7.55-7.48(m, 6H), 4.55-4.45(m, 2H), 3.98-3.90(m, 5H), 3.84 (q, 2H), 3.80-3.70(m, 1H), 3.64(s, 3H), 3.57(m, 2H), 3.39(s, 3H), 3.37(s, 3H), 2.8 3(s, 3H), 2.58-2.37(m, 2H), 2.08-1.94(m, 2H), 1.88-1.66(m, 20H), -2.18(brs, 2H).
[0413] Synthesis Example 35 - Synthesis of reduced chlorin e4 dimethyl ester (compound 35) [ka] A three-necked 100 mL RBF was charged with chlorin e4 dimethyl ester (200 mg, 0.344 mmol), 10% Pd / C (20 mg), ethyl acetate (40 mL), and a stir bar. A hydrogen balloon was connected to the mid-joint of the flask via a short-length air condenser, and the side arm was connected to a three-way tap. The flask was evacuated and refilled with nitrogen (three times), then evacuated and refilled with hydrogen (twice). The reaction mixture was then stirred under a hydrogen atmosphere for 45 minutes. The flask was evacuated and refilled with nitrogen (three times). The reaction mixture was then filtered through Celite® (0.5 × 3 cm) and washed with ethyl acetate (approximately 10 mL). The solvent was then removed under reduced pressure to give a green residue (0.25 g). The residue was purified by column chromatography (3 × 15 cm) eluting with 0.5–1% MeOH / DCM. The major dark green spot (R in 3% MeOH / DCM) f =0.70) were combined to give compound 35 as a metallic blue / green solid (152 mg, 76%).
[0414] 1 H NMR (400MHz, CDCl3) δ9.68(s, 1H), 9.39(s, 1H), 8.67(s, 1H), 4.50-4.40(m, 2H), 4.29(s, 3H), 3.91-3.85(q, 2H), 3.80(m, 5H), 3.61(s, 3H), 3.58( s, 3H), 3.35(s, 3H), 3.31(s, 3H), 2.60-2.52(m, 1H), 2.48-2.38(m, 1H), 2 .25-2.16(m, 1H), 1.98-1.88(m, 1H), 1.78-1.69(m, 9H), -1.50(brs, 2H).
[0415] Synthesis Example 36 - Synthesis of reduced chlorin e4 (compound 36) [ka] A three-necked 250 mL RBF was charged with chlorin e4 (2.0 g, 3.619 mmol), 10% Pd / C (100 mg), acetone (50 mL), THF (25 mL), and a stir bar. A hydrogen balloon was connected to the flask's mid-joint via a short-length air condenser, and the side arm was connected to a three-way tap. The flask was evacuated and refilled with nitrogen (three times), then evacuated and refilled with hydrogen (twice). The reaction mixture was then stirred under a hydrogen atmosphere at ambient temperature for 3 h. The flask was evacuated and refilled with nitrogen (three times). The reaction mixture was then filtered through Celite® and washed with THF (2 × 15 mL). The solvent was removed under reduced pressure to give a blue-black residue (approximately 2 g). The residue was purified by column chromatography (5 × 12 cm) eluting with 5–12% MeOH / DCM. The major dark green spot (R in 10% MeOH / DCM) f =0.20) were combined to give compound 36 as a metallic blue / green solid (0.98 g, 49%).
[0416] 1 H NMR (400 MHz, DMSO-d) δ 9.70 (s, 1H), 9.52 (s, 1H), 8.94 (s, 1H), 4.54 (q, 1H), 4.43 (m, 1H), 3.91 (q, 2H), 3.86-3.75 (m, 5H), 3.54 (s, 3H), (region 3.45-3.25 partially obscured by HO signals), 3.30 (s, 3H), 2.65-2.55 (m, 1H), 2.33-2.20 (m, 2H), 1.73-1.64 (m, 9H), −1.88 (s, 1H), −2.06 (s, 1H).
[0417] Synthesis Example 37 - Synthesis of reduced chlorin e6 triol-triacetate (compound 37) [ka] Step 1: To a 250 mL RBF was added chlorin e6 trimethyl ester (1.00 g, 1.566 mmol, 1 equiv.) and THF (100 mL). The solution was stirred (350 rpm) and cooled under nitrogen using an ice / water bath for 10 minutes. Lithium aluminum hydride (625 mg, 15.65 mmol, 10 equiv.) was added portionwise over 5 minutes, and the mixture was then warmed to room temperature and stirred for 1 hour. Additional lithium aluminum hydride (310 mg, 5 equiv.) was added portionwise, and stirring continued for 1 hour. The flask was cooled (ice / water bath), and water (1 mL) was added, followed by 4 M NaOH (1 mL). After stirring for 10 minutes, additional water (3 mL) was added, and the solution was warmed to room temperature and stirred for 15 minutes. Sodium sulfate was added, and the mixture was stirred for 10 minutes, then filtered and rinsed with DCM until no more color eluted. The solvent was then removed under reduced pressure to give the crude product (approximately 0.7 g), which was purified by column chromatography (4 × 20 cm) eluting with 4–6% MeOH / DCM. The major dark green spot (R in 10% MeOH / DCM) f =0.25) were combined to give chlorin e6 triol as a dark green solid (158 mg, 18%).
[0418] 1 H NMR (400MHz, DMSO-d6) δ9.78(s, 1H), 9.76(s, 1H), 9.14(s, 1H), 8.33(dd, 1H), 6.45 (dd, 1H), 6.14(dd, 1H), 5.74(s, 3H), 5.25(m, 1H), 5.18(m, 1H), 4.68-4.58(m, 2H), 4 .37(m, 1H), 4.19(m, 3H), 3.82(q, 2H), 3.63(s, 3H), 3.54(s, 3H), 3.31(s, 3H), 2.03 -1.91(m, 1H), 1.81-1.67(m, 8H), 1.58-1.40(m, 2H), -1.86(br, 1H), -2.28(br, 1H).
[0419] Step 2: To a 50 mL RBF was added chlorin e6 triol (60 mg, 0.108 mmol, 1 equiv.), pyridine (1 mL), acetic anhydride (0.11 g, 1.08 mmol, 10 equiv.), and DMAP (1 mg). The solution was stirred at 30 °C for 1 h. Ethyl acetate (10 mL) and water (10 mL) were added,...
Claims
1. A compound of formula (1) or a complex of formula (2): [Case 1] or a pharma- ceutically acceptable salt thereof [In the formula, -R 1 is -CH 2 OR 2 , -CH 2 S.R. 2 , -CH 2 S(O)R 2 , -CH 2 S (O) 2 R 2 , -CH 2 N (R 2 ) 2 , -R 2 , —C(O)—OR 3 , —C(O)—SR 3 , -C(O)-N(R 3 ) 2 , -C(S)-OR 3 , -C(S)-SR 3 or -C(S)-N(R 3 ) 2 Selected from: -R 2 are each independently H, -C(O)R 4 , —C(O)—OR 4 , —C(O)—SR 4 , -C(O)-N(R 4 ) 2 , -C(S)-OR 4 , -C(S)-SR 4 , -C(S)-N(R 4 ) 2 , -R α -H, -R β , -R α -R β , -R α -OH, -R α -OR β , -R α -SH, -R α -SR β , -R α -S(O)R β , -R α -S (O) 2 R β, -R α -NH 2 , -R α -NH(R β ), -R α -N(R β ) 2 , -R α -X, -R α -[N(R 5 ) 3 ]Y, -R α - [P(R 5 ) 3 ]Y, -R α - [R 8 ]Y, -R α -[N(R 5 ) 2 (R 5’ )], -R α - [P(R 5 ) 2 (R 5’ ) or -R α - [R 8’ ] is selected from; -R 3 and -R 4 are each independently -H, -R α -H, -R β , -R α -R β , -R α -OH, -R α -OR β , -R α -SH, -R α -SR β , -R α -NH 2 , -R α -NH(R β ), -R α -N(R β ) 2 , -R α -X, -R α -[N(R 5 ) 3 ]Y, -R α - [P(R 5 ) 3 ]Y, -R α - [R 8 ]Y, -R α -[N(R 5 ) 2 (R 5’ )], -R α - [P(R 5 ) 2 (R 5’ ) or -R α - [R 8’ ] is selected from; -R α - is independently C 1 -C 42 alkylene groups, said alkylene groups being selected from one or more C 1 -C 4 Alkyl, C 1 -C 4 may be optionally substituted with a haloalkyl or halo group, and one or more carbon atoms in the backbone of the alkylene group may be optionally substituted with a heteroatom or group independently selected from O, S, NH, or NMe; -R β are each independently a saturated or unsaturated hydrocarbyl group which may be linear or branched or may be or contain a cyclic group, said hydrocarbyl group may optionally be substituted, and said hydrocarbyl group may optionally include one or more heteroatoms N, O, S, P and Se in its carbon backbone; -R 5 are each independently 1 -C 4 Alkyl, C 1 -C 4 Haloalkyl, -(CH 2 CH 2 O) n -H, -(CH 2 CH 2 O) n -CH 3 , phenyl or C 5 -C 6 heteroaryl, wherein said phenyl or C 5 -C 6 Heteroaryl optionally includes one or more C 1 -C 6 Alkyl, C 1 -C 6 Haloalkyl, —O(C 1 -C 6 alkyl), -O(C 1 -C 6 haloalkyl), halo, -CO 2 H, -CO 2 Z, -CO 2 N.H. 2 , —O—(CH 2 CH 2 O) n -H or -O-(CH 2 CH 2 O) n -CH 3 may be substituted with a group; -R 5’ is C 1 -C 4 Alkyl, C 1 -C 4 Haloalkyl, -(CH 2 CH 2 O) n -H, -(CH 2 CH 2 O) n -CH 3 , phenyl or C 5 -C 6 heteroaryl, each of which is —CO 2 - and the phenyl or C 5 -C 6 Heteroaryl is one or more C 1 -C 6 Alkyl, C 1 -C 6 Haloalkyl, —O(C 1 -C 6 alkyl), -O(C 1 -C 6 haloalkyl), halo, -CO 2 H, -CO 2 Z, -CO 2 N.H. 2 , —O—(CH 2 CH 2 O) n -H or -O-(CH 2 CH 2 O) n -CH 3 may be further substituted with a group; -R 6 is hydrogen, -C(O)-OR 3 , —C(O)—SR 3 , -C(O)-N(R 3 ) 2 , -C(S)-OR 3 , -C(S)-SR 3 or -C(S)-N(R 3 ) 2 Selected from: -R 7 is hydrogen, -C(O)-OR 3 , —C(O)—SR 3 , -C(O)-N(R 3 ) 2 , -C(S)-OR 3 , -C(S)-SR 3 or -C(S)-N(R 3 ) 2 Selected from; Or -R 6 and-R 7 together form -C(O)-O-, -R 8 may optionally contain one or more C 1 -C 6 Alkyl, C 1 -C 6 Haloalkyl, —O(C 1 -C 6 alkyl), -O(C 1 -C 6 haloalkyl), halo, -CO 2 H, -CO 2 Z, -CO 2 N.H. 2 , —O—(CH 2 CH 2 O) n -H or -O-(CH 2 CH 2 O) n -CH 3 -[NC substituted with a group 5 H 5 ]; -R 8’ is -CO 2 - and optionally one or more C 1 -C 6 Alkyl, C 1 -C 6Haloalkyl, —O(C 1 -C 6 alkyl), -O(C 1 -C 6 haloalkyl), halo, -CO 2 H, -CO 2 Z, -CO 2 N.H. 2 , —O—(CH 2 CH 2 O) n -H or -O-(CH 2 CH 2 O) n -CH 3 -[NC 5 H 5 ]; n is 1, 2, 3, 4, 5 or 6; X is a halo group; Y is a counter anion; Z is a counter cation; M 2+ is a metal cation.
2. A compound of formula (1) or a complex of formula (2): [Case 2] or a pharma- ceutically acceptable salt thereof [In the formula, -R 1 is -CH 2 OR 2 , -CH 2 S.R. 2 , -CH 2 S(O)R 2 , -CH 2 S (O) 2 R 2 , -CH 2 N (R 2 ) 2 , -R 2 , —C(O)—OR 3 , —C(O)—SR 3 , -C(O)-N(R 3 ) 2 , -C(S)-OR 3 , -C(S)-SR 3 or -C(S)-N(R 3) 2 Selected from: -R 2 are each independently H, -C(O)R 4 , —C(O)—OR 4 , —C(O)—SR 4 , -C(O)-N(R 4 ) 2 , -C(S)-OR 4 , -C(S)-SR 4 , -C(S)-N(R 4 ) 2 , -R α -H, -R β , -R α -R β , -R α -OH, -R α -OR β , -R α -SH, -R α -SR β , -R α -S(O)R β , -R α -S (O) 2 R β , -R α -NH 2 , -R α -NH(R β ), -R α -N(R β ) 2 , -R α -X, -R α -[N(R 5 ) 3 ]Y, -R α - [P(R 5 ) 3 ]Y, -R α - [R 8 ]Y, -R α -[N(R 5 ) 2 (R 5’ )], -R α - [P(R 5 ) 2 (R 5’ ) or -R α - [R 8’ ] is selected from; -R 3 and -R 4 are each independently -H, -R α -H, -R β , -R α -R β , -R α -OH, -R α -OR β , -R α -SH, -R α -SR β , -R α -NH 2 , -R α -NH(R β ), -R α -N(R β ) 2 , -R α -X, -R α -[N(R 5 ) 3 ]Y, -R α - [P(R 5 ) 3 ]Y, -R α - [R 8 ]Y, -R α -[N(R 5 ) 2 (R 5’ )], -R α - [P(R 5 ) 2 (R 5’ ) or -R α - [R 8’ ] is selected from; -R α - is independently C 1 -C 42 alkylene groups, said alkylene groups being selected from one or more C 1 -C 4 Alkyl, C 1 -C 4 may be optionally substituted with a haloalkyl or halo group, and one or more carbon atoms in the backbone of the alkylene group may be optionally substituted with a heteroatom or group independently selected from O, S, NH, or NMe; -R βare each independently a saturated or unsaturated hydrocarbyl group which may be linear or branched or may be or contain a cyclic group, said hydrocarbyl group may optionally be substituted, and said hydrocarbyl group may optionally include one or more heteroatoms N, O, S, P and Se in its carbon backbone; -R 5 are each independently 1 -C 4 Alkyl, C 1 -C 4 Haloalkyl, -(CH 2 CH 2 O) n -H, -(CH 2 CH 2 O) n -CH 3 , phenyl or C 5 -C 6 heteroaryl, wherein said phenyl or C 5 -C 6 Heteroaryl optionally includes one or more C 1 -C 6 Alkyl, C 1 -C 6 Haloalkyl, —O(C 1 -C 6 alkyl), -O(C 1 -C 6 haloalkyl), halo, -CO 2 H, -CO 2 Z, -CO 2 N.H. 2 , —O—(CH 2 CH 2 O) n -H or -O-(CH 2 CH 2 O) n -CH 3 may be substituted with a group; -R 5’ is C 1 -C 4 Alkyl, C 1 -C 4 Haloalkyl, -(CH 2 CH 2 O) n -H, -(CH 2 CH 2 O) n -CH 3 , phenyl or C 5 -C 6 heteroaryl, each of which is —CO 2 - and the phenyl or C 5 -C 6 Heteroaryl is one or more C 1 -C 6 Alkyl, C 1 -C 6 Haloalkyl, —O(C 1 -C 6 alkyl), -O(C 1 -C 6 haloalkyl), halo, -CO 2 H, -CO 2 Z, -CO 2 N.H. 2 , —O—(CH 2 CH 2 O) n -H or -O-(CH 2 CH 2 O) n -CH 3 may be further substituted with a group; -R 6 is hydrogen, -C(O)-OR 3 , —C(O)—SR 3 , -C(O)-N(R 3 ) 2 , -C(S)-OR 3 , -C(S)-SR 3 or -C(S)-N(R 3 ) 2 Selected from: -R 7 is hydrogen, -C(O)-OR 3 , —C(O)—SR 3 , -C(O)-N(R 3 ) 2 , -C(S)-OR 3 , -C(S)-SR 3 or -C(S)-N(R 3 ) 2 Selected from; Or -R 6and-R 7 together form -C(O)-O-, -R 8 may optionally contain one or more C 1 -C 6 Alkyl, C 1 -C 6 Haloalkyl, —O(C 1 -C 6 alkyl), -O(C 1 -C 6 haloalkyl), halo, -CO 2 H, -CO 2 Z, -CO 2 N.H. 2 , —O—(CH 2 CH 2 O) n -H or -O-(CH 2 CH 2 O) n -CH 3 -[NC substituted with a group 5 H 5 ]; -R 8’ is -CO 2 - and optionally one or more C 1 -C 6 Alkyl, C 1 -C 6 Haloalkyl, —O(C 1 -C 6 alkyl), -O(C 1 -C 6 haloalkyl), halo, -CO 2 H, -CO 2 Z, -CO 2 N.H. 2 , —O—(CH 2 CH 2 O) n -H or -O-(CH 2 CH 2 O) n -CH 3 -[NC 5 H 5 ]; n is 1, 2, 3, 4, 5 or 6; X is a halo group; Y is a counter anion; Z is a counter cation; M 2+ is a metal cation.
3. Each -R α - but independently, C 1 ~C 6 3. The compound or complex according to claim 1 or 2, selected from alkylene.
4. -R 2 , -R 3 and -R 4 At least one of the following is -R α -OR β Or -R α -SR β -R β 2. A compound or complex according to any one of the preceding claims, wherein is a saccharidyl group.
5. -R β but the following: [C3] 5. The compound or complex of claim 4, wherein the saccharidyl group is selected from:
6. The saccharidyl group is: [C4] 6. The compound or complex of claim 5,
7. -R β but: [C5] is a saccharidyl group selected from In the formula, -R 9 But, C 1 -C 4 5. The compound or complex of claim 4, wherein the alkyl is selected from the group consisting of alkyl, aryl, aryl and alkyl.
8. -R 9 8. The compound or complex of claim 7, wherein is methyl.
9. -R 1 is -C(O)-N(R 3 ) 2 2. A compound or complex according to any one of the preceding claims, wherein
10. -R 1 is -C(O)-N(R 3 ) (R 3’ ) in which -R 3 Ga-R α -OR β Or -R α -SR β -R β is a saccharidyl group, -R 3’ is H or C 1 -C 4 10. The compound or complex of claim 9, which is alkyl.
11. -R 6 2. A compound or complex according to any one of the preceding claims, wherein is hydrogen.
12. -R 6 -C(O)-OR 3 and -R 3 C 1 -C 4 The compound or complex according to any one of claims 1 to 10, which is alkyl.
13. -R 6 -C(O)-OR 3 , —C(O)—SR 3 or -C(O)-N(R 3 ) (R 3’ ) selected from -R 3 Ga-R α -OR β , -R α -SR β , -R α -S(O)R β Or -R α -S (O) 2 R β -R β is a saccharidyl group, -R 3’ is H or C 1 -C 4 The compound or complex according to any one of claims 1 to 10, which is alkyl.
14. -R 7 2. A compound or complex according to any one of the preceding claims, wherein is hydrogen.
15. -R 7 -C(O)-OR 3 and -R 3 C 1 -C 4 14. The compound or complex of any one of claims 1 to 13, wherein the compound or complex is alkyl.
16. -R 7 -C(O)-OR 3 , —C(O)—SR 3 or -C(O)-N(R 3 ) (R 3’ ) selected from -R 3 Ga-R α -OR β , -R α -SR β , -R α -S(O)R β Or -R α -S (O) 2 R β -R β is a saccharidyl group, -R 3’ is H or C 1 -C 4 14. The compound or complex of any one of claims 1 to 13, which is alkyl.
17. The compound or complex is: [C6] [ka] [ka] [ka] [ka] [ka] [ka] or a metal cation complex thereof, or a pharma- ceutically acceptable salt thereof.
18. 3. The compound or complex according to claim 1 or 2, wherein the compound is a reduced phyllochlorin in the form of a pharma- ceutically acceptable salt.
19. 19. The compound or complex of claim 18, wherein the compound is reduced monosodium phyllochlorin.
20. The compound comprising: (1) reduced phyllochlorin free acid; or (2) The compound or complex according to claim 2, which is a reduced phyllochlorin methyl ester.
21. 13. A compound or complex according to any one of the preceding claims for use in photodynamic therapy or cytoluminescent therapy.
22. atherosclerosis; multiple sclerosis; diabetes; diabetic retinopathy; arthritis; rheumatoid arthritis; fungal, viral, chlamydial, bacterial, nanobacterial or parasitic infections; HIV; AIDS; infection with SARS virus (preferably Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)), Asian (Chicken) Influenza virus, Dengue virus, Herpes simplex or Shingles; hepatitis; viral hepatitis; cardiovascular disease; coronary artery stenosis; carotid artery stenosis; intermittent claudication; dermatological conditions; acne; psoriasis; benign or malignant cell hyperproliferation or blood 10. A compound or complex as claimed in any one of the preceding claims for use in the treatment of a disease characterised by areas of neovascularisation; a benign or malignant tumour; early stage cancer; cervical dysplasia; soft tissue sarcoma; germ cell tumour; retinoblastoma; age-related macular degeneration; lymphoma; Hodgkin's lymphoma; head and neck cancer; oral cancer; or cancer of the blood, prostate, cervix, uterus, vagina or other female adnexa, breast, nasopharynx, trachea, larynx, bronchi, bronchioles, lungs, hollow organs, esophagus, stomach, bile duct, intestine, colon, colorectum, rectum, bladder, ureter, kidney, liver, gallbladder, spleen, brain, lymphatic system, bone, skin or pancreas.
23. 10. A compound or complex according to any one of the preceding claims for use in the treatment of a disease characterised by areas of benign or malignant cellular hyperproliferation or angiogenesis.
24. 10. A compound or complex according to any one of the preceding claims for use in the treatment of benign or malignant tumours.
25. 10. A compound or complex as claimed in any one of the preceding claims for use in the treatment of early stage cancer; cervical dysplasia; soft tissue sarcoma; germ cell tumours; retinoblastoma; age-related macular degeneration; lymphoma; Hodgkin's lymphoma; head and neck cancer; oral cancer; or cancer of the blood, prostate, cervix, uterus, vagina or other female adnexa, breast, nasopharynx, trachea, larynx, bronchi, bronchioles, lungs, hollow organs, esophagus, stomach, bile duct, intestine, colon, colorectum, rectum, bladder, ureter, kidney, liver, gallbladder, spleen, brain, lymphatic system, bone, skin or pancreas.
26. 10. A compound or complex according to any one of the preceding claims for use in photodynamic diagnosis.
27. 10. A compound or complex according to any one of the preceding claims, wherein the compound is adapted to be administered prior to the administration of radiation.
28. 28. The compound or complex of claim 27, wherein the irradiation is electromagnetic radiation having a wavelength in the range of 500 nm to 1000 nm.
29. 10. A pharmaceutical composition comprising a compound or complex according to any one of the preceding claims and a pharma- ceutically acceptable carrier or diluent.
30. 30. The pharmaceutical composition of claim 29, further comprising polyvinylpyrrolidone.
31. 31. The pharmaceutical composition of claim 29 or 30, further comprising an immune checkpoint inhibitor.
32. 32. The pharmaceutical composition of claim 31 , wherein the immune checkpoint inhibitor is selected from pembrolizumab, nivolumab, cemiplimab, atezolizumab, avelumab, durvalumab, or ipilimumab.
33. A pharmaceutical composition according to any one of claims 29 to 32 for use in photodynamic therapy or cytoluminescence therapy.
34. atherosclerosis; multiple sclerosis; diabetes; diabetic retinopathy; arthritis; rheumatoid arthritis; fungal, viral, chlamydial, bacterial, nanobacterial or parasitic infections; HIV; AIDS; infection with SARS virus (preferably Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)), Asian (Chicken) Influenza virus, Dengue virus, Herpes simplex or Shingles; hepatitis; viral hepatitis; cardiovascular disease; coronary artery stenosis; carotid artery stenosis; intermittent claudication; dermatological conditions; acne; psoriasis; benign or malignant cell hyperproliferation or blood 34. The pharmaceutical composition of any one of claims 29 to 33 for use in the treatment of a disease characterised by areas of neovascularisation; a benign or malignant tumour; early stage cancer; cervical dysplasia; soft tissue sarcoma; germ cell tumour; retinoblastoma; age-related macular degeneration; lymphoma; Hodgkin's lymphoma; head and neck cancer; oral cancer; or cancer of the blood, prostate, cervix, uterus, vagina or other female adnexa, breast, nasopharynx, trachea, larynx, bronchi, bronchioles, lungs, hollow organs, esophagus, stomach, bile duct, intestine, colon, colorectum, rectum, bladder, ureter, kidney, liver, gallbladder, spleen, brain, lymphatic system, bone, skin or pancreas.
35. A pharmaceutical composition according to any one of claims 29 to 34 for use in the treatment of a disease characterised by benign or malignant cellular hyperproliferation or by areas of neovascularisation.
36. A pharmaceutical composition according to any one of claims 29 to 35 for use in the treatment of benign or malignant tumors.
37. 37. The pharmaceutical composition of any one of claims 29 to 36 for use in the treatment of early stage cancer; cervical dysplasia; soft tissue sarcoma; germ cell tumors; retinoblastoma; age-related macular degeneration; lymphoma; Hodgkin's lymphoma; head and neck cancer; oral cancer; or cancer of the blood, prostate, cervix, uterus, vagina or other female adnexa, breast, nasopharynx, trachea, larynx, bronchi, bronchioles, lung, hollow organs, esophagus, stomach, bile duct, intestine, colon, colorectum, rectum, bladder, ureter, kidney, liver, gallbladder, spleen, brain, lymphatic system, bone, skin or pancreas.
38. 31. A pharmaceutical composition according to claim 29 or 30 for use in photodynamic diagnosis.
39. The pharmaceutical composition according to any one of claims 29 to 38, wherein the pharmaceutical composition is adapted for administration prior to the administration of radiation.
40. 40. The pharmaceutical composition of claim 39, wherein the irradiation is electromagnetic radiation having a wavelength in the range of 500 nm to 1000 nm.
41. 41. The pharmaceutical composition according to any one of claims 29 to 40, wherein the pharmaceutical composition is in a form suitable for oral, parenteral (including intravenous, subcutaneous, intramuscular, intradermal, intratracheal, intraperitoneal, intratumoral, intraarticular, intraperitoneal, intracranial and epidural), transdermal, airway (aerosol), rectal, vaginal or topical (including buccal, mucosal and sublingual) administration.
42. 42. The pharmaceutical composition of claim 41, wherein the pharmaceutical composition is in a form suitable for oral or parenteral administration.
43. atherosclerosis; multiple sclerosis; diabetes; diabetic retinopathy; arthritis; rheumatoid arthritis; fungal, viral, chlamydial, bacterial, nanobacterial or parasitic infections; HIV; AIDS; infection with SARS virus (preferably Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)), Asian (Chicken) Influenza virus, Dengue virus, Herpes simplex or Shingles; hepatitis; viral hepatitis; cardiovascular disease; coronary artery stenosis; carotid artery stenosis; intermittent claudication; dermatological conditions; acne; psoriasis; areas of benign or malignant cell hyperproliferation or angiogenesis.
29. Use of a compound or complex according to any one of claims 1 to 28 in the manufacture of a medicament for the treatment of a disease characterized by a range of conditions, including cancers, benign or malignant tumors, early stage cancers, cervical dysplasia, soft tissue sarcoma, germ cell tumors, retinoblastoma, age-related macular degeneration, lymphoma, Hodgkin's lymphoma, head and neck cancer, oral cancer, or cancer of the blood, prostate, cervix, uterus, vagina or other female adnexa, breast, nasopharynx, trachea, larynx, bronchi, bronchioles, lungs, hollow organs, esophagus, stomach, bile duct, intestine, colon, colorectum, rectum, bladder, ureter, kidney, liver, gallbladder, spleen, brain, lymphatic system, bone, skin or pancreas.
44. 29. Use of a compound or complex according to any one of claims 1 to 28 in the manufacture of a phototherapeutic agent for use in photodynamic therapy or cytoluminescence therapy.
45. The phototherapeutic agent is for treating atherosclerosis; multiple sclerosis; diabetes; diabetic retinopathy; arthritis; rheumatoid arthritis; fungal, viral, chlamydial, bacterial, nanobacterial or parasitic infections; HIV; AIDS; infection with SARS virus (preferably Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)), Asian (Chicken) Influenza virus, Dengue virus, Herpes simplex or Shingles; hepatitis; viral hepatitis; cardiovascular disease; coronary artery stenosis; carotid artery stenosis; intermittent claudication; dermatological conditions; acne; psoriasis; benign or malignant 45. The use of claim 44 for the treatment of a disease characterized by areas of cellular hyperproliferation or angiogenesis; a benign or malignant tumor; early stage cancer; cervical dysplasia; soft tissue sarcoma; germ cell tumor; retinoblastoma; age-related macular degeneration; lymphoma; Hodgkin's lymphoma; head and neck cancer; oral cancer; or cancer of the blood, prostate, cervix, uterus, vagina or other female adnexa, breast, nasopharynx, trachea, larynx, bronchi, bronchioles, lungs, hollow organs, esophagus, stomach, bile duct, intestine, colon, colorectum, rectum, bladder, ureter, kidney, liver, gallbladder, spleen, brain, lymphatic system, bone, skin or pancreas.
46. The use according to any one of claims 43 to 45, wherein said medicament or said phototherapeutic agent is for the treatment of a disease characterised by benign or malignant cellular hyperproliferation or by areas of neovascularisation.
47. The use according to any one of claims 43 to 46, wherein the medicament or the phototherapeutic agent is for the treatment of a benign or malignant tumor.
48. 48. The use according to any one of claims 43 to 47, wherein the medicament or phototherapy agent is for the treatment of early stage cancer; cervical dysplasia; soft tissue sarcoma; germ cell tumors; retinoblastoma; age-related macular degeneration; lymphoma; Hodgkin's lymphoma; head and neck cancer; oral cancer; or cancer of the blood, prostate, cervix, uterus, vagina or other female adnexa, breast, nasopharynx, trachea, larynx, bronchi, bronchioles, lungs, hollow organs, esophagus, stomach, bile duct, intestine, colon, colorectum, rectum, bladder, ureter, kidney, liver, gallbladder, spleen, brain, lymphatic system, bone, skin or pancreas.
49. 30. Use of a compound or complex according to any one of claims 1 to 28 in the manufacture of a photodiagnostic agent for use in photodynamic diagnosis.
50. The use according to any one of claims 43 to 49, wherein the medicament, the phototherapeutic agent or the photodiagnostic agent is adapted for administration prior to the administration of radiation.
51. 51. The use according to claim 50, wherein the irradiation is electromagnetic radiation having a wavelength in the range of 500 nm to 1000 nm.
52. atherosclerosis; multiple sclerosis; diabetes; diabetic retinopathy; arthritis; rheumatoid arthritis; fungal, viral, chlamydial, bacterial, nanobacterial or parasitic infections; HIV; AIDS; infection with SARS virus (preferably Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)), Asian (Chicken) Influenza virus, Dengue virus, Herpes simplex or Shingles; hepatitis; viral hepatitis; cardiovascular disease; coronary artery stenosis; carotid artery stenosis; intermittent claudication; dermatological conditions; acne; psoriasis; diseases characterized by areas of benign or malignant cellular hyperproliferation or angiogenesis; benign or malignant 29. A method of treating a tumor; early stage cancer; cervical dysplasia; soft tissue sarcoma; germ cell tumor; retinoblastoma; age-related macular degeneration; lymphoma; Hodgkin's lymphoma; head and neck cancer; oral cancer; or cancer of the blood, prostate, cervix, uterus, vagina or other female adnexa, breast, nasopharynx, trachea, larynx, bronchi, bronchioles, lung, hollow organs, esophagus, stomach, bile duct, intestine, colon, colorectal, rectum, bladder, ureter, kidney, liver, gallbladder, spleen, brain, lymphatic system, bone, skin or pancreas, said method comprising administering to a human or animal in need thereof a therapeutically effective amount of a compound or complex according to any one of claims 1 to 28.
53. A method for photodynamic or cytoluminescent therapy of a disease in humans or animals, said method comprising administering to a human or animal in need thereof a therapeutically effective amount of a compound or complex according to any one of claims 1 to 28.
54. The human or animal disease may be atherosclerosis; multiple sclerosis; diabetes; diabetic retinopathy; arthritis; rheumatoid arthritis; fungal, viral, chlamydial, bacterial, nanobacterial or parasitic infection; HIV; AIDS; infection with SARS virus (preferably Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)), Asian (Chicken) Influenza virus, Dengue virus, Herpes simplex or Shingles; hepatitis; viral hepatitis; cardiovascular disease; coronary artery stenosis; carotid artery stenosis; intermittent claudication; dermatological conditions; acne; psoriasis; benign or a disease characterized by areas of malignant cellular hyperproliferation or angiogenesis; a benign or malignant tumor; early stage cancer; cervical dysplasia; soft tissue sarcoma; germ cell tumors; retinoblastoma; age-related macular degeneration; lymphoma; Hodgkin's lymphoma; head and neck cancer; oral cancer; or cancer of the blood, prostate, cervix, uterus, vagina or other female adnexa, breast, nasopharynx, trachea, larynx, bronchi, bronchioles, lung, hollow organs, esophagus, stomach, bile duct, intestine, colon, colorectum, rectum, bladder, ureter, kidney, liver, gallbladder, spleen, brain, lymphatic system, bone, skin or pancreas.
55. The method of any one of claims 52 to 54, wherein the human or animal disease is characterized by benign or malignant cellular hyperproliferation or by areas of neovascularization.
56. The method according to any one of claims 52 to 55, wherein the human or animal disease is a benign or malignant tumor.
57. 57. The method of any one of claims 52 to 56, wherein the human or animal disease is early stage cancer; cervical dysplasia; soft tissue sarcoma; germ cell tumor; retinoblastoma; age-related macular degeneration; lymphoma; Hodgkin's lymphoma; head and neck cancer; oral cancer; or cancer of the blood, prostate, cervix, uterus, vagina or other female adnexa, breast, nasopharynx, trachea, larynx, bronchi, bronchioles, lungs, hollow organs, esophagus, stomach, bile duct, intestine, colon, colorectum, rectum, bladder, ureter, kidney, liver, gallbladder, spleen, brain, lymphatic system, bone, skin, or pancreas.
58. A method for the photodynamic diagnosis of a disease in a human or animal, said method comprising administering to the human or animal a diagnostically effective amount of a compound or complex according to any one of claims 1 to 28.
59. A method according to any one of claims 52 to 58, wherein the human or animal is irradiated after administration of a compound or complex according to any one of claims 1 to 28.
60. 60. The method of claim 59, wherein the irradiation is electromagnetic radiation having a wavelength in the range of 500 nm to 1000 nm.
61. 1. A pharmaceutical combination or kit comprising: (a) a compound or complex according to any one of claims 1 to 28; and (b) the pharmaceutical combination or kit, which comprises an immune checkpoint inhibitor.
62. 62. The pharmaceutical combination or kit of claim 61 , wherein the immune checkpoint inhibitor is selected from pembrolizumab, nivolumab, cemiplimab, atezolizumab, avelumab, durvalumab, or ipilimumab.
